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Abstract 
 
Fibroblasts are important regulators of inflammatory processes. The phenotypes of 
fibroblasts differ according to anatomical site which may determine immune 
functions such as leukocyte accumulation and predilection for inflammatory disease 
in certain tissues. 
This thesis describes the expression profile and explores the function of a family of 
immunomodulatory proteins (galectins) in fibroblasts from rheumatoid arthritis 
patients. Synovial fibroblasts were found to differ significantly from bone marrow 
and skin fibroblasts with higher expression of galectin-9 and galectin-12 in synovial 
fibroblasts.  
Galectin-9 and galectin-3 expression was also examined in situ in synovial tissue 
from rheumatoid arthritis (RA) and osteoarthritis (OA) patients. Expression of both 
galectins was higher in RA synovial tissue compared to OA but not in synovial 
fibroblasts cultured in vitro. Galectin-3 expression seemed to be controlled by 
epigenetic factors (methylation) but not cytokine stimulation.  Galectin-9 production 
was up-regulated by interferon-γ, interleukin-1β and ligands for Toll-like receptors 3 
(TLR3) and 4 (TLR4). It was found that intracellular presence of galectin-9 in RA 
synovial fibroblasts increased their resistance to apoptosis. 
 
Galectin-3 levels are increased in the joints of patients with rheumatoid arthritis. 
Studies on the effect and mechanism of galectin-3 action on fibroblasts revealed that 
exogenously added galectin-3 induced production of cytokines (IL-6) from synovial 
and skin fibroblasts but the production of monocyte attracting chemokines (CCL5, 
CCL2) was induced uniquely in fibroblasts derived from the synovium. Different 
signalling pathways mediated the secretion of those mediators. IL-6 release depended 
on MAP kinases p38, ERK and JNK as well as NFκB transcription factor, whereas 
CCL5 production required PI3K/Akt and NFκB. 
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1.0 INTRODUCTION 
1.1 Galectins 
1.1.1 Structure and specificity 
Lectins are nonenzymatic and non-immunoglobulin proteins that bind carbohydrates. 
Galectins (previously called S-type lectins) constitute one of the several families of 
endogenous lectins and are named after their ability to bind β-galactosides (Barondes 
et al., 1994). Galectins and galectin-like proteins are present in all animal kingdoms 
and are reasonably well conserved throughout evolution (Cooper and Barondes, 
1999). For example, all galectins display sequence similarity in the carbohydrate-
recognition domain (CRD) which consists of about 130 amino acids with a globular 
tertiary structure forming a groove in which carbohydrate is bound (Leffler et al., 
2004).   
Currently there are 15 mammalian galectins known, 11 of which can be found in 
humans, namely galectins 1-4, 7-10, 12, 13 and 14 (Liu and Rabinovich, 2005). They 
can be subdivided into three groups based on their structural organisation (Fig.1.1). 
 
Fig. 1.1 Structure and classification of human galectins.  
Galectins containing only one carbohydrate-recognition domain (CRD) are called 
proto-type and include galectins: 1, 2, 5, 7, 10, 11, 13, 14 and 15. Those with two 
distinct CRDs in tandem connected by a linker region (tandem repeat-type) are 
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galectin-4, 6, 9, 12. Third is a chimera-type with one CRD plus an unusual non-lectin 
domain rich in proline and glycine. The only representative of the latter group is 
galectin-3 (Rubinstein et al., 2004). Recently discovered multiple isoforms of 
galectin-8 confound slightly this classification as three of them belong to tandem-
repeat group while other three to the prototype one (Bidon et al., 2001). There are no 
human counterparts of galectin-5, -6, -11 and -15 (Fig. 1.1). 
The endogenous ligands for galectins are saccharide chains of glycoconjugates (i.e. 
glycoproteins or glycolipids). Galectins show a particular preference for glycans 
containing the ubiquitous disaccharide N-acetyllactosamine (Galβ1-3GlcNAc or 
Galβ1-4GlcNAc) (Hirabayashi et al., 2002; Patnaik et al., 2006). Most of such 
ligands would be found in the extracellular compartment or within the luminal spaces 
of cellular organelles. Considering the wide variety of glycosylated molecules there 
are numerous potential ligands for galectins. However, most information on the 
sugar-specificity of galectins comes from in vitro biochemical studies where the 
carbohydrate structures are not presented in their natural context of membrane-
associated proteins or lipids. This presents a serious hurdle to identifying the real 
binding partners. However, new tools are being developed to facilitate further 
research (de Melo et al., 2007). 
Ligands for galectin binding that have been successfully demonstrated so far 
comprise  glycoconjugates of the extracellular matrix (ECM) such as laminin 
(Barboni et al., 1999), fibronectin (Ozeki et al., 1995), elastin (Ochieng et al., 1999) 
as well as cell surface glycoproteins including integrins (Hadari et al., 2000; 
Fukumori et al., 2003; Ochieng et al., 1998b), carcino-embrionic antigen (CEA) 
(Ohannesian et al., 1995) or bacterial lipopolysaccharides (LPS) (Gupta et al., 1997). 
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Other cell-type specific receptors identified for galectins are CD43 and CD45 on T 
cells  (Hernandez et al., 2006) or CD66 on neutrophils (Feuk-Lagerstedt et al., 1999).  
Certain galectins can also interact with other proteins independently of their 
carbohydrate-binding sites which further extends the range of their potential ligands. 
In fact, some galectins, for example galectin-10, possess low affinity for galactosides 
and may have other specificities (Leffler et al., 2004).  
1.1.2 Cellular localization and tissue distribution 
Although galectins have features of cytosolic proteins they can be found not only 
inside the cells but also in the extracellular space. The mechanism of secretion is not 
clear since galectins lack the signal sequence required for classical secretory pathway 
via endoplasmic reticulum (ER) and vesicles of the Golgi apparatus (Hughes, 1999). 
Proposed mechanisms include membrane blebbing into exosomes which then detach 
from the cell and release their contents into the extracellular space (Nickel, 2003).  
Another possibility of crossing lipid bilayers that was described for galectin-3 is by 
direct interaction with phospholipids or cholesterol (Lukyanov et al., 2005). The 
unique N-terminal non-lectin sequence may be responsible for this phenomenon 
(Menon and Hughes, 1999). More recently exit of galectin-1 from the cell via 
interaction with specific counter receptors was demonstrated (Seelenmeyer et al., 
2005). These β-galactoside-containing glycolipids would translocate between the 
outer and inner leaflets of plasma membrane with an attached galectin, a process 
catalyzed by a membrane-resident enzyme.  
Localisation of galectins inside the cells can be cytoplasmic or nuclear (Wang et al., 
2004; Liu et al., 2002). Galectin-9 also exhibits unusual membrane localization and 
was described to function as a urate transporter (Lipkowitz et al., 2004). This 
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indicates that despite the lack of a signal sequence characteristic for transmembrane 
proteins, refolding of these molecules and incorporation into cell membranes may 
occur. 
Tissue distribution of galectins varies for different members of the family (Table 
1.1). Several of them such as galectin-1, -3 or -8 are expressed in a wide range of 
tissues (Chiariotti et al., 2004). Others have a more restricted localization. Galectin-7 
for example is characteristic only for stratified epithelia (Magnaldo et al., 1998). On 
the other hand, galectin-4 is confined to epithelial cells of the gastro-intestinal (GI) 
tract (Huflejt and Leffler, 2004). Similar localization in the GI tract was reported for 
galectin-2 (Sturm et al., 2004). Galectin-10, also referred to as Charcot-Leyden 
crystal protein (CLC), seems to be unique for eosinophilic and basophilic leukocytes 
(Dyer and Rosenberg, 2001) and T regulatory cells (Kubach et al., 2007).  
Importantly, some galectins may be induced in pathological conditions in different 
cell types, for example galectin-7 in aggressive T cell lymphoma (Demers et al., 
2007) or galectin-2 which was shown in atherosclerotic plaques (Ozaki et al., 2004). 
It has also been suggested that expression of certain galectins may be correlated with 
the stage of the cell cycle. Galectin-12, first identified as adipose tissue-specific 
(Hotta et al., 2001), was later reported in heart, pancreas, spleen, thymus, and 
peripheral leukocytes (Yang et al., 2001). It was particularly expressed in cells 
synchronized at the G1 phase or the G1/S boundary of the cell cycle.   
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Table. 1.1 Tissue distribution of galectins. 
 tissues cells References 
galectin-1 lymphoid organs, muscles, 
kidney, brain, placenta, 
cornea 
thymic epithelial cells, 
neurons, T cells,  
macrophages, B cells 
(Camby et al., 2006; 
Perillo et al., 1997; 
Blaser et al., 1998; 
Zuniga et al., 2001) 
galectin-2 intestine, induced in 
atherosclerotic plaques 
epithelial cells, induced in 
smooth muscle cells, 
macrophages 
(Hokama et al., 
2004; Ozaki et al., 
2004; Hokama et 
al., 2008) 
galectin-3 multiple organs 
(lung, thymus, intestine, 
kidney, pancreas, breast, 
prostate, blood cells) 
epithelial cells, fibroblasts, 
chondrocytes, osteoblasts, 
keratinocytes, dendritic cells, 
neutrophils, basophils, 
eosinophils, mast cells, 
monocytes, macrophages, 
induced in lymphocytes 
(Dumic et al., 2006; 
Openo et al., 2000) 
galectin-4 alimentary tract (particularly 
intestine and colon); 
induced in epithelial cancers  
epithelial cells (Huflejt and Leffler, 
2004; Rechreche et 
al., 1997; Kondoh et 
al., 1999) 
galectin-7 stratified epithelia 
(epidermis, tongue, 
esophagus) 
keratinocytes, epithelial cells, 
induced in T cell lymphoma  
(Madsen et al., 
1995) 
galectin-8 ubiquitous  (Gopalkrishnan et 
al., 2000; Bidon et 
al., 2001) 
galectin-9 peripheral blood leukocytes T cells, induced in 
fibroblasts, endothelial cells 
(Tureci et al., 1997; 
Matsumoto et al., 
1998; Imaizumi et 
al., 2002) 
galectin-10  eosinophils, Treg cells  (Dyer and 
Rosenberg, 1996; 
Kubach et al., 2007) 
galectin-12 adipose tissue, heart, 
pancreas, spleen, thymus,  
adipocytes, leukocytes (Hotta et al., 2001; 
Yang et al., 2001) 
galectin-13 placenta  (Yang et al., 2002) 
 
1.1.3 Functions of galectins 
Depending on their particular structure, galectins can act as bivalent or multivalent 
carbohydrate-binding molecules. In addition to those already having two binding 
sites, one-CRD galectins form non-covalent dimers, while galectin-3 aggregates into 
oligomers via its tandem-repeat region (Ahmad et al., 2004). Such aggregation 
appears to be required for biological activity since monomeric forms do not induce 
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an intracellular signal despite binding to the cells (Dias-Baruffi et al., 2003; Karlsson 
et al., 1998).  
The multivalent structure of galectins allows them to bind different carbohydrate 
moieties of molecules present on the cell surface and in the extracellular matrix. In 
this way galectins can mediate cell adhesion, migration and cell-cell interactions (Liu 
and Rabinovich, 2005). On the other hand cross-linking of glycoreceptors within the 
same cell can initiate intracellular signal transduction (Fig. 1.2). The ability to 
reorganize membrane glycoproteins into lipid rafts may have implications in 
signalling events not directly induced by galectins such as TCR signalling (Miceli et 
al., 2001; Demetriou et al., 2001). It also prevents endocytosis of receptors trapped in 
such surface lattices thereby regulating cell responsiveness to stimuli (Rabinovich et 
al., 2007). In this respect it is interesting to note that many receptors for growth 
factors (eg. epidermal-EGFR, fibroblast-FGFR, insulin-like-IGFR, platelet-derived-
PDGFR) are rich in N-glycans  that are targets for binding by galectins (Lau et al., 
2007). 
In addition to their extracellular roles, galectins can also act inside the cell (Fig.1.2) 
participating in RNA processing in the nucleus (Wang et al., 2004) or regulating cell 
cycle progression (Yang et al., 2001b). Another example is modulation of apoptosis 
via interaction with Bcl-2 family members in the cytoplasm (Yang et al., 1996; Liu et 
al., 2002). These functions of galectins are typically independent of their sugar-
binding activities and rely rather on protein-protein interactions (Rabinovich et al., 
2002). Interestingly, the same galectin (e.g. galectin-3) may exert different and 
opposing effects on a cell depending on whether it acts from the outside or inside of 
the cell (Nangia-Makker et al., 2007; Liu and Rabinovich, 2005). In the first case it 
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can trigger cell death (Rubinstein et al., 2004), in the latter it protects the cell from 
apoptosis (Hoyer et al., 2004).  
 
 
Fig. 1.2 Examples of the biological actions of galectins  
The figure shows mechanisms of action of galectins (cross-linking surface molecules 
or direct protein-protein interactions) as exemplified by galectin-3. Biological effects 
regulated by galectins range from cell adhesion and migration to cell growth, 
differentiation, activation and finally apoptosis.  
 
Adhesion and migration of cells requires coordinated recognition and binding to 
extracellular matrix (ECM) components. Many of these glycoproteins including 
fibronectin and laminin are recognized by galectins. The presence of galectins may 
facilitate cell adhesion by bridging and cross-linking adhesion molecules with the 
matrix or, conversely, cause detachment by saturating the available binding sites  
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(Elola et al., 2007). Binding of galectin-1 or galectin-8 to β1-integrin was shown to 
modulate cell adhesion to laminin and trigger cytoskeleton reorganization (Moiseeva 
et al., 2003). Moreover, engagement of integrins on the cell surface can trigger 
signals regulating cell fate. For example, inhibition of cell adhesion caused by 
galectin-8 induces apoptosis of human carcinoma (Hadari et al., 2000). On the other 
hand, enhanced attachement to extracellular-matrix proteins mediated by galectin-3 
may protect certain cells from death (Matarrese et al., 2000). Galectins can also 
regulate cell-cell interactions as exemplified by an enhancement of dendritic cells 
and naïve T cells interactions in lymph nodes (Swarte et al., 1998). 
 
Many observations implicate a role for galectins in growth regulation of various 
cells. Expression of galectin-3, for example, is related to the proliferative state of the 
cells with marked upregulation in proliferating cells (Yang and Liu, 2003). Their 
growth-promoting effect occurs through induction of cyclin D1 and c-myc oncogene 
(Yoshii et al., 2002; Shimura et al., 2004). Galectins also exert cytostatic effects. 
Galectin-1 can inhibit antigen-induced proliferation of T cells (Blaser et al., 1998). In 
another study, however, it displayed a biphasic effect on cell proliferation which was 
dependant upon its concentration (Adams et al., 1996). The mechanism of growth 
modulation performed by galectin-1 might be through its association with the 
oncogenic protein H-Ras (Paz et al., 2001; Elad-Sfadia et al., 2004). Cell cycle arrest 
was demonstrated for galectin-12 and may be associated with terminal cellular 
differentiation (Yang et al., 2001). 
Both adhesive and growth regulatory properties of galectins are of particular 
importance for tumour development and metastasis. Variations in glycosylation 
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patterns and glycan structures on the surface of tumour cells strongly affect galectin 
binding and functions for these cells (Dube and Bertozzi, 2005; Ohtsubo and Marth, 
2006; Guo et al., 2008; Zhuo et al., 2008). Also the expression of galectins in cancer 
cells is often altered, either increased or lost. The detailed description of these 
alterations is beyond the scope of this thesis and was reviewed elsewhere (van den 
Brule et al., 2004; Berberat et al., 2001; Lahm et al., 2004; Takenaka et al., 2004; 
Huflejt and Leffler, 2004; Kageshita et al., 2002). Also a change in subcellular 
localization of galectins has been observed and related to cancerous phenotype (Liu 
and Rabinovich, 2005).  
 
Cell differentiation is another process where galectins have a role. Changes in the 
expression profile of galectins were reported during the differentiation of myeloid 
cells (Abedin et al., 2003). Progression to neutrophil and eosinophil lineages was 
associated with an increase in galectin-10 transcript, while galectin-3 was 
upregulated during monocyte differentiation. Galectin-7 is a marker for keratinocyte 
differentiation (Saussez and Kiss, 2006) and appears at the time of epidermal 
stratification. As dysregulated differentiation is a feature of cancer, the altered 
expression of galectins seen in many cancers, may be linked to disruption of normal 
cell differentiation. 
Pro-apoptotic properties were demonstrated for the majority of human galectins 
including: galectin-1 (Perillo et al., 1997), galectin-2 (Sturm et al., 2004), galectin-3 
(Fukumori et al., 2003), galectin-7 (Kuwabara et al., 2002), galectin-9 (Kageshita et 
al., 2002; Wada et al., 1997) and galectin-12 (Hotta et al., 2001). The important role 
for galectins in apoptosis of immune cells is discussed in more detail below.  
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1.1.4 Role of galectins in immunomodulation 
A very important feature of galectin family members is their immunomodulatory 
properties and indeed this has been the central focus of this thesis. They act as 
cytokines, chemokines, growth factors as well as delivering cell death or survival 
signals. Since a more detailed description of the functions of galectin-3 and -9 is 
presented in later sections, this passage will primarily focus on other members of the 
galectin family. 
1.1.4.1 Galectins and adaptive immunity 
Galectins were found to have a profound effect on T cell biology. The best studied 
example in this area is galectin-1, an important inducer of T cell apoptosis.  Galectin-
1 is expressed on thymic epithelial cells and takes part in clonal deletion of 
thymocytes during development (Perillo et al., 1997). This process promotes central 
tolerance by eliminating autoreactive lymphocytes. Galectin-1 contributes also to the 
termination of immune responses by inducing programmed cell death in activated but 
not resting T cells (Perillo et al., 1997; Ilarregui et al., 2005). T cell surface 
molecules bound by galectin-1 are CD45, CD43, CD3, CD7 (Pace et al., 2000; Pace 
et al., 1999; Elola et al., 2005). Ligation of these molecules by galectin-1 initiates 
various signalling cascades including death receptor and mitochondrial pathways and 
caspase-independent mechanisms (Matarrese et al., 2005; Brandt et al., 2008; Hahn 
et al., 2004). Further proof for a role of galectins in T cell apoptosis came from a 
study by Toscano et al. which demonstrated that susceptibility of Th1 but not Th2 
cells to galectin-1 induced apoptosis depends on differential glycosylation of surface 
molecules in these cell subpopulations (Toscano et al., 2007). Due to the 
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immunosuppressive role of galectin-1 its overproduction might be used by certain 
tumour cells as a way to escape immune surveillance (Liu and Rabinovich, 2005). In 
normal conditions high expression of galectin-1 was observed at immune-privileged 
sites such as cornea, placenta, testis or brain (Rabinovich et al., 2000) and probably 
serves as a mechanism preventing activated T cell infiltration by induction of 
apoptosis.  
Apart from its apoptotic function, galectin-1 can modulate signalling from T cell 
receptors (TCR) (Chung et al., 2000; Liu et al., 2009) and TCR-directed selection 
(Liu et al., 2008). Cytokine production may also be influenced by galectin-1, 
specifically suppression of IL-2 and IFNγ secretion from activated T cells (Vespa et 
al., 1999; Rabinovich et al., 1999; Camby et al., 2006). 
With regard to other galectins, which overall have received less attention than 
galectins 1 and 3, a pro-apoptotic effect towards T cells was also shown for galectins 
-2 and –9 (Sturm et al., 2004; Wada et al., 1997; Fukumori et al., 2003). 
Interestingly, different surface molecules seem to be utilized by various galectins to 
induce cell death, galectin-3 cross-links CD29 and CD7 (Fukumori et al., 2003) and 
galectin-9 binds to TIM-3 (Zhu et al., 2005). An interesting recent finding is a co-
stimulatory function of galectin-8 for T lymphocytes in the spleen which can induce 
both proliferation and cytokine production by these cells (Tribulatti et al., 2009). 
Galectin-10 has also been identified as a marker for regulatory 
(CD4+CD25+Foxp3+) T cells maintaining their anergic state (Kubach et al., 2007). 
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1.1.4.2 Galectins and innate immunity 
The impact of galectins on immune cells is not limited to T cells and includes 
modulation of chemotaxis. Galectin-3 is a strong chemoattractant towards monocytes 
and macrophages (Sano et al., 2000) and galectin-9 acts on eosinophils (Matsumoto 
et al., 1998). Activation of cells of the innate immune system (neutrophils or 
macrophages) is another of their functions. Release of toxic oxidative metabolites 
(oxidative burst) in primed neutrophils that have transmigrated through the 
endothelium can be induced by both galectin-1 and -3 (Almkvist et al., 2002; 
Karlsson et al., 1998). Furthermore, galectin-3 enhances phagocytic activity of 
macrophages and their production of inflammatory mediators (Sano et al., 2003) and 
opsonizes apoptotic neutrophils to facilitate their clearance (Karlsson et al., 2009). 
Galectin-1 on the other hand modulates expression of receptors for the Fc portion of 
immmunoglobulins (FcγR) which mediate phagocytosis and inhibit the expression of 
major histocompatibility complex (MHC) II molecules which enable macrophages to 
present antigens to T cells (Barrionuevo et al., 2007). In general, these two galectins 
have opposing pro- and anti-inflammatory roles. For example galectin-3 causes 
activation of mast cells, whereas galectin-1 prevents their degranulation (Chen et al., 
2006; Rabinovich et al., 2000). Galectin-1 inhibits neutrophil chemotaxis and 
transendothelial migration (La et al., 2003) while galectins -3 or -8 stimulate this 
process (Sato et al., 2002; Nishi et al., 2003). Some role in pathogen recognition was 
also proposed for galectins as they can bind to non-host carbohydrate structures on 
the surface of various microorganisms (Mey et al., 1996; Sato and Nieminen, 2004; 
Vasta, 2009). 
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Another anti-inflammatory function of galectins is their contribution to the clearance 
of activated immune cells. Treatment with galectin-1 induced exposure of 
phosphatidylserine on the surface of activated neutrophils preparing them for 
recognition by phagocytes (Dias-Baruffi et al., 2003). Similar effect on neutrophils 
but not T cells was reported for galectin-2 and -4 (Stowell et al., 2007). 
1.1.4.3 Galectins and immune pathology 
All these functions of galectins have implications for immune related disease, 
including chronic inflammation, autoimmunity, infection and cancer. Several in vivo 
models have shown a role for galectins in chronic inflammation (Rubinstein et al., 
2004). Anti-inflammatory effects of galectin-1 were documented in collagen-induced 
arthritis (CIA) where administration of this protein suppressed development of the 
disease (Rabinovich et al., 1999). Galectin-1 also prevented experimental 
autoimmune encephalomyelitis (EAE) (Offner et al., 1990), liver injury in 
concanavalin A-induced hepatitis (Santucci et al., 2000) and suppressed colitis 
(Santucci et al., 2003). A beneficial effect of galectin-1 was found in graft-versus-
host disease (GvHD) (Baum et al., 2003).  
On the other hand, a role for galectin-3 in development of airway inflammation has 
been demonstrated in a murine model of asthma (Zuberi et al., 2004; Lopez et al., 
2006). Galectin-3 knock-out animals had attenuated inflammatory responses (Hsu et 
al., 2000). Other studies suggest that it may also play a role in the pathogenesis of 
autoimmune disease (Dumic et al., 2006). Indeed, the severity of autoimmune 
encephalomyelitis in galectin-3 knockout animals was markedly reduced (Jiang et 
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al., 2009). Due to the proposed role for galectin-3 in chronic inflammation this 
galectin will now be discussed in more detail. 
 
1.1.5 Galectin-3 
Galectin-3, described earlier under a variety of names (Mac-2, CBP-35, HL-29, LBP) 
(Dumic et al., 2006), has a unique structure among the galectins. The atypical N-
terminal domain responsible for multimer forming can be selectively cleaved by 
matrix metalloproteinases (MMP-2, MMP-9) (Ochieng et al., 1998a). Such 
modification increases the affinity of the CRD domain but reduces self-aggregation 
and thus impacts upon certain biological properties.  
A characteristic anti-death sequence motif similar to BH1 domain found in Bcl-2 
family proteins is present in galecitn-3 within the carbohydrate-recognition domain 
(Akahani et al., 1997). This explains the association with Bcl-2 proteins and the 
mechanism by which galectin-3 exerts its anti-apoptotic effect (Yang et al., 1996). 
Apart from Bcl-2, other intracellular molecules identified as binding partners for 
galectin-3 include components of signalling pathways: K-Ras, AIP1 or synexin in the 
cytoplasm and Gemin4, carbohydrate binding protein 70 (CBP70) and β-catenin in 
the nucleus (Dumic et al., 2006; Shimura et al., 2004). Transport between these two 
compartments through the nuclear pores depends on phosphorylation of galectin 
(Takenaka et al., 2004) and is mediated by importins (Nakahara et al., 2006). 
Based on the observation that galectin-3 associates with ribonucleoproteins (RNP) of 
the nuclear matrix and the RNA cleavage capacity assayed in a cell-free system, a 
role for galectin-3 in pre-mRNA splicing was put forward (Wang et al., 1995; 
Dagher et al., 1995).  
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In fibroblasts the localization of galecitn-3 in subcellular compartments varies 
depending on the proliferative status of the cell. In quiescent cells it was found 
mostly in the cytoplasm while in dividing cells it translocated to the nucleus (Liu et 
al., 2002). This growth-related localization as well as increased expression in 
proliferating cells implies participation of galectin-3 in regulation of cell 
proliferation. Positive growth regulatory functions on various cells were described 
following transfection of galectin-3 into T cells (Joo et al., 2001) and breast cancer 
cells (Honjo et al., 2001). It was also implicated in control of the cell cycle through 
G1 or G2/M arrest (Lin et al., 2000; Kim et al., 1999b). While intracellular galectin-3 
protects from apoptosis induced by Fas ligation or a broad spectrum protein kinase 
inhibitor staurosporine (Yang et al., 1996) the same protein located exogenously may 
promote cell death, as exemplified by apoptotic effect on T cells (Fukumori et al., 
2003). 
However, most functions described for this galectin seem to amplify rather than shut 
down an inflammatory process and to support this conclusion, elevated levels of 
serum galectin-3 have been reported in various inflammatory diseases, for example 
rheumatoid arthritis (Ohshima et al., 2003) and Behcets disease (Lee et al., 2007). Its 
pro-inflammatory role is indicated by a variety of effects on immune processes. For 
example, galectin-3 facilitates the influx of immune cells into tissues. Interactions of 
circulating leukocytes with endothelium are primarily mediated by selectins and 
integrins but galectins may further strengthen the adherence of these cells to vessel 
walls. It was demonstrated that galectin-3 promotes both neutrophil extravasation 
(Sato et al., 2002) and adhesion to laminin (Kuwabara and Liu, 1996). Furthermore, 
in galectin-3 knockout mice the recruitment of phagocytic cells in response to 
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inflammatory agent was severely impaired (Colnot et al., 1998). Through binding to 
cell surface glycoconjugates galectin-3 also activates various immune cells. 
Respiratory burst in both neutrophils and monocytes is induced in the presence of 
galectin-3 (Karlsson et al., 1998). It also increases neutrophil bacteriostatic and 
phagocytic functions (Farnworth et al., 2008). Another recent finding revealed that 
galectin-3 can reverse the desensitized state of neutrophils caused by chemotactic 
peptide fMLP (formyl-Met.Leu-Phe peptide) (Forsman et al., 2008). Cross-linking of 
IgE receptors, particularly on basophils, triggers degranulation and cytotoxicity 
towards intracellular parasites (Zuberi et al., 1994). 
Macrophages are also recruited to sites of inflammation by galectin-3. It was 
demonstrated that galectin-3 exhibits more potent chemotactic properties for 
monocytes and macrophages than the classical chemokine monocyte chemoattractant 
protein-1 (MCP-1/CCL2) (Sano et al., 2000). In contrast to MCP-1 whose receptor is 
present on monocytes but not macrophages, galectin-3 binds to different surface 
molecules and acts on both cell types. Galectin-3 binding enhances phagocytosis by 
these cells (Sano et al., 2003) and production of cytokines (IL-1) (Jeng et al., 1994; 
Almkvist and Karlsson, 2004). Through binding to CD98 receptor galectin-3 
regulates alternative (i.e. IL-4-induced) macrophage activation (Mackinnon et al., 
2008). Monocyte chemoattraction and induction of various chemokines from 
macrophages was implicated in vascular inflammation of atherosclerosis 
(Papaspyridonos et al., 2008). In addition, galectin-3 was shown to induce mediator 
release by mast cells (Chen et al., 2006) and therefore may play a role in allergic 
reactions. Galectin-3 also affects angiogenesis as it can attract endothelial cells 
(Nangia-Makker et al., 2000). 
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1.1.6 Galectin-9 
Galectin-9 belongs to the tandem-repeat class of galectins i.e. it consists of two 
carbohydrate-recognition domains (CRDs) connected by a link peptide. Frame-shift 
mutations leading to a truncated product with only one functional CRD were found 
in the coding sequence of galectin-9 in some cancer cells (Lahm et al., 2000).  Three 
isoforms that differ in the length of this linker regions have been identified (Chabot 
et al., 2002). These isoforms are thought to arise from alternative splicing of the 
original transcript. The full-length protein may also be post-transcriptionally cleaved 
by enzymes such as thrombin (Nishi et al., 2006). 
Galectin-9, known also as ecalectin, was first described as a selective 
chemoattractant for eosinophils (Matsumoto et al., 1998). New data accumulated 
since the first discoveries indicate that it has much broader functions. Galectin-9 is 
expressed in: endothelial cells, macrophages, T cells (Jurkat) (Spitzenberger et al., 
2001; Chabot et al., 2002). It can be localized both intracellularly and, unusually for 
a galectin, on a cell surface. Release from the cell surface to a soluble form requires 
action of certain matrix metalloproteinases (Hirashima et al., 2004). 
In parallel with identification as an eosinophil chemoattractant, galectin-9 was 
described as a urate transporter in the kidney (Lipkowitz et al., 2004). It functions as 
a voltage-sensitive channel fused into the lipid bilayer and mediates transport of 
urate. This product of purine metobolism is elevated in serum of individuals with 
renal dysfuctions and associated with development of conditions such as gout. 
Mediation of cell adhesion and aggregation was also demonstrated for galectin-9 and 
it has been implicated in the metastatic potential of tumour cells (Kageshita et al., 
2002; Irie et al., 2005). 
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Of relevance to this thesis, galectin-9 also serves a variety of immunological 
functions. It regulates interactions between thymic epithelial cells and thymocytes 
and promotes apoptosis of immature thymocytes (Wada et al., 1997). Similar to 
galectin-1 it induces cell death of mature activated T cells through caspase and 
calpain-dependent pathways (Kashio et al., 2003). The surface receptor that is crucial 
for galectin-9 function is TIM3 (T cell immunoglobulin- and mucin domain-
containing molecule) characteristic for fully differentiated T helper type 1 
lymphocytes (Zhu et al., 2005; van de Weyer et al., 2006). Dysregulation of this 
pathway was documented in autoimmune diseases such as diabetes or multiple 
sclerosis (Koguchi et al., 2006; Hastings et al., 2007). Activation of the galectin-
9/TIM3 pathway was also shown to be important in graft rejection (Naka et al., 
2009). In addition to pro-apoptotic activity, galectin-9 induces differentiation of 
naïve T cells into a regulatory phenotype while inhibiting their development into 
Th17 cells (Seki et al., 2008) and stimulates maturation of dendritic cells with 
production of Th1-type cytokines (Dai et al., 2005). 
 With the emerging role for galectins in immune modulation and inflammatory 
diseases the present study examined galectins in the specific context of rheumatoid 
arthritis. 
 
1.2 Rheumatoid arthritis 
1.2.1 General information 
Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic disease characterised 
by inflammation and destruction of peripheral joints which leads to deformity and 
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disability. It primarily affects small joints of the hands and feet but can progress 
involving other joints in a symmetrical fashion (knee, hip, elbow, shoulder; (Zvaifler, 
2006). RA usually begins over weeks or months with pain, stiffness and swelling of 
the joints. In more advanced disease extra-articular manifestations may be present 
including vasculitis, scleritis, pericarditis, and subcutaneous and pulmonary nodule 
formation (Young and Koduri, 2007). RA prevalence in the adult population 
worldwide is estimated at around 1%. The condition is more common in women then 
in men (ratio 3:1) and the peak onset of the disease is in the fifth decade of life. RA 
is not just a chronic condition that reduces quality of life, it decreases life expectancy 
by 3-10 years (Calvo-Alen and Alarcon, 2006).  
The aetiology of this disease is not fully understood and several factors and pathways 
are implicated in its pathology. Genetic factors predisposing to the occurrence of 
rheumatoid arthritis include certain MHC class II alleles (HLA-DR4-related) sharing 
the same epitope (Gregersen et al., 1987) or the PTPN22 (protein tyrosine 
phosphatase) gene which confers susceptibility to various autoimmune diseases. 
Other candidate gene associations are PADI4 (peptidylarginine deaminase) or 
CTLA4 (cytotoxic T lymphocyte-associated antigen), to name but two (Gregersen et 
al., 2006). Overall the genetic contribution is thought to account for around 30% of 
individual’s susceptibility to RA. Infectious agents have been implicated in the 
aetiology of RA (Toivanen, 2006; Rashid and Ebringer, 2007), though direct 
evidence of infection in affected patients is lacking. It is, however, documented that 
infections may trigger flares of the disease and contribute to its progression (Hyrich 
and Inman, 2001). Hormonal factors are also likely to modulate the susceptibility and 
course of arthritis as suggested by the sex imbalance in the occurrence of RA (Calvo-
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Alen and Alarcon, 2006) and the fact that females experience clinical fluctuations in 
RA symptoms during the menstrual cycle and pregnancy (Cutolo and Lahita, 2005). 
Another environmental factor with an emerging role in the onset of RA is smoking 
(Klareskog et al., 2007; Harrison, 2002; Lundstrom et al., 2009). 
Rheumatoid arthritis, as defined by the ARA criteria modified in 1987 (Arnett et al., 
1988), appears as a group of heterogeneous conditions with varied clinical courses 
and outcomes. The disease ranges from mild non-erosive arthritis to a progressive 
multisystem disorder (Lee and Weinblatt, 2001). The most common features used in 
diagnosis are serum positivity for rheumatoid factor (RF) which is an antibody 
reacting with Fc portions of autologous IgG molecules and antibodies against cyclic 
citrullinated peptides (anti-CCP) (Nielen et al., 2004; Raza et al., 2005b).  
1.2.2 Histopathology of RA 
The most characteristic histological feature of the rheumatoid joint is the hypertrophy 
of the synovial membrane accompanied by persistent leukocyte infiltrate and 
increased synovial fluid volume. The synovial membrane is normally a thin (1-3 cells 
thick) layer which lines the non-cartilaginous surfaces of the joint cavity. Two types 
of cells can be distinguished in this intimal lining layer, namely macrophage-like 
synoviocytes (or type A) and fibroblast-like synoviocytes (or type B, referred to later 
as synovial fibroblasts).  The sublining layer is composed mainly of extracellular 
matrix with scattered blood and lymphatic vessels, adipocytes and fibroblasts (Tak, 
2006).  
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Fig. 1.3 Schematic representation of joint structure in health and disease.  
Left side represents normal joint structure, right side changes that occur in 
rheumatoid arthritis which include pannus invading cartilage and bone, outgrowth of 
synovial tissue into the joint cavity and presence of infiltrate consisting of various 
immune cells. 
 
In RA the synovium becomes hyperplastic, overgrows into the joint cavity and 
invades local articular structures along with the underlying bone. This aggressive 
tissue, often called pannus, is able to destroy components of the extracellular matrix 
via expression of degradative enzymes, including metalloproteinases, serine 
proteases and aggrecanases (Firestein, 2003; Rengel et al., 2007). The rheumatoid 
joint is also heavily infiltrated with immune cells.  Neutrophils are present in large 
numbers in the synovial fluid (Edwards and Hallett, 1997). Monocytes, plasma cells, 
T and B lymphocytes increase the cellularity of the sublining layer (Fig.1.3). 
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Follicular dendritic cells as well as mast cells can also be found in the rheumatoid 
synovium. There is marked formation of new blood vessels (neoangiogenesis) which 
provide oxygen and nutrients to support the expanded tissue (Paleolog, 2002). Of 
interest, microvessels in rheumatoid synovial tissue closely resemble those found in 
the lymph nodes (Szekanecz and Koch, 2000). This abnormal vascular structure may 
facilitate pathological homing and transmigration of leukocytes into the synovium. 
Moreover, the expanded endothelial cell themselves are capable of cytokine 
production and leukocyte recruitment (Szekanecz and Koch, 2000) and therefore 
contribute to persistence of disease.   
 
As mentioned previously, RA is emerging as a heterogenous disease and this is also 
reflected in its histological picture (Weyand and Goronzy, 2003). Distinct types of 
leukocyte synovial infiltrate have been described (Takemura et al., 2001). In some 
cases infiltrating T and B lymphocytes may acquire a high degree of cellular 
organization forming follicles with germinal centre (GC) reactions, i.e. similar to 
those arising in secondary lymphoid tissues during antigen-specific responses. 
Indeed these lymphoid microstructures in the synovium resemble those found in 
peripheral lymph nodes and have been named tertiary lymphoid tissue. In another 
pattern of lymphocytic infiltrate T cells and B cells form aggregates but without 
follicular dendritic cells inside and therefore lacking germinal centre reactions. The 
third subtype is characterized by a diffuse distribution of lymphocytes without 
apparent clustering. These distinct phenotypes of lymphoid architecture in the 
synovium are associated with differences in production of cytokines and chemokines 
(Klimiuk et al., 1997; Klimiuk et al., 2005) which further influences clinical 
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parameters and outcome. For example, the type with the highest organisation of 
lymphoid infiltrate with GC-like follicles correlates with an aggressive disease and 
was not observed in seronegative patients (i.e. patients without detectable rheumatoid 
factor) (Silverman, 2006).  It is not established whether these histological patterns 
change over time or with the disease progression.  
1.2.3 Components of the inflammatory infiltrate 
Neutrophils 
Neutrophils are part of the innate immune system and possess potent phagocytic and 
anti-microbial functions. They are normally short-lived cells but their life span can 
be increased when recruited to the sites of inflammation. In the synovial fluid of 
patients with active rheumatoid arthritis neutrophils constitute the most abundant cell 
type  (Edwards and Hallett, 1997). Interestingly, they are scarce in the synovial tissue 
itself with the exception of the cartilage-pannus junction which is the primary site of 
erosion (Tak et al., 1997). The relative absence of neutrophils from the synovium 
may result from specific expression of integrin receptors which would promote 
migration of the cells through the tissue (Gao and Issekutz, 1997) rather than retain 
them inside. In order for neutrophils to migrate into sites of inflammation they have 
to be previously activated. Such activation may occur via receptors for constant 
region of immunoglobulins (Fc receptors) (Edwards et al., 1997) and may be 
triggered by immune complexes (Coxon et al., 2001). In RA patients immune 
complexes (formed by antigens cross-linked by multivalent antibodies) were found 
both in the joint deposited on cartilage as well as in the circulation (Mageed et al., 
1991). It was also shown that cytokines present in the rheumatoid joint enhance 
neutrophil activation by immune complexes (Fossati et al., 2002). Once in the joint 
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neutrophils contribute to the local production of proinflammatory cytokines such as 
tumour necrosis factor (TNFα), interleukin-1 (IL-1), IL-6 and chemokines: CXCL8 
(IL-8), CCL3 (MIP-1α), CCL4 (macrophage inhibitory protein, MIP-1β), CXCL1 
(growth regulated oncogene, GROα) (Cassatella et al., 1997; Scapini et al., 2000). In 
addition, neutrophils’ release of reactive oxygen intermediates and granule 
constituents can create a toxic microenvironment in the joint space. These 
polymorphonuclear leukocytes contain a variety of potent degradative enzymes in 
their intracellular granules (procollagenase, elastase, gelatinase) which are capable of 
cartilage destruction (Hilbert et al., 2002; Velvart and Fehr, 1987). On the other 
hand, reactive oxidants may cause damage to various biological molecules. For 
example, degradation of proteoglycans and hyaluronate by hypochloric acid was 
shown to decrease synovial fluid viscosity and hence its lubricative properties 
(Schiller et al., 1996).  
A critical role for neutrophils was shown in animal models of autoantibody-mediated 
arthritis (Wipke and Allen, 2001) where depletion of these cells prevented the onset 
of joint inflammation. 
 
Macrophages 
Another cell type that contributes considerably to inflammation and joint damage in 
RA is the macrophage. Macrophage population in the inflamed synovial membrane 
is significantly expanded and their numbers correlate with radiological progression 
of joint destruction (Mulherin et al., 1996). Moreover, they show an activated 
phenotype as defined by expression of MHC class II molecules and production of 
inflammatory mediators (Kinne et al., 2007).  Two subpopulations of macrophages 
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have been described based on differential expression of  proinflammatory and 
regulatory cytokines (Mills et al., 2000). An important function for macrophages is 
the clearance of apoptotic cells and immune complexes (Blom et al., 2003). The 
expression of receptors for the latter (FcγRIIIa) seems to be unique for synovial 
macrophages in RA. Macrophages take part in antigen presentation and activation of 
T cells (McInnes et al., 2000; Brennan and Foey, 2002). Interactions of these two 
cells types has a major role in induction of TNFα (Brennan and Foey, 2002). As 
already mentioned, in the synovial membrane macrophages are the major source of 
TNFα. However, they also generate a large array of other mediators including 
interleukins: 1, 6, 15, GM-CSF (granulocyte-macrophage colony stimulating factor), 
CXCL8, CCL2, CCL3, proinflammatory prostaglandins and leukotrienes, to name 
but a few (Szekanecz and Koch, 2007). These mediators are involved in crucial 
pathological processes such as recruitment of other inflammatory cells, activation of 
synovial fibroblasts or development of new blood vessels. Macrophages produce also 
anti-inflammatory cytokine IL-10 and IL-1receptor antagonist (IL-1Ra) which 
normally take part in termination of an inflammatory response. The  perpetuation of 
the disease depends on the balance between these signals in RA synovium (Miossec, 
2004). 
Although the production of matrix metalloproteinases (MMP-9, MMP-12) elaborated 
by a macrophage population may have little effect on degradation of cartilage matrix 
components, these cells are regarded as important amplifiers of the destruction 
mediated by fibroblasts (Kinne et al., 2006). Indeed contact of these two cell types 
enhances the production of mediators such as IL-6, IL-8 or GM-CSF (Chomarat et 
al., 1995). Another possibility of macrophages’ contribution to joint destruction is 
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their differentiation, under the influence of receptor activator of NFκB ligand 
(RANKL), into osteoclasts responsible for bone resorption (Danks et al., 2002).  
T cells 
T cells are present in the synovium in large numbers particularly in areas surrounding 
blood vessels. It is proposed that the transition of T cells to the synovium may occur 
in an antigen-independent way and be triggered by non-specific cytokine stimulation 
(Zhang et al., 2005).  Synovial T cells are distinct in many respects from peripheral 
blood T cells. They display higher CD4+/CD8+ ratio (Tak, 2006) and consist mostly 
of memory cell as characterised by the expression of CD45RO molecule (Potocnik et 
al., 1990). They express activation markers such as HLA-DR, CD27, VLA-1 (very 
late antigen), CD69, CD28 and CD40 ligand (CD40L) (Kinne et al., 1997) but show 
little or no proliferation in this microenvironment (Salmon et al., 1997). Another 
alteration observed in RA patients is the restricted repertoire of T cell receptors in 
resting cells (Wagner et al., 1998; Goronzy et al., 1998). This reduced diversity in 
TCR repertoire is likely to result from premature senescence of these cells (Goronzy 
and Weyand, 2003) Signalling from antigen T cell receptors may also be defective 
(Maurice et al., 1997) although this has recently been questioned as an ex vivo effect 
(Abreu et al., 2009). The fact that RA in many cases is associated with certain major 
histocompatibility complex (MHC II) haplotypes that present antigens to T cells led 
to the hypothesis of a central role of T cells in RA pathogenesis. However, no 
definite arthritogenic peptide has been found although few candidates such as type II 
collagen, citrullinated peptides or heat shock proteins can potentially bind to the 
‘shared epitope’ (Fox, 2009; Kinne et al., 1997). Other autoantigens proposed for RA 
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pathology are cartilage link protein, proteoglycan, cartilage glycoprotein gp39 (de 
Jong H. et al., 2009; Kotzin et al., 2000; Tsark et al., 2002). 
Most T cells in the rheumatoid joint are of the type 1 helper cells (Th1) (Yamada et 
al., 2007; van Amelsfort et al., 2004). T cells with regulatory functions 
(CD4+CD25+Foxp3+) also seem to be present in RA synovial fluid but are not fully 
functional (van Amelsfort et al., 2004). Remarkably, only small amounts of T cell-
derived cytokines such as IL-2, IL-4 or IFNγ were detected in synovial fluid from 
established disease indicating low T cell activity (Firestein and Zvaifler, 2002; 
Feldmann et al., 1996). However, for the perpetuation of an inflammatory process T 
lymphocytes are of crucial importance. Their interaction with synovial macrophages 
drives TNFα production (Brennan and Foey, 2002) and fibroblasts are stimulated to 
secrete IL-6, IL-8 or prostaglandin E (PGE2) (Yamamura et al., 2001). A factor 
significantly contributing to synovial activation is IL-17 produced by a subset of T 
cells named Th17 (Chabaud et al., 1999; Toh and Miossec, 2007; Stamp et al., 2004).  
Particularly high levels of this interleukin were found in RA synovial fluid 
(Ziolkowska et al., 2000; Kotake et al., 1999). T cell are also capable of activating 
osteoclasts via expression of RANK-ligand (also known as osteoclast differentiation 
factor, ODF) (Goldring and Gravallese, 2000).  
The importance of T cells in the initiation of rheumatic disease is a matter of debate 
in the literature as some animal models show T cell independence in the early stages 
(Firestein and Zvaifler, 2002). Also T cell-directed  therapies showed little success 
although inhibition of co-stimulation by CTLA4-Ig (cytotoxic T lymphocyte antigen-
4 bound to immunoglobulin heavy chain) proved to be a more promising approach 
(Buch et al., 2008; Smolen et al., 2007). 
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B cells 
B cells are found in the synovium in lower numbers than T cells or macrophages, 
however they have important functions in the pathogenesis of disease. They can 
proliferate locally in the synovium, particularly within the follicle-like structures and 
mature into plasma cells. These terminally differentiated cells synthesize and secrete 
rheumatoid factor and other autoantibodies that subsequently form immune 
complexes (Schroder et al., 1996; Kim et al., 1999a). It was found that B cells 
express on their surface lymphotoxin-α and thereby contribute to the formation of the 
ectopic germinal centres (Fu et al., 1998). B cells are responsible for maintenance of 
memory response to autoantigens. Furthermore, they have a capacity for antigen 
presentation to T cells and provide co-stimulatory signals for their activation 
(Silverman, 2006). Synthesis of chemokines that induce leukocytes infiltration and 
factors that sustain angiogenesis constitute an additional mechanism in the 
pathogenesis of synovial inflammation (Mauri and Ehrenstein, 2007). The 
importance of B cell was shown by improvement in disease scores following B cell-
depleting therapies with an anti-CD20 antibody (Edwards et al., 2004).  
 
Dendritic cells 
Dendritic cells are the most potent antigen-presenting cells. They are found in 
rheumatoid synovium (Page et al., 2002) particularly within the aggregates of T and 
B cells and in perivascular lymphocytic areas (Pettit et al., 2000). It is generally 
accepted that under normal conditions dendritic cells migrate from local tissues to 
lymph nodes. A possible cause for their retention in the synovial tissue is the 
expression of ligands for lymph node-homing receptor CCR7 such as CCL19 and 
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CCL21 by rheumatoid synovial fibroblasts (Page et al., 2002). Dendritic cells in the 
synovium serve primarily as antigen-presenting cells for memory T cells as 
suggested by their localization in close proximity to CD4+ T cells (Tak, 2006). 
Follicular dendritic cells (FDCs) also play a role in the accumulation of B cells and 
their differentiation into plasma cells (Schroder et al., 1996b) thereby promoting 
humoral immune responses. Production of cytokines and chemokines (eg. IL-1β, 
TNFα, CCL3, CCL4) by dendritic cells is another feature regulating the 
inflammatory process (Foti et al., 2004). Finally, in the rheumatoid 
microenvironment they may transdifferentiate into osteoclasts (Rivollier et al., 2004). 
 
Taken together this cellular inflammatory infiltrate, among other functions,  drives 
the local cytokine production and leads to persistence of the disease processes 
(McInnes and Schett, 2007);Buckley 2003b). It is becoming apparent that resident 
synovial fibroblasts play an important role in the retention of immune cells in the 
inflamed joint (Huber et al., 2006). Their contribution to the perpetuation of the 
disease will be described in later sections. 
 
1.3 Osteoarthritis 
Osteoarthritis (OA) is another most common cause of joint dysfunction and 
disability. In contrast to RA, pathological changes involve mainly large, weigh-
bearing joints (hips, knees). The main feature of the disease is joint space narrowing, 
cartilage mineralization and new bone formation (osteophytes) within the joint that 
impairs its function. Although the mechanisms leading to cartilage loss are not 
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entirely understood, biomechanical factors such as usage and trauma are believed to 
play a main role in its pathology (Samuels et al., 2008).  
Osteoarthritis used to be regarded as a non-inflammatory disease and as such 
opposed to RA.  However, the inflammatory component is not entirely absent and 
markers of inflammation such as raised levels of C-reactive protein (CRP) or 
hyaluronic acid are often associated with active disease (Pelletier et al., 2001). It is 
unclear whether the inflammatory episodes observed during the course of the disease 
are primary events or whether they result from other destructive changes. Moreover, 
at later stages of the disease, the histopathological picture of synovitis may be 
indistinguishable from RA (Samuels et al., 2008). Cytokines and chemokines 
characteristic for RA such as TNFα, IL-1 or IL-6, are also present in OA although at 
lower levels (Farahat et al., 1993; Smith et al., 1997a) which likely results from 
lower density of inflammatory infiltrate.  
1.4 Fibroblasts 
1.4.1 Fibroblasts and the immune system 
Fibroblasts are the most important cell type constituting tissue stroma. They are 
responsible for extracellular matrix synthesis, degradation and rebuilding of the 
tissue during wound healing. However, their function is not limited to providing 
structural scaffold for tissues and organs. Fibroblasts may also be considered as part 
of the immune system (Smith et al., 1997b). They express a wide variety of 
receptors, adhesion molecules and immune mediators, which enable them to sense 
danger signals in the environment, interact with other immune cells and regulate their 
behaviour. For example, recruitment of immune cells is mediated by 
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chemoattractants such as CXCL8 (IL-8), CCL3 (MIP-1α), CCL2 (MCP-1), CCL5 
(RANTES) (Brouty-Boye et al., 2000; Kontoyiannis and Kollias, 2000). As well as 
initiating inflammation by recruiting leukocytes to the site of tissue injury, 
fibroblasts may provide signals for retention, differentiation, survival and exit to the 
infiltrating cells when their presence is no longer required (Parsonage et al., 2005; 
Smith et al., 1997b). Crucial molecules that support leukocyte survival are CXCL-12 
(stromal-derived factor-1, SDF-1), CXCL-13 (B cell-attracting chemokine-1, BCA-
1), CCL-21 (Bradfield et al., 2003; Parsonage et al., 2005; Buckley, 2003b), type 1 
interferons (Pilling et al., 1999; Wang et al., 2003) and co-stimulation is provided by 
CD40 or CD106 (Buckley et al., 2004a; Brouty-Boye et al., 2000). At the end of an 
inflammatory response effector cells have to be cleared from the affected site to 
allow it to re-establish its normal integrity and function (Buckley, 2003a). It is 
plausible to hypothesise that by withdrawing their survival signals fibroblasts would 
play a pivotal role in the resolution phase. Fibroblasts also have the capacity to 
produce anti-inflammatory mediators limiting the acute inflammatory response such 
as IL-10, TGFβ (transforming growth factor), soluble TNF receptor (Ritchlin, 2000). 
As described above fibroblasts play an important role during the inflammatory 
reaction as well as in its resolution, therefore it seems likely that, any alterations in 
their behaviour may lead to persistence of inflammatory state and pathology. The 
consequences of disordered fibroblast behaviour are clearly seen in chronic diseases 
such as rheumatoid arthritis. 
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1.4.2 Fibroblast diversity 
Fibroblasts from different anatomical sites have distinctive features depending on 
their site of origin (Parsonage et al., 2005). These differences appear remarkably 
stable and are likely reflect variable demands of certain tissue types. Global 
transcriptome analysis showed that fibroblasts can be clustered into groups defined 
by anatomical site (Chang et al., 2002; Rinn et al., 2006). Moreover, even within one 
tissue (e.g. lung or spleen) fibroblasts were found to be heterogeneous in surface 
marker expression, matrix protein production and proliferation (Borrello and Phipps, 
1996; Fries et al., 1994). Several studies of fibroblast transcriptomes have revealed 
distinct expression patterns of cytokines and chemokines and variable levels of co-
stimulatory molecules (Buckley et al., 2004; Buckley, 2003c; Parsonage et al., 2003; 
Chang et al., 2002; Brouty-Boye et al., 2000) Such properties largely affect 
immunoregulatory functions of fibroblasts and therefore tissue-specificity of immune 
responses. Unlike other cell types, for example endothelial cells, which revert to a 
common phenotype when grown in vitro (Garlanda and Dejana, 1997), the tissue 
specific characteristic phenotypes of fibroblast are retained even when cells are 
cultured for several passages (Smith et al., 1997b; Chang et al., 2002) This implies 
existence of an imprinted ‘memory’ of their tissue identity.  
The capacity of fibroblasts to modulate inflammation may also be influenced by 
external stimuli. Treatment with inflammatory cytokines changed the pattern of gene 
expression in fibroblasts of different origin (Parsonage et al., 2003). For example, 
TNF-α induced production of IL-6, IL-8 and CCL2 (MCP-1) in synovial but not skin 
fibroblasts. Conversely, skin fibroblasts responded in a similar way upon stimulation 
with a Th2-type cytokine, IL-4. This recent evidence suggests that differences in 
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stromal cell phenotype and behaviour may explain a predilection of chronic 
inflammatory reactions for certain sites within the body (Filer et al., 2006b). 
 
1.5 Synovial fibroblasts in rheumatoid arthritis 
Apart from the inflammatory infiltrate present in the synovium, the predominant 
feature of active RA is an increase in synovial fibroblast numbers. The initial events 
underlying this process have not been defined. It is interesting to note that fibroblast 
tissue expansion may occur even before chronic inflammation becomes clinically 
evident and may therefore represent a rational therapeutic target in early arthritis 
(Ospelt et al., 2004b).    
1.5.1 Activation of synovial fibroblasts 
Rheumatoid synovial fibroblasts show increased metabolic activity and a 
characteristic activated phenotype, reflected by changes to the normal spindle-shaped 
cytoskeleton, dense rough endoplasmic reticulum (RER) and large nucleus with 
prominent nucleoli indicating both active RNA metabolism and protein production 
(Muller-Ladner and Gay, 2006). Indeed a constitutive overproduction of matrix 
proteins and various cytokines by rheumatoid synovial fibroblasts has been noted 
(Pap et al., 2006; Bucala et al., 1991). Inflammatory cytokines secreted by fibroblasts 
in the synovium include IL-1β, IL-6, IL-7, IL-15,  IL-16, lymphotoxin β (LTβ), type 
1 IFN, or GM-CSF, whereas chemokines among others include CCL3 (MIP-1a), 
CCL2 (MCP-1) and CCL5 (RANTES) (McInnes and Schett, 2007; Lally et al., 2005; 
Ritchlin, 2000). All these mediators display potent abilities to attract and activate 
immune cells. Fibroblasts in the inflamed synovium are also targeted by stimuli 
 34
derived from infiltrating leukocytes such as IL-1β, TNF-α or IL-17 (McInnes and 
Schett, 2007) and this inflammatory microenvironment further activates them and 
perpetuates the disease process. In addition to having a role in the crosstalk between 
fibroblasts and other cell types in the synovium these cytokines provide constant 
autocrine stimulation and survival signals for synovial fibroblasts.  
Cell-cell interactions with recruited immune cells are facilitated by up-regulated 
adhesion molecules. For example a member of immunoglobulin family, CD106 
(vascular cell adhesion molecule-1, VCAM-1) mediates cell contact with B cells 
(Bradfield et al., 2003; Burger et al., 2001). More importantly adhesion molecules 
enable strong adhesion of fibroblasts to extracellular matrix. This attachment to 
cartilage and bone is a characteristic feature of RA synovial fibroblasts and 
distinguishes them from other forms of arthritides (Pap et al., 2006). Interactions 
allowing for attachment to components of cartilage such as collagens and cartilage 
oligomeric matrix protein (COMP) are mediated mainly by integrins, subunits α3-5 
(very late antigen, VLA 3-5) and β1 (Huber et al., 2006; Rinaldi et al., 1997). Upon 
adhesion integrins activate signalling pathways within the cell regulating early cell 
cycle genes such as c-fos and c-myc and activate expression of matrix 
metalloproteinases (Schwartz, 1997; Sarkissian and Lafyatis, 1999). Interesting 
findings in the biology of rheumatoid synovial fibroblast came from studies in severe 
combined immunodeficient (SCID) mice (Muller-Ladner et al., 1996). This animal 
model displays severe defects in both cellular and humoral immune responses which 
make it unable to reject implants. Co-implantation of synovial fibroblasts from RA 
patients with normal human cartilage into SCID mouse revealed that invasion of RA 
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fibroblasts can occur even in the absence of inflammatory cells or other mediators. 
Fibroblasts from skin or osteoarthritic synovium did not show such properties.    
Invasion into the cartilage proves the destructive potential of rheumatoid fibroblasts. 
This process is mediated by matrix degrading enzymes from various families: matrix 
metalloproteinases (MMPs), cathepsins and activated plasmin system. MMPs 
expressed by synovial fibroblasts include  collagenases (MMP-1, MMP-13), 
stromelysin (MMP-3) and gelatinases (MMP-2, MMP-9) as well as some membrane 
bound forms (Pap et al., 2000; Konttinen et al., 1999).  Apart from their role in tissue 
remodelling, matrix metalloproteinases are also involved in regulation of cytokines 
or other MMPs i.e. their activation from precursor forms by cleavage (Ra and Parks, 
2007).  
Joint destruction can also occur via proteolytic enzymes called cathepsins. Members 
of this family of cysteine proteases which are up-regulated in RA include cathepsins 
B, D, L or K (Keyszer et al., 1998; Hummel et al., 1998). They degrade collagen and 
proteoglycans and have also been linked to activation of proto-oncogenes.  
Activation of plasminogen system provides yet another route for matrix degradation. 
RA synovial fibroblasts synthesize high amounts of urokinase-plasminogen activator 
(u-PA) and the resulting active serine protease plasmin exerts direct proteolytic effect 
both on matrix components and pro-MMPs (Muller-Ladner and Gay, 2006). 
Invasiveness of rheumatoid fibroblasts varies among individuals and correlates with 
the rate of joint erosions (Tolboom et al., 2005). 
Angiogenesis is another hallmark of the inflamed synovial tissue (Huber et al., 
2006). Synovial fibroblasts are capable of promoting this process by secreting 
growth factors of which the most important is vascular endothelial growth factor 
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(VEGF) (Ritchlin, 2000; Sone et al., 2001). VEGF expression is further enhanced by 
low oxygen tensions which were reported in RA joint (Gaber et al., 2005). Other 
fibroblast-produced mediators of vascularization include transforming growth factor 
beta (TGFβ), fibroblast growth factor (FGF) and platelet-derived growth factor 
(PDGF), the latter two having potent proliferative activities on fibroblasts as well 
(Muller-Ladner and Gay, 2006). Effector molecules secreted by synovial fibroblasts 
include also arachidonic acid-derivative prostaglandin E2 (PGE2) – a potent mediator 
of inflammation (Alsalameh et al., 2003) or osteoclast-activating RANKL (Nakano 
et al., 2004). 
Recently a role for conserved pattern recognition receptors (Toll-like receptors, 
TLRs) in the activation of synovial fibroblasts has been recognised suggesting a 
possible role for an innate immune system in the early events of the disease. Ligation 
of these receptors can induce expression of adhesion molecules in fibroblasts (eg. 
intracellular adhesion molecule-1, ICAM-1), matrix degrading enzymes (MMP-1, -3, 
-13),  proinflammatory cytokines such as IL-1 and TNFα  and chemokines attracting 
inflammatory cells to the  synovium (Kyburz et al., 2003; Pierer et al., 2004; 
Brentano et al., 2005).  A role for these receptors in the onset of synovitis is further 
suggested by animal models of arthritis induced by bacterial products (Liu et al., 
2001).   
1.5.2 Transformed phenotype of RA synovial fibroblasts 
The altered behaviour of fibroblasts is, however, not a mere response to cytokines or 
other external stimuli. There seem to be a number of intrinsic alterations in 
rheumatoid synovial fibroblasts often referred to as a transformed phenotype. Even 
in the absence of continuous external stimulation these cells show a range of 
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molecular changes including alterations in expression of regulatory genes, signalling 
cascades as well as apoptotic pathways (Burman et al., 2005; Pap et al., 2000b). One 
of the constitutively overexpressed proto-oncogene is egr-1 (early response gene-1) 
which regulates transcription of several other genes relevant to RA pathology, for 
example cathepsin L (Pap et al., 2006). c-fos which forms part of AP-1 transcription 
complex and activates transcription of MMPs was also found to be up-regulated in 
RA synovial fibroblasts (Asahara et al., 1997; Benbow and Brinckerhoff, 1997). A 
number of other oncogenes including ras, raf, myb, myc were detected in synovial 
cells, particularly those attaching to cartilage and bone (Pap et al., 2006) which 
further proves their relevance for the aggressive  behaviour (Pap et al., 2004).  
On the other hand tumour suppressor PTEN involved in focal adhesion regulation 
was absent from invasive fibroblasts (Tamura et al., 1998; Pap et al., 2000a). 
Another remarkable feature is the high activation of  nuclear factor κB (NFκB) 
(Miagkov et al., 1998; Li and Makarov, 2006) which likely contributes to 
perpetuation of disease. This ubiquitously expressed transcription factor is normally 
retained in the cytoplasm by its counterpart IκB. Translocation of the released NFκB 
to the nucleus of RA synovial fibroblasts results in binding to promoters of its target 
genes such as IL-6, IL-8, CCL2, CCL5, CD40, MMP, cyclooxygenase-2 or 
plasminogen activator (u-PA) (Huber et al., 2006; Roman-Blas and Jimenez, 2006). 
TNFα and IL-1 are important activators of NFκB-dependent pathways (Fujisawa et 
al., 1996). 
RA synovial fibroblasts display also characteristic alterations in cell death pathways 
and the rate of apoptosis in the activated cell population is very low (less then 3%) 
(Matsumoto et al., 1996). They are relatively resistant to apoptosis induced by 
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ligation of the surface death receptor Fas, though this depends on presence of other 
stimuli as well as stage of the cell cycle (Perlman et al., 2001; Kobayashi et al., 2000; 
Pundt et al., 2009). This phenomenon might result from an increased expression of 
anti-apoptotic FLIP protein (FADD-like interleukin-1 beta-converting enzyme -
inhibitory protein). Inhibitors of the mitochondrial pathway of apoptosis such as Bcl-
2 may also be up-regulated (Matsumoto et al., 1996). Other survival proteins that are 
aberrantly expressed are heat-shock protein 70 (HSP70), sentrin and sumoylated 
proteins (Pap et al., 2000b).  
In addition to dysregulated signalling pathways some chromosomal abnormalities 
similar to alterations in malignant transformation were observed in synovial cells 
(Kinne et al., 2003). The phenotype of rheumatoid synovial fibroblasts indeed 
resembles that of transformed cells with an anchorage-independent growth, loss of 
contact inhibition and increased proliferation (Meyer et al., 2006; Li and Makarov, 
2006; Ritchlin, 2000; Lafyatis et al., 1989). This phenotype is maintained in culture 
(Pap et al., 2000b; Zimmermann et al., 2001) and favours the hypothesis of its 
intrinsic cytokine-independent character. Similarly, the aggressive behaviour and 
invasion into cartilage occurs in the absence of external stimuli (Muller-Ladner et al., 
1996).  
1.5.3 Synovial fibroblasts in rheumatoid arthritis and osteoarthritis 
Synovial fibroblasts from osteoarthritis patients are often used as comparators to RA 
fibroblasts. They lack the invasive properties of RA synovial fibroblasts and appear 
less activated in vivo. In culture OA fibroblast show some similarities in  responses 
to stimuli (cytokine or chemokine expression) (Cheon et al., 2002; Pierer et al., 2004) 
which may reflect some generic site-determined properties. Nevertheless there are 
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also a number of differences in expression of genes, including proto-oncogenes, 
between RA and OA synovial fibroblasts (Scaife et al., 2004; Seki et al., 1998).  The 
fact that these differences are maintained in culture (Zimmermann et al., 2001; 
Ritchlin et al., 1994) supports the existence of a distinctive rheumatoid phenotype 
characterized by stable activation. 
 
1.5.4 Interactions of fibroblasts with immune cells in the rheumatoid joint 
The first event triggering joint inflammation in human RA is not known. However, it 
is well established that for the development and persistence of an inflammatory state 
a concerted action of synovial fibroblasts and various immune cells is needed. This 
interplay includes secretion of soluble mediators on the one hand and direct cell-cell 
interactions on the other. Multiple cytokines, chemokines, growth factors and other 
mediators present in RA synovial tissue comprise a complex network where many 
factors show synergistic or complementary effects. Due to their large secretory 
capacity fibroblasts and macrophages are the primary producers of many 
inflammatory mediators. Nevertheless, other cells, for example T cells, also 
contribute to production of cytokines and establishment of the specific inflammatory 
milieu.  
In the disordered synovial  microenvironment fibroblasts interact with a wide variety 
of leukocyte subtypes promoting their survival and accumulation (Buckley et al., 
2001). Moreover, such interactions are largely reciprocal and affect both cells 
involved. An example is the crosstalk between fibroblasts and T cells occurring via 
CD40/CD40L system. Engagement of the receptor by a ligand provided by activated 
T cells results in increased production of chemokines , adhesion molecules (ICAM-1, 
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VCAM-1) and proliferation of fibroblasts (Min et al., 2004; Rissoan et al., 1996). T 
cells can also induce production of IL-6, IL-8 or PGE2 from synovial fibroblasts  as 
well as matrix metalloproteinases (Yamamura et al., 2001; Schurigt et al., 2008). 
Fibroblasts in turn release the potent T cell chemoattractant IL-16 which facilitates 
influx of lymphocytes into synovial tissue (Franz et al., 1998).  They also activate T 
cells via secreted interleukins IL-7, IL-15 or IL-18 (McInnes et al., 2000; Tran et al., 
2005) therefore many positive feedback loops exist between these cells. Furthermore, 
fibroblasts in the synovium have the capacity to present antigens to T lymphocytes 
(Tran et al., 2007). 
Synovial fibroblasts also promote homing, maturation and survival of B cells in the 
synovium. Crucial for these interaction and protection of B cells from apoptosis are 
the constitutively expressed chemokine CXCL12 (SDF-1) and adhesion molecule 
CD106 (VCAM-1) (Burger et al., 2001). Another study revealed that RA synovial 
fibroblasts exhibit follicular dendritic cell (FDC) activity and may play an active role 
in ectopic germinal centre formation (Lindhout et al., 1999). 
Fibroblasts’ interactions with resident or blood-derived macrophages are also of 
crucial importance for the inflammatory process. Chemokines released by fibroblasts 
such as CCL2(MCP-1) or CCL3 (MIP-1α) are major factors attracting  monocytes 
into the synovium (Smith et al., 1997b). Macrophages in turn elaborate fibroblast-
activating cytokines TNFα and IL-1β (Szekanecz and Koch, 2007). Their 
contribution to joint degradation processes has already been described.  
In addition to stimulating leukocyte recruitment and activation in the synovium 
fibroblasts have a capacity to retain them at this site by providing survival signals. T 
cell survival is crucially dependent on the interaction with surrounding stromal cells 
 41
as the autocrine production of IL-2 is very low. It has been shown that co-culture 
with fibroblasts from rheumatoid synovium provides such signals for synovial T cells 
(Salmon et al., 1997). Soluble interferon α and β  secreted by stromal cells induce up-
regulation of anti-apoptotic Bcl-xL in T cells and can rescue them from cell death 
(Pilling et al., 1999; Gombert et al., 1996). Interestingly, synovial fibroblasts seem to 
be much more potent in supporting T cell survival than those derived from skin 
providing possible explanation for specific accumulation of leukocytes in this 
microenvironment (Filer, 2006).  
Neutrophil survival at the site of inflammation is also increased by the interaction 
with stromal fibroblasts. Adhesion molecule VCAM-1 present on the surface of 
fibroblasts has been shown to mediate neutrophil survival (Ross et al., 2006). 
However, support for neutrophils seems to occur mainly by soluble factors produced 
both by fibroblasts and resident macrophages (e.g. IL-8, GM-CSF, TGF-β, type 1 
IFN) (Kobayashi et al., 2005; Wang et al., 2003), though research in this area is 
relatively limited. Identification of such fibroblast-derived survival factors for 
neutrophils was therefore one of the subjects of this thesis.  
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1.6  AIMS OF THE THESIS 
 
 
From the previous text it is clear that interactions between leukocytes and fibroblasts 
within the rheumatoid synovium play a key role in the generation and maintenance of 
the inflamed site, but the key factors involved in the cross-talk have not been fully 
characterised. Moreover the phenotype of synovial fibroblasts appears to play a 
specific role in maintaining the chronicity of inflammation within articulated joints. 
In this context the expression and role of fibroblast derived galectins in the chronic 
inflammation of RA was poorly understood. The influence that galectins may have 
on synovial fibroblasts was not defined and was another focus of the thesis.  
 
The main questions posed at the start of the thesis were: 
1. What are the neutrophil survival factors produced by cytokine activated synovial 
fibroblasts? 
2. Do galectins play a role in neutrophil survival mediated by activated synovial 
fibroblasts? 
3. Do fibroblasts show tissue- or disease-specific expression of galectins? 
4. Do any of the differentially expressed galectins modulate function of RA 
synovial fibroblasts? 
5. What is the mechanism of galectin-3 induced effects in fibroblasts? 
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2.0 MATERIALS AND METHODS 
2.1 Antibodies 
All antibodies used for stainings are summarized in Table 2.1. 
 
Table 2.1 
Antibody (species) Dilution Source 
Western blot    
Primary antibodies   
Galectin-1 (rabbit) 1:1000 Peprotech 
Galectin-3 (rabbit) 1:2000 Peprotech 
Galectin-9 (mouse)  GalPharma 
Akt/PKB (mouse) 1:1000 Transduction Lab 
phospho-Akt (rabbit) 1:1000 Cell Signalling 
p44/43 (ERK1/2) (rabbit) 1:1000 Cell Signalling 
phospho-p44/42 (rabbit) 1:1000 Cell Signalling 
p38 MAPK (rabbit) 1:1000 Santa Cruz Biotech 
phospho-p38 MAPK (mouse) 1:1000 Santa Cruz Biotech 
JNK1 (rabbit) 1:1000 Santa Cruz Biotech 
phospho-JNK (rabbit) 1:2000 Promega 
phospho-STAT1 (rabbit) 1:1000 Cell Signalling 
β-actin 1:5000 Sigma 
α-tubulin 1:1000 Sigma 
   
Secondary antibodies   
Anti-rabbit-HRP (goat) 1:5000 Amersham 
Anti-mouse-HRP (goat) 1:5000 Amersham 
Anti-rabbit-HRP (goat) 1:10 000 Jackson Immunoresearch 
Anti-mouse-HRP (goat) 1:10 000 Jackson Immunoresearch 
   
Fluorescence microscopy   
STAT1 (mouse) 1:50 Transduction Lab 
Anti-mouseIgG1-FITC (goat) 1:50 Southern Biotech 
   
Immunhistochemistry    
Primary antibodies   
Galecin-3 Final concentration 10µg/ml Abcam 
Galectin-9 Final concentration 10µg/ml GalPharma 
Prolyl-hydroxylase β Final concentration 10µg/ml Acris 
CD68 Final concentration 4µg/ml Dako 
Von Willebrand factor Final concentration 10µg/ml Abcam 
 
  
Isotype controls   
Mouse IgG1 * Dako 
Rabbit IgG * Dako 
Secondary antibodies   
Anti-mouse-biotin (goat) 1:2000 Jackson Immunoresearch 
Anti-rabbit-biotin (goat) 1:5000 Jackson Immunoresearch 
Anit-mouse-AP (goat) 1:20  
Anti-rabbit-AP (goat) 1:5000  
• - used at the same concentration as the primary antibody 
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2.2 Cell cultures 
2.2.1 Fibroblast culture 
All fibroblasts lines were obtained from the Rheumatology department tissue bank 
frozen in liquid nitrogen. Tissue samples of synovium, bone marrow and skin were 
collected during joint replacement surgery from patients who fulfilled the American 
College of Rheumatology 1987 revised criteria for rheumatoid arthritis (Arnett et al., 
1988). Due to lack of detailed clinical data of the patients no correlations with 
parameters such as disease activity or previous therapy were made. Lung, spleen, 
tonsil and thyroid tissue were obtained by, respectively, bronchoscopic biopsy, 
splenectomy, tonsillectomy or thyroidectomy from donors not diagnosed with 
inflammatory disease. Collection of human tissue was approved by the local ethics 
committee and all patients gave consent for the use and storage of tissue for research 
purposes. 
Cells were recovered from liquid nitrogen storage by quickly defrosting the vial at 
370C and resuspending cells in complete fibroblast medium. After washing off the 
DMSO-containing freezing medium, cells were again resuspended in the medium in 
which they were grown. Complete fibroblast medium consisted of 87.4% RPMI 1640 
(Sigma Ltd), 10% heat-inactivated FCS (Sera Laboratories International), 0.87X 
MEM non-essential amino acids, 0.87mM sodium orthopyruvate, 1.75mM 
glutamine, 87U/ml penicillin, 87µg/ml streptomycin (all from Sigma). A medium for 
transfection experiments consisted of Dulbecco’s minimum essential medium 
(DMEM), 10% heat-inactivated FCS, 2 mM L-glutamine and 10 mM HEPES (all 
reagents provided by Gibco-Invitrogen). Cells were incubated in a humdified 
atmosphere at 370 C and 5% CO2 and used for experiments between passages 4-8. 
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For passaging, mRNA isolation or nuclear extract preparation cells were trypsinized 
with 2X Trypsin-EDTA solution (Sigma) for 5 minutes, collected into polypropylene 
tubes with complete medium and centifuged for 6 min at 300g. For FACS staining 
cells were detached with a milder enzymatic solution Accutase (PAA Laboratiories) 
and washed with PBS with 1% FCS.   
2.2.2 Neutrophil isolation 
Neutrophils were isolated from peripheral blood of healthy volunteers who had given 
their informed consent. Blood was collected into Falcon™ tubes containing EDTA 
(3mg/ml of blood) as anti coagulant. 1 ml of 2% Dextran was added per 7 ml of 
blood to sediment the red blood cells. After 45 minutes leukocyte-rich plasma was 
collected and overlaid on to a Percoll (Sigma) gradient consisting of 79% (1.095 
g/ml) Percoll (2.5 ml) and 54% (1.077 g/ml) Percoll (5 ml) in a sterile 15 ml Falcon 
tube and centrifuged for 20 minutes at 130g. The neutrophil enriched layer at the 79-
54% interface was removed by sterile pasteur-pipette into a sterile Falcon tube. The 
cells were then washed in cold (4°C) PBS and spun at 270g for 8 minutes. Hypotonic 
lysis with cold sterile water was performed to remove any contaminating red blood 
cells. The number of neutrophils was counted using a haemocytometer and the cells 
were resuspended in RPMI 1640 medium, supplemented with 10% fetal calf serum, 
100µg/ml streptomycin, 100 units/ml penicillin and 2 mM L-glutamine (all from 
Sigma), at a final concentration 2-4 × 106 cells/ml. The purity of the cells was 
assessed by differential staining of a cytospin preparation using a commercial May-
Grunwald Giemsa stain, REASTAIN Quick Diff Kit (Reagena). Only neutrophil 
preparations with a purity of >95% were used. Contaminating cells were mostly 
eosinophils. 
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2.3 Cell treatments 
2.3.1 Cytokines 
Synovial, bone marrow and skin fibroblasts were grown in fibroblasts complete 
medium until near confluence. The medium was replaced then with medium 
containing 10 ng/ml of one of the following cytokines: IL-1β, IL-6, IFNγ, TNF-α, 
TGFβ, IL-17 or IL-4 (20 ng/ml) and cultured for 24h before  mRNA was extracted. 
2.3.2 TLR ligands 
The following Toll-like receptor ligands were used to stimulate synovial fibroblasts: 
10 µg/ml poly(I-C) (InvivoGen), 100 ng/ml lipopolysaccharide (LPS) from 
Escherichia coli (List Biological Laboratories), 300 ng/ml bacterial lipoprotein (bLP, 
InvivoGen), 1 ng/ml recombinant interleukin-1β (R&D Systems), and 10 ng/ml 
tumor necrosis factor-α (R&D Systems). Cells were treated for 24h, then lysed and 
total RNA isolated. 
2.3.3 DNA methylation inhibitor 
To obtain a global demethylation of DNA in fibroblasts, cells were seeded on 6-well 
plates at 30-50% confluence and treated for 7 days with 0.1 or 1µM DNA 
methyltransferase  inhibitor 5-aza-2'-deoxycytidine (5-AzaC). This inhibitor prevents 
the methylation of CpG islands in the promoters of genes in proliferating cells. Due 
to its low stability in culture, during the 7 days of treatment medium was changed 
every day with a fresh portion of the inhibitor. Protein cell lysates were then prepared 
for Western blotting.      
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2.3.4 Galectin-3 and inhibitors 
Fibroblasts were grown on 96- or 24-well plates and stimulated with 10µg/ml 
galectin-3 (Peprotech). In experiments where inhibitors were used, the inhibitors 
were added 1h before galectin stimulation. The following signaling pathway 
inhibitors were used: Bay11-7085 (5µM; Alexis), LY294002 (10µM; Calbiochem), 
bisindolylmaleimide I (2µM; Calbiochem), Go¨6976 (10nM; Calbiochem), 
SB202190 (10µM; Calbiochem), R406 (10µM; supplied by David L. Simmons, 
Cellzome), and PD98059 (10µM; Cell Signaling). Medium containing galectin-3 
with the highest concentration of DMSO found in any of the inhibitor solutions was 
included as a control. Cells were cultured for 24h then supernatant was taken off, 
spun down at 10000 rpm for 3 min. to remove any solid debris and frozen at -700 C 
for later measurement of cytokines by ELISA. Cells remaining on the plate were 
fixed with methanol, stained by Quick Diff and counted under a microscope to 
ensure the observed effect in cytokine production was not due to cell loss caused by 
inhibitor toxicity. Concentrations of all inhibitiors to be used were titrated in this 
way.  
For assessment of kinase phosphorylation following galectin-3 stimulation, cells  
were treated with 10 µg/ml galectin-3 for 5, 15, 30 or 60 min.  and cell lysates 
prepared for Western blotting. For STAT phosphorylation following IFNγ treatment 
cell lysates were prepared in the same way. 
 
2.3.5 Fibroblast-conditioned medium production 
Synovial fibroblasts were stimulated with 10 ng/ml TNF-α (Serotec) and/or 10 ng/ml 
IL-17A (R&D Systems) in complete fibroblast medium and incubated for 24 h. 
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Control fibroblasts were cultured without the addition of cytokines. Cells were then 
washed, resuspended in fresh medium and incubated for a further 24 hours. The 
conditioned media (FCM) from untreated as well as cytokine-activated fibroblasts 
were then harvested and stored at -700 C. In some experiments FCM were used 
immediately after collection for culturing neutrophils to avoid the effect of freeze-
thawing. 
 
2.4 Cytokine depletion and blockade studies 
2.4.1 Receptor blocking on neutrophils 
Freshly isolated neutrophils were incubated for 1h at 370 C with 2.5 µg/ml antibody 
against IFNβ (mouse anti-CD118, Calbiochem) or IL-6 receptor (mouse anti-IL6R, 
R&D Systems), with 2.5 µg/ml irrelevant IgG of the same isotype or left untreated. 
Cells from each condition were then plated on 96-well plates with four different 
treatments: medium alone, medium with 800 U/ml IFNβ (PBL Interferon Source) or 
10 ng/ml IL-6 (Immunotools), respectively, fibroblast-conditioned medium (FCM) 
form unstimulated synovial fibroblasts and FCM from fibroblasts pre-treated with 
IL-17 and TNFα. Neutrophils were then cultured for 20h before the apoptosis assay 
was performed.   
2.4.2 Cytokine depletion from FCM 
To deplete fibroblast-conditioned media from cytokines protein A-conjugated 
agarose beads (Upstate) with immunoglobulin binding capacity were used. Beads 
were washed 10 times with PBS, then bound to respective antibodies for 20 min. at 
room temperature on a rotor mixer. The antibodies used were: anti-GM-CSF (R&D 
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Systems) 2 µg per depletion step, anti-TNFα (R&D Systems) 4 µg per depletion step 
or both together. Control beads were bound to an irrelevant IgG. Next beads were 
washed twice with PBS and once with RPMI and aliquoted into triplicate eppendorf 
tubes. Fibroblast-conditioned medium was added into a tube with antibody-bound 
beads or control beads and incubated for 30 min. on a rotor mixer. Beads were then 
spun down at 5000rpm for 5 min. and supernatant transferred into the next tube 
containing fresh aliquot of beads. A total of three depletion steps were performed on 
each FCM before they were used for neutrophil culture.  
 
2.5 Galectin RNA expression in fibroblasts  
2.5.1 Fibroblasts mRNA isolation 
For analysis of gene expression cells grown on 6-well plates were washed with PBS 
and lysed in the wells with Lysis/binding buffer (Ambion). Total mRNA isolation 
was performed using RNAqueous kit (Ambion) according to the manufacturer’s 
protocol. Any contaminating DNA was removed by using DNAfree™ kit (Ambion) 
following the manufacturer’s protocol. The total RNA isolated was then quantified 
by UV absorbance at 260nm wave length (BioPhotometer, Eppendorf).  
2.5.2 cDNA synthesis 
1.5 µg of the isolated RNA was immediately converted to cDNA to prevent 
degradation. Reverse transcription to first-strand cDNA was done with 1.25 µM 
oligo(dT) primer (Invitrogen), 0.25 mM dNTPs mixture and 400 units M-MLV 
Superscript II reverse transcriptase (Invitrogen) for 60 min. at  42°C. 
cDNA samples were stored at -20°C until used for PCR amplification. 
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2.5.3 End-point PCR  
Polymerase chain reaction was performed using 2 µl of cDNA in a 50µl reaction 
volume. The PCR buffer contained 1.5 mM MgCl2, 0.3 mM dNTP mixture, 0.25µM  
of each primer and  1.75 U of Expand High Fidelity Enzyme mix containing Taq 
DNA polymerase and Tgo DNA polymerase (Roche). Oligonucleotide primers and 
PCR product size for each gene were as follows: 
 
Table.2.2 Sequences of primers for PCR. 
Gene Forward primer Reverse primer Annealing 
temp. (°C) 
Product 
size (base 
pairs) 
Galectin-1 AAC CTG GAG AGT GCC 
TTC GA               
AAC CTG GAG AGT GCC 
TTC GA               
60 321 
Galectin-2 ATG ACG GGG GAA CTT 
GAG GTT    
TTA CGC TCA GGT AGC 
TCA GGT        
60 358 
Galectin-3 ATG GCA GAC AAT TTT 
TCG CTC C 
ATG TCA CCA GAA ATT 
CCC AGT 
60 719 
Galectin-4 GCT CAA CGT GGG AAT 
GTC TGT 
GAG CCC ACC TTG AAG 
TTG ATA 
60 609 
Galectin-7 ATG TCC AAC GTC CCC 
CAC AAG 
TGA CGC GAT GAT GAG 
CAC CTC 
65 282 
Galectin-8 GTT GTC CTT AAA CAA 
CCT ACA G 
TAA CGA CGA CAG TTC 
GTC CAG 
60 608 
Galectin-9 ACT ATT CAA GGA GGT 
CTC CAG 
GGA TGG ACT TGG ATG 
GGT ACA 
60 571 
Galectin-10 CCA CTT GCC TGT TTC 
TTG AAT GAA C 
TCT CCA CAC TTG CAC 
CAT CTT CAC 
60 369 
Galectin-12 CCA GCT CTA CTG TGT 
CCA CTC CTG AGG ATG 
GTT CCA GG 
TAG TCT ACA ACA CTT 
GCC TCT GTG AGT GCA 
GTC CAG GC 
68 308 
β-actin TTCAACTCCATCATGAA
GTGTGACGTG 
CTAAGTCATAGTCCGCCT
AGAAGCATT 
58 310 
 
Amplification of β-actin gene was used as a control. 
Thermal cycling reaction commenced with 4 min heat activation at 94°C, followed 
by 32-37 cycles of denaturation at 94°C for 60s, annealing at 60-65°C for 60s and 
extension at 72°C for 2 min. A final extension time of 10 min followed the last cycle. 
The amplification was performed on Px2 Thermal Cycler (Therma). 
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Products were separated on a 1.2 % agarose gel in Tris-Acetate-EDTA buffer and 
visualised using ethidium bromide staining.  
2.5.4 Real-time PCR 
To assess quantitative differences in gene expression real-time PCR using TaqMan® 
Gene Expression Assays (Applied Biosystems) was performed. Commercially 
available probes and primers labelled with the reporter dye FAM were used to assess 
galectins expression.  β-actin was used as an endogenous control in general screening 
for galectins expression. In all other experiments 18S probe was used as a reference 
gene. For the PCR reaction 100ng of cDNA was taken. 10µl universal PCR master 
mix and 1µl of the TaqMan® Gene Expression Assay mix containing primers and 
probe were added and the volume was adapted with water to give a total volume of 
20µl. Each reaction was performed in triplicate on a 348-well clear optical reaction 
plate (Applied Biosystems). Detection was performed using the ABI prism 7900HT 
sequence detector (Applied Biosystems). PCR cycling conditions were set to 50oC 
for 2 minutes, 95oC for 10 minutes and 40-45 cycles of 95oC for 15 seconds and 
60oC for 1 minute. Data was collected and analysed using the ABI Prism 7900HT 
Sequence Detection System software, version 2.2.  
Target gene expression was normalised to the endogenous control. The relative 
quantity of the product was calculated as follows; RQ = 2-∆Ct, where ∆Ct is the 
difference in the number of cycles at the threshold line between target and control 
gene. The fold change of each gene expression (eg. after cytokine stimulation) was 
calculated as: fold change = 2 –∆∆Ct , where ∆∆ Ct is the difference between  ∆Ct of 
stimulated and control sample. Where samples were not matched (i.e. in comparisons 
of RA vs. OA) only -∆Ct was plotted on graphs. 
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2.6 Protein expression and secretion 
2.6.1 Immunohistochemistry 
All tissue sections were obtained from Centre of Experimental Rheumatology, 
University Hospital Zurich (Switzerland). Sample collection was approved by local 
ethical committee.  
Tissue fixation and preparation of paraffin blocks 
Synovial tissue was fixed with 4% paraformaldehyde for up to 12h, then in 50% 
ethanol and embedded in paraffin by tissue processor (Shandon). Paraffin block were 
sectioned to 3 µm thickness on a microtome, transferred onto Superfrost slides and 
left to dry.  
Immunohisotchemical staining  
Before proceding to the staining the tissue was deparaffinized and re-hydrated by 
immersing the slides in xylene (2x 10min.) and graded alcohol (absolute: 2x 3min, 
96%: 2 min, 80%: 2 min.) and then washed in water. Antigen retrieval was 
performed by pre-treatment of the tissue with 10mM citrate buffer (pH=6.0) for 
30min. at 800 C. After washing with water the endogenous peroxidise activity was 
blocked by incubating the sections in 3% H2O2 for 15 min. Next, slides were washed 
with water and then with buffer1 (TBS with 0.05% Tween, ph=7.6). Blocking of 
non-specific immunoglobulin binding was performed by incubation with 5% goat 
serum and 1% BSA in buffer1 for 40min. in a humidified chamber. 100µl of diluted 
primary antibody or immunoglobulin of the same isotype as a negative control was 
applied on the slides and incubated overnight at 40 C in a humidified chamber. Slides 
were next washed for 5 min. in buffer1 and respective secondary antibody 
(biotinylated or enzyme-conjugated) was applied (30min. at room temperature). If 
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secondary antibody was biotinylated additional incubation with streptavidin-HRP 
complexes (Vectastain Elite ABC kit, Vector) was performed before final washing 
and adding a substrate for the enzyme. The substrate for horseradish peroxidise 
(HRP) was 3-amino-9-ethylcarbazole (AEC, Sigma) producing red colour or DAB 
(Vector Labs) with brown/grey-coloured product. As a substrate for alkaline 
phosphatase (AP) naphthol AS-MX phosphate and fast blue RR salt (Sigma) or 
BIICP violet kit (Vector Labs) were used. Colour reaction was stopped with water 
and slides mounted with glycerine/gelatine covering medium. For double staining, 
after developing the first reaction the whole staining procedure (starting from the 
blocking step) was repeated with another primary antibody. Antibodies used are 
summarized in Table.2.1. 
 
2.6.2 Western blotting 
To analyse cell protein content by Western blotting, cells were washed with PBS and 
lysed with SDS loading buffer (0.125M Tris pH 6.8, 20% glycerol, 2% SDS, 5% 2-
mercaptoethanol and 25µg/ml bromophenol blue). Lysates were then heated for 10 
minutes at 100oC and stored at -20oC until further use.  
Depending on their size the proteins were separated on 12% or 15% SDS-PAGE gels 
with 5% acrylamide as a stacking gel. Molecular weight marker (Fermentas or  
National Diagnostics) was loaded in a separate lane on each gel. The gels were run at 
40V until suitable separation was obtained. The proteins were then transferred to 
0.45 micron PDVF membrane (Flowgen Limited) pre-activated shortly in methanol. 
Transfer was perfomed for 90 minutes at 450 mA using a wet blotting system 
(Biorad). The membranes were then blocked with 5% non-fat milk powder in Tris-
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buffered saline (TBS; 50mM Tris pH 7.6, 150mM NaCl) with 0.1% Tween20 for 1-
2h at room temperature. For analysing phosphorylated proteins the membranes were 
blocked with 5% BSA in 0.1% Tween-TBS. The specific primary antibodies were 
diluted in 0.1% Tween-TBS with 1% milk or BSA depending on the protein of 
interest. Antibodies used and their working dilutions are listed in Table 2.1. The 
membranes were incubated with an appropriate primary antibody overnight with 
shaking at 40C. The membranes were then washed 3 times for 10 minutes with 0.1% 
Tween-TBS and incubated with species specific secondary antibody conjugated to 
horseradish peroxidise for 1h at room temperature. After washing (3x 10 minutes) 
blots were incubated in ECL solution (Amersham Pharmacia) for about 1 minute to 
detect the bound antibody. The membranes were wrapped in Saran wrap and placed 
in film cassette boxes with an X-ray film (Kodak-x-omat LS). Time of exposure 
varied depending on the strength of the signal. The films were developed with an 
automated developing system (AGFA Curix 60). The control of equal loading was 
assessed after stripping the blots and re-probing them with anti-β-actin or anti-α-
tubulin antibodies according to the procedure described above. Stripping was 
performed for 30 min. at 550C with agitation in 62.5mM Tris-HCl buffer (pH 6.7) 
with 100mM mercaptoethanol and 2% SDS. 
Quantitative analysis of galectin expression was performed by scanning the 
developed films using Syngene gel documentation system and analysing the 
absorption with GeneTools image analysis software. The relative expression of a 
protein of interest was normalized to the loading control and represented as a 
percentage of the control sample value. 
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2.6.3 Enzyme-linked immuno-sorbent assays (ELISAs) 
Levels of cytokines, chemokines, MMP-3 and galectin-3 in supernatants of cultured 
fibroblasts were measured by ELISA according to the manufacturer’s instructions. 
The kits used were IL-6 OptEIA (BD Pharmingen 555220), IL-8 OptEIA (BD 
Pharmingen 555244), CCL5/RANTES Duoset (R&D DY278), MMP-3 Duoset 
(R&D DY513), galectin-3 (Bender MedSystems). The lower detection limits for IL-6 
and CCL5 ELISA kits used were 15 pg/ml, for IL-8 3pg/ml, for  MMP-3 30 pg/ml 
and for galectin-3 0.12 ng/ml. 
The plates were analysed immediately using an ELISA plate reader (Molecular 
Devices) and Soft Max Pro software. The OD values were determined by reading the 
absorbance at 450nm as the primary wave length and 650nm as a reference. The 
values of blank wells were subtracted from the values of sample wells.  Standard 
curve was created by plotting the mean absorbance against each concentration of the 
recombinant standard. The concentrations of protein in samples were calculated from 
the standard curve and multiplied by the dilution factor. 
 
2.7 Transcription factor activation 
2.7.1 NFκB activation - TransAM assay 
To assess the activation of transcription factor NFκB (p65 subunit), nuclear extracts 
from galectin-3/or TNFα-stimulated fibroblasts were prepared using the Nuclear 
Extract Kit (ActiveMotif) according to the manufacturer’s instructions. Protein 
content in each sample was then measured with BCA assay (Pierce) and calculated 
from the standard curve prepared with dilutions of BSA.  Equal amounts of protein 
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from each sample were taken to perform the TransAM p65 assay (ActiveMotif). This 
assay uses microwells coated with oligonucleotides to which NFκB contained in the 
nuclear extract binds. Primary antibody recognizing an epitope exposed only in 
activated DNA-bound form of p65 subunit detects then the activated form of the 
transcription factor that has translocated into the nucleus. The detection was 
performed following manufacturer’s instruction and results calculated as a fold 
increase compared to non-stimulated cells. 
 
2.7.2 STAT translocation – confocal microscopy 
Synovial fibroblasts were seeded onto 8-well chamber slides (BD Falcon).  For 
STAT translocation experiments cells were serum-starved (fibroblast medium with 
0.5% FCS) for 3 days with medium changed at day 2. Cells were stimulated with 100 
ng/ml IFNγ (Immunotools) for 15 min then medium and plastic well chambers were 
removed and slides were washed with TBS for 10 min and fixed with 4% 
paraformaldahyde. After washing with TBS 3 times for 5 min permeabilization step 
was perfomed with ice-cold methanol for 10 min at -200C.  Blocking buffer (10% 
FCS in TBS) was applied on the slides for 30 min at room temperature. Next slides 
were incubated with primary mouse anti-human STAT1 antibody diluted 1:50 in 2% 
blocking buffer for 1h in a humidified chamber. Primary antibody was omitted in 
negative control wells. Slides were washed twice with TBS for 10 min, secondary 
anti-mouse fluorochrome-conjugated antibody was applied and incubated as 
previously. Slides were washed twice and nuclei were counterstained by dipping 
slides in propidium iodide (PI) solution for 1-2 min. After final wash slides were 
mounted with 2.4% 1,4-diazabicyclo[2.2.2]octane (Aldrich) in glycerol pH 8.6 
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(Fisons Scientific). A Zeiss 510 laser-scanning confocal microscope was used to 
visualise staining with images captured and processed using the Zeiss LSM Image 
Examiner software (Zeiss). 
 
2.8 Galectin-9 silencing 
Small-interfering RNAs (siRNA) play a role in post-transcriptional gene silencing. 
The mechanism involves recognition and binding of short RNA sequences to target 
mRNA molecules which results in mRNA degradation and therefore prevents its 
translation into a protein. This phenomenon can be utilised to experimentally silence 
specific genes.  
Galectin-9 siRNA used in these studies contained four different sequences targeting 
all isoforms. Control siRNA was a mixture of nucleotide sequences not binding any 
know target mRNAs.  
Synovial fibroblasts were seeded on 12-well plates at a density of 5x104 in a medium 
without antibiotics. Next day two hours before the transfection the medium was 
exchanged. Galectin-9 siRNA and control siRNA (Santa Cruz Biotechnology) were 
diluted with Opti-MEM I Reduced Serum medium (Invitrogen) and then combined 
with transfection agent Lipofectamine2000 (Invitrogen) prepared according to the 
manufacturer’s instruction. The mixture was incubated at room temperature for 
20min. to form complexes before adding to the cells. The final concentration of each 
siRNA added to the cells was 33nM. After 24, 48 and 72h cell lysates for RNA 
isolation and for Western blotting were prepared. Additionally supernatants for 
ELISA were collected after 72h. 
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2.9 Functional assays 
2.9.1 Neutrophil survival assays and assessment of apoptosis 
Freshly isolated neutrophils were resuspended at a concentration of 2x106 cells/ml. 
50 µl of cell suspension was placed into 96-well flat-bottom plates and 100 µl of 
neutrophil medium or fibroblast-conditioned medium (FCM) was added to each well. 
Recombinant proteins used in neutrophil survival studies are listed in Table 2.3. 
Table.2.3 Recombinant proteins used in neutrophil survival assays 
Recombinant Protein Working concentration Source 
GM-CSF 100 pg/ml Peprotech  
IFNβ 800 U/ml Biosource International 
IL-6 1-100 ng/ml Peprotech 
TNFα 1-100 ng/ml R&D Systems 
Galectin-3 0.1-10 µg/ml Peprotech 
 
Neutrophil apoptosis was evaluated by analyzing the loss of mitochondrial 
membrane potential which is an early event in programmed cell death preceding cell 
shrinkage and nuclear fragmentation (Zamzami et al., 1995). Cells (2 x 106/ml) were 
incubated with a cationic fluorochrome DiOC6 (3,3'-dihexyloxacarbocyanine iodide; 
Molecular Probes) at a concentration of 40 nM for 30 min at 37°C. DiOC6 is a 
positively charged molecule that permeates through the plasma membrane and 
accumulates in mitochondria due to their large negative membrane potential. This 
membrane potential is lost in cells undergoing apoptosis and the fluorescence signal 
from DiOC6 decreases. Therefore healthy cells can be distinguished by high DiOC6 
staining whereas
 
DiOC6 low cells are apoptotic. After incubation with the dye the 
cells were washed twice with PBS and analyzed by flow cytometry. Flow cytometry 
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was performed using a fixed volume (20 µl) counts protocol on a Beckman Coulter 
Epics XL flow cytometer. Data was analyzed with the Win MDI version 2.8 
programme. Neutrophils were gated based on their forward scatter and side scatter 
profile (Fig 2.1B). Identification of apoptotic cells were performed as shown in Fig 
2.2. Percentage of cell survival was quantified by comparing the number of DiOC6 
high cells after 20 of culture to that at the start of culture.   
 
Fig. 2.1 Gating of neutrophils based on their forward scatter vs. side scatter 
profile A. Dot plot of freshly isolated neutrophils.  B. Dot plot of neutrophils after 
20h in culture. 
 
  
Fig. 2.2 Identification of apoptotic cells using DiOC6 staining.  A. Freshly 
isolated neutrophils.  B. Neutrophils after 20 h of culture. Gate set as shown in 
Fig.2.1B 
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Neutrophil apoptosis was also assessed by cell morphology. Apoptotic neutrophils 
can be distinguished by morphological features such as nuclear condensation, loss of 
connection between lobules of the nucleus and reduced cytoplasm (Savill et al., 
1989). 
Cytospin slides were differentially stained with Diff Quick and the percentage of 
apoptotic cells was quantified by blind counting of 200 cells per field under light 
microscopy (×1000). Three fields of total 600 cells were counted per slide. Results 
from both methods gave comparable levels of apoptosis.  
 
2.9.2 Fibroblasts apoptosis assay 
Synovial fibroblasts transfected with galectin-9 or control siRNA were treated with 
5µM staurosporine (Sigma) to induce apoptotic cell death. After 6h cells were 
detached with accutase (PAA Laboratoories), combined with those floating in the 
medium and washed with cold PBS. Supernatants were removed and 100µl of 
Labelling solution (consisting of incubation buffer: 10 mM HEPES, pH 7.4; 140 mM 
NaCl; 2.5 mM CaCl2 with 2µl Annexin-V-FITC and 2µl propidium iodide) was 
added to each tube. Cells were incubated for 15 min. at 40 C protected from light, 
then washed once with incubation buffer and analysed using FACS Calibur and 
CellQuest software. Annexin-V binds to phosphatydylserine which is exposed on cell 
surface early during apoptotic process. Propidium iodide stains dead cells (late 
apoptotic and necrotic). Annexin-V-high cells were considered as apoptotic (both 
early and late). 
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2.9.3 Fibroblasts proliferation assay 
Proliferation of fibroblasts was assessed using an XTT assay (Cell proliferation kit, 
Biological Industries). This method is based on the ability of live cells to reduce 
tetrazolium salt XTT into coloured formazan compound. The intensity of the formed 
dye is proportional to the number of metabolic active cells and can be read using a 
spectrophotometer. Fibroblasts were cultured on 96-well plates at the density of 
8x104 in 100µl of medium. For positive control they were treated with 10ng/ml 
TNFα and 10ng/ml IL-1β. Cell proliferation was assessed at 24, 48 and 72h after 
addition of cytokines. XTT substrate was prepared by mixing 5ml of XTT Reagent 
and 0.1ml Activation Reagent and 50µl of the solution was added into duplicate 
wells. Plates were incubated at 370 C for 3h and read at 450nm with a reference 
wavelength of 620nm.  
 
2.10 Statistical analysis 
Non-parametric distribution was assumed for all assays. For comparison of two 
groups (eg. expression in RA vs OA) Mann-Whitney test was used. Comparisons 
across multiple groups (eg. neutrophil survival, fibroblast stimulations, galectin 
expression in matched fibroblasts) were performed with Kruskal-Wallis one-way 
analysis of variance and Dunn’s post test. The differences between paired samples 
(eg. depletion and blocking experiments, inhibitors, fibroblasts apoptosis) were 
assessed with Wilcoxon signed rank test with 2-tailed P values.    
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RESULTS AND DISCUSSION 
3.0 Fibroblast-induced neutrophil survival 
3.1 Background 
Rheumatoid synovial fibroblasts are key players in the development of the disease. In 
addition to their aberrant proliferation and invasive properties they also contribute to 
the pathology indirectly by attracting and supporting the inflammatory infiltrate in 
the synovial microenvironment. Synovial fibroblasts are a source of a variety of 
immune mediators with potent activation and anti-apoptotic properties. One of the 
cell types that may be influenced by these cells are neutrophils. These 
polymorphonuclear leukocytes persist in the synovial fluid in rheumatoid arthritis 
(RA) in large quantities, in part because their normal entry into apoptosis is delayed 
(Edwards and Hallett, 1997). It was hypothesized that factors produced by RA 
synovial fibroblasts and released into the synovial fluid may be responsible for this 
effect. 
Previous studies from this laboratory have shown that fibroblasts from the 
rheumatoid joint produce soluble factors able to prolong neutrophil survival in vitro 
(Filer, 2006). In this chapter the ability of cytokines present within the RA joint to 
influence fibroblast effects upon neutrophils was determined. Specifically, the effect 
of pretreatment of fibroblasts with the inflammatory cytokines IL-17 and TNFα was 
assessed.  TNFα is at the top of proinflammatory cascade and is present at high levels 
in the rheumatoid joint (Brennan et al., 1998). IL-17, a T cell derived cytokine, is 
also an important factor promoting inflammation in the joint (Chabaud et al., 1999; 
Lubberts et al., 2005). It has recently been described as part of a transient cytokine 
profile present in synovial fluid at early stages of RA (Raza et al., 2005a). 
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Furthermore, both cytokines are potent activators of synovial fibroblasts and can act 
in a synergistic manner (McInnes and Schett, 2007; Ruddy et al., 2004).  
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a well-known 
neutrophil activation and survival agent (Lee et al., 1993; Kobayashi et al., 2005). It 
was found previously that GM-CSF partially accounted for the increased survival of 
neutrophils in medium conditioned by cytokine-activated fibroblasts. However, 
depletion of this molecule from the conditioned medium did not abolish the 
neutrophil survival activity completely, reducing it only by around 50% (Filer, 
2006). The present series of studies was undertaken to identify the factors secreted 
by activated fibroblasts that contribute to prolonged neutrophil survival. 
3.2 Identification of neutrophil survival factors produced by 
activated fibroblasts 
It was first confirmed that fibroblast-conditioned medium promoted in vitro survival 
of neutrophils. Synovial fibroblasts were pretreated with the respective cytokines for 
24h, then medium containing the stimulants was washed off and cells cultured in 
medium alone for the next 24h. The latter was collected and will be referred to as 
“fibroblast-conditioned medium”. Neutrophils isolated from the blood of healthy 
donors were cultured in the fibroblast conditioned medium or medium with 100pg/ml 
recombinant GM-SCF as a positive control. Apoptosis of neutrophils was measured 
after 20h of culture by flow cytometry of DiOC6–stained cells, as a measure of 
mitochondrial membrane integrity. Cells were also stained with a commercial 
Giemsa stain (Diff Quick) and examined for morphological changes indicative of 
apoptosis. Both methods yielded comparable results.  
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Fig. 3.1. Effect of conditioned media from cytokine-activated fibroblasts on 
neutrophil survival in culture. 
RA synovial fibroblasts were pretreated with 10ng/ml TNFα and/or 10ng/ml IL-17 
for 24h. Conditioned media were collected after another 24h and used to culture 
freshly isolated neutrophils from peripheral blood of healthy donors. Neutrophil 
survival was assessed after 20h of culture. A. Flow cytometry dot plots from a 
representative experiment. FITC vs forward scatter plots show cells with high 
(viable) and low (apoptotic) membrane potential after DIOC6 staining. B. 
Summarized data from 4 independent experiments run in duplicate. Survival is 
expressed as % DiOC6-positive cells as compared to the number at the start of the 
culture. Bars represent mean +SEM. ** p<0.01 compared to survival in media from 
unstimulated fibroblasts. 
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Fig. 3.2 Effect of GM-CSF depletion on neutrophil survival. 
Neutrophils were cultured with media alone (control), medium with 100pg/ml GM-
SCF (GM), fibroblast-conditioned media from unstimulated cells (SY), fibroblast 
conditioned media from cells treated with TNF and IL-17 (SY+TNF). Additionally, 
conditioned media were depleted with anti-GM-CSF antibody or control IgG (irrel). 
Apoptosis was measured by DiOC6-staining. Bars represent means +SEM of 
triplicate assays from 4 independent experiments. * p<0.05, ** p<0.01 comparison 
between indicated bars. Figure taken from (Filer, 2006). 
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Conditioned media from cytokine-activated fibroblasts extended neutrophil survival 
significantly, reducing apoptosis after 20h by approximately 60%. The survival 
effect was comparable to that seen with GM-CSF, but media from unstimulated 
fibroblasts had no significant effect on neutrophil survival (Fig 3.1A). The results 
also showed that combined pre-treatment of fibroblasts with TNFα and IL-17 
produced a medium that induced much greater neutrophil survival than medium from 
cells treated with a single treatment alone (Fig. 3.1B.) 
As potential factors contributing to prolonged neutrophil survival several 
inflammatory mediators were tested including: GM-CSF, IFNβ, IL-6, TNFα and 
galectin-3. Figure 3.2 shows that depletion of GM-CSF from the conditioned 
medium reduced the survival effect by approximately 50% (Filer, 2006) and 
suggesting that other survival factors were also present in the medium.  
It was reported previously that IFNβ produced by stromal cells mediates T cell 
rescue from apoptosis (Pilling et al., 1999). It can also delay apoptosis of neutrophils 
in vitro (Scheel-Toellner et al., 2002; Wang et al., 2003). Because it was not possible 
to directly measure IFNβ levels in fibroblast-conditioned media, another approach 
was taken to test whether it contributed to the prolonged survival of neutrophils 
observed in the fibroblast conditioned medium. After isolation neutrophils were pre-
treated with a blocking antibody against type I IFN receptor (CD118) for 1h and then 
cultured for 20h in either medium alone, medium with recombinant IFNβ (800U/ml) 
or fibroblast-conditioned medium (from non-stimulated or IL-17+TNFα-stimulated 
cells). As a control untreated neutrophils were cultured in the same conditions. 
Because the presence of receptors for Fc fragments of immunoglobulins on 
neutrophils could cause non-specific activation and therefore affect survival of 
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neutrophils an additional control was added, namely cells that were pre-treated with 
an irrelevant IgG of the same isotype. As shown in Fig. 3.3, pre-treatment of 
neutrophils with anti-CD118 receptor antibody effectively blocked the survival effect 
of recombinant IFNβ but did not affect the survival of neutrophils in fibroblast-
conditioned medium. There was no effect on cell survival from the exposure to an 
isotype matched irrelevant antibody. This result suggests that IFNβ is unlikely to be 
present in IL-17-TNFα fibroblast-conditioned media at a level that could account for 
increased neutrophil survival.  
Another cytokine that is produced in large quantities by synovial fibroblasts is IL-6. 
Its level in media collected from fibroblasts after their activation by IL-17 and TNFα 
was greatly increased as measured by ELISA (Fig.3.4). The role of IL-6 as a 
neutrophil survival factor remains controversial. Although some reports show its 
possible anti-apoptotic action towards neutrophils (Daffern et al., 1999), in these 
experiments no such effect was observed. Recombinant IL-6 was used across the 
range of concentrations found in fibroblast-conditioned media (Fig.3.4) but failed to 
rescue neutrophils from apoptosis when added to culture medium (Fig.3.5). Since the 
recombinant protein might behave in a different way to the natural cytokine present 
in the supernatant together with other factors, a receptor blocking experiment was 
also performed. Neutrophils were pre-treated with an anti-IL6R antibody or 
irrelevant IgG and then cultured with or without IL-6 or in conditioned media. No 
reduction in survival rates in the TNF-IL17 conditioned medium was noted ruling 
out the possibility of IL-6 contributing to the survival effect (Fig.3.6).  
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Fig. 3.3. Blocking of IFN receptors on neutrophils - effect on survival induced 
by recombinant IFNβ and fibroblast-conditioned media.  
Neutrophils were pretreated with anti-CD118 blocking antibody or irrelevant IgG for 
1h and then cultured with medium alone, 800U/ml recombinant IFNβ or fibroblast-
conditioned media (FCM) from unstimulated or TNF+IL-17-treated cells. Apoptosis 
was assessed after 20h of culture. Bars represent mean +SEM from 3 independent 
experiments run in duplicate. * p<0.05 compared to survival in medium alone. 
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Fig. 3.4 Interleukin-6 levels in fibroblast-conditioned media. 
Synovial fibroblasts were treated with 10ng/ml TNFα and IL-17 for 24h, then 
medium was exchanged and collected after another 24h. The level of IL-6 in 
conditioned media was measured by ELISA. Boxes show mean and 5%-95% 
percentile, whiskers show range. 
  
 
Fig. 3.5 Effect of recombinant IL-6 on neutrophil survival. 
Neutrophils were cultured in vitro with 100pg/ml GM-CSF, 1, 10 or 100ng/ml IL-6. 
Survival was assessed after 20h with DiOC6 staining. Bars represent mean +SEM 
from 3 independent experiments.  
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Fig. 3.6. Blocking of IL-6 receptors on neutrophils - effect on survival induced 
by recombinant IL-6 and fibroblast-conditioned media.  
Neutrophils were pretreated with anti-IL6R blocking antibody or irrelevant IgG for 
1h and then cultured with medium alone, 10ng/ml recombinant IL-6 or fibroblast-
conditioned media (FCM) from unstimulated or TNF+IL-17-treated cells. Apoptosis 
was assessed after 20h of culture. Bars represent mean +SEM from 3 independent 
experiments run in duplicate.  
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Another possible factor that was tested was TNFα. This cytokine has been described 
to have a dual role in the regulation of neutrophil survival, either protecting them or 
inducing apoptosis (van den Berg et al., 2001; Walmsley et al., 2004). To assess the 
role of TNFα for the survival of neutrophils in our experimental setting, cells were 
cultured with different concentrations of the recombinant protein. In contrast to the 
study by van den Berg et al. where anti-apoptotic effect was observed at 
concentrations lower than 1 ng/ml, here it was protective only at high concentrations 
(100ng/ml) (Fig. 3.7A). To examine if the presence of TNFα in fibroblast-
conditioned media might contribute to its survival-promoting effect, depletion of this 
cytokine was performed. Fibroblast-conditioned media (FCM) were incubated with 
agarose beads bound to anti-TNFα antibody. The beads with captured cytokine were 
then removed by centrifugation at high speed. Additionally depletion with an 
irrelevant control antibody was performed. To ensure the efficiency of the depletion 
the same procedure was applied to medium with exogenously added 100ng/ml 
recombinant TNFα. As can be seen in Fig. 3.7B there was a significant reduction in 
TNF-induced cell survival if the medium was depleted of TNFα. Depletion of TNFα 
had no effect on the survival effect induced by fibroblast conditioned medium (Fig. 
3.7B). Finally, to assess whether GM-CSF may synergize with any of the tested 
cytokines (IFNβ, IL-6 or TNFα) in supporting neutrophil survival, an assay 
combining all the treatments was performed. In this case neutrophils were first pre-
treated with both anti-CD118 and anti-IL6R antibodies and then cultured in FCM 
depleted of GM-CSF and TNFα. Although all depletions and blocking experiments 
were efficient as observed in single experiments, there was no additive effect of the 
combined treatment (Fig.3.7B), indicating that none of these factors contributes to 
survival promoted by GM-CSF.  
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Fig. 3.7 Effect of recombinant TNFα (A) and depletion of TNFα and/or GM-
CSF from fibroblast-conditioned media combined with receptor blocking on 
neutrophils (B) for their survival. 
A.Neutrophils were cultured in vitro with 100pg/ml GM-CSF, 1, 10 or 100ng/ml 
TNFα. B. Neutrophils were cultured in medium containing 100pg/ml GM-CSF or 
100ng/ml TNFα. Depletion was performed with anti-GM-CSF and anti-TNF 
antibodies, respectively. Fibroblast-conditioned media were depleted from both 
cytokines and used on neutrophils that were pre-treated with anti-CD118 and anti-
IL6R antibodies or with irrelevant IgG. Survival was assessed after 20h with DiOC6 
staining. Bars represent mean +SEM from 3 experiments run in duplicate. * p<0.05, 
**p<0.01 compared to control (part A) or between indicated bars (part B). 
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3.3 Role of fibroblast-produced galectin-3 in neutrophil survival 
Galectin-3 is an immunomodulatory lectin identified in many inflammatory 
conditions. It is known to modulate the survival and apoptosis of different cell types 
(Hsu et al., 2006). Secretion of galectin-3 from rheumatoid synovial fibroblasts and 
its elevated levels in synovial fluid are already described in RA patients (Ohshima et 
al., 2003). Therefore it was hypothesized that galectin-3 might act as a survival factor 
for neutrophils and be present in the FCM.  
In order to test this possibility neutrophils were cultured with different concentrations 
of the recombinant protein and then their apoptosis was measured as previously by 
DiOC6 staining. Galectin-3 prolonged neutrophil survival in culture in a dose-
dependent manner (Fig.3.8A). However, when the levels of galectin-3 in fibroblast-
conditioned media were measured, there was no difference between unstimulated and 
TNFα+IL-17-treated cell media (Fig.3.8B). Moreover, the levels observed in the 
supernatant were much lower that those required to effectively delay neutrophil 
apoptosis in vitro (Fig. 3.8A), although they were in the range found commonly in 
serum. It was concluded that galectin-3 is unlikely to mediate the enhanced 
neutrophil life span observed in media from cytokine activated fibroblasts. 
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Fig. 3.8 Effect of recombinant galectin-3 on neutrophil survival and levels of 
galectin-3 in fibroblast-conditioned media. 
A. Neutrophils were cultured with 100pg/ml GM-CSF, 0.1, 1, 10 µg/ml recombinant 
galectin-3. Apoptosis was assessed after 20h of culture. Bars represent mean +SEM 
from 5 independent experiments run in duplicate. * p<0.05 compared to survival in 
medium alone (C - control). B. Levels of galectin-3 in FCM measured by ELISA. 
Results are mean ± SD from 3 different experiments. a-Median values and ranges for 
human serum and plasma taken from ELISA kit datasheet. 
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3.4 DISCUSSION 
Our studies revealed that cytokine activation of RA synovial fibroblasts leads to the 
production of soluble factors able to delay neutrophil apoptosis. TNFα and IL-17 act 
in a synergistic manner on fibroblasts to induce those factors. GM-CSF is partially 
responsible for neutrophil rescuing effect, the rest of it could not be accounted for by 
IFNβ, IL-6, TNFα or galectin-3. 
Accumulation of neutrophils in the joint of rheumatoid arthritis patients is a 
phenomenon that is not fully understood. One reason for this observation may be 
their enhanced recruitment from the circulation which fails to be down-regulated in 
chronic inflammation (Wong and Lord, 2004). Another is their prolonged survival in 
the diseased joint microenvironment. The persistence of this inflammatory infiltrate 
is important in RA pathology as it may lead to increased tissue damage by activated 
neutrophils and a failure of inflammation to resolve (Edwards and Hallett, 1997; 
Cross et al., 2006). The literature suggests that extended neutrophil life span is likely 
to result in part from interactions with synovial stromal cells. It was demonstrated 
that ligation of α9 β1 integrin on the surface of neutrophils by vascular endothelial 
adhesion molecule (VCAM-1) provides survival signal for these cells (Ross et al., 
2006). Also other reports show that modulation of apoptotic death in neutrophils 
depends on their adhesion to subendothelial matrix after extravasation (Watson et al., 
1997; Ginis and Faller, 1997).  
However, most neutrophils in the joint migrate through the tissue and are located in 
the synovial fluid without direct cell-cell contact with other cell types. Therefore 
soluble factors are likely to play a major role in maintaining them within the joint for 
extended periods of time. Typically the main sources of inflammatory cytokines in 
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the environment of a rheumatoid joint are fibroblasts and macrophages. Some 
fibroblasts even in the absence of any stimulation were shown to produce neutrophil 
survival factors (Southey et al., 1994). Rheumatoid synovial fibroblasts are likely to 
be constantly activated by cytokines present in the synovium such as TNFα or IL-17 
(Miossec, 2003) and the role of such processes was considered here. 
A number of papers showed synergistic effects of these two cytokines in stimulating 
RA synovial fibroblasts. Such activation led to increased production of IL-6, IL-8 
and IL-1 (Katz et al., 2001). A specific synergism between TNFα and IL-17 in 
fibroblasts was shown here and is in agreement with the data of Goldberg et al. 
(Goldberg et al., 2009). These authors proposed that IL-17 acted on fibroblasts as a 
priming agent making them hyperresponsive to TNFα. A few studies showed that 
fibroblasts can increase the production of potential neutrophil survival factors (GM-
CSF, G-CSF, IL-6) upon stimulation with IL-17 (Fossiez et al., 1996; Laan et al., 
2003). Elaboration of neutrophil survival factors as a result of TNFα and IL-17 
stimulation was also shown in other cell types, such as epithelial, and contributed to 
persistence of neutrophil infiltrate in the affected organs (Daffern et al., 1999; Laan 
et al., 2003).  
The finding initially made by our group (Filer, 2006) and confirmed in the present 
study that synovial fibroblasts produce neutrophil survival factors in response to 
TNFα and IL-17 therefore agrees with the previous observations. GM-CSF was 
found to account for part of this effect. A role for this cytokine in accumulation of 
neutrophils was shown in the lung where it was induced from bronchial epithelial 
cells by TNFα and IL17 (Laan et al., 2003; Numasaki et al., 2004). Here we tested 
other putative factors that could be responsible for delaying neutrophil apoptosis 
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such as IFNβ, IL-6 and TNFα. Although the anti-apoptotic function of the latter two 
is a matter of debate in the literature with some studies showing the opposite actions 
(Salamone et al., 2001), we found that TNFα, but not IL-6, could delay neutrophil 
apoptosis in our culture system. Recombinant IL-6 had no effect on the rate of 
neutrophil cell death. 
The overall actions of these two cytokines are probably more complex than being 
simply pro- or anti-apoptotic and may largely depend on other signals present in the 
environment, on activation status of the cell or, in vitro, on a particular experimental 
setup. However, they do not seem to play a role in neutrophil rescue from apoptosis 
exerted by fibroblast-conditioned medium as shown by depletion and blocking 
experiments. Other candidate survival factors that were found at elevated levels in 
FCM, such as G-CSF, CCL2 (MCP-1) or CXCL8 (IL-8), were tested previously but 
did not add to the effect of GM-CSF (Filer, 2006; Parsonage et al., 2008). That study 
also excluded a role for PGE2, a lipid mediator that may delay neutrophil apoptosis 
and whose production by fibroblasts is augmented after TNFα and IL-17 treatment 
(Fossiez et al., 1996) 
Despite the reports by Ottonello (Ottonello et al., 2002) about anti-apoptotic effects 
of adenosine, a nucleoside present in the synovial fluid, in our hands this substance 
did not show any effect towards neutrophils (A. Filer, personal communication). It is 
however important to stress that different agents may exert their role only in certain 
conditions, such as low oxygen tension. The synovial microenvironment is hypoxic 
(Gaber et al., 2005) and, as was demonstrated by Cross et al., that determines the 
action of various factors from the synovial fluid on neutrophil apoptosis (Cross et al., 
2006). Indeed, studies performed under hypoxic conditions identified novel 
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fibroblast-derived neutrophil survival factors such as CCL4 (MIP-1β) (Walmsley et 
al., 2005). 
Although this situation does not apply to experiments with fibroblast-conditioned 
media as they were all performed in standard cell culture conditions (i.e. atmospheric 
oxygen levels), it underlines that caution should be taken when extrapolating results 
obtained in vitro to the situation that occurs in vivo.  Another factor that may account 
for possible differences with the actual in vivo situation is the fact that all our studies 
used peripheral blood and not synovial fluid neutrophils. As already mentioned the 
transmigration through the endothelium may itself alter the survival properties of 
neutrophils (Hu et al., 2005) as compared to naïve cells.  
Another immunomodulatory protein that was of interest in our study was galectin-3. 
High expression of galectin-3 in the rheumatoid synovium and its release in soluble 
form by RA synovial fibroblasts was reported in a study by Ohshima et al.  
Moreover, the production of galectin-3 in RA synovium was much higher compared 
to OA or healthy controls (Ohshima et al., 2003). As neutrophil apoptosis is delayed 
in the RA synovium but not the OA synovium (Raza et al., 2006) this could indicate 
a role for this lectin in extended neutrophil life span in RA synovial fluid. The effects 
of galectin-3 on neutrophils that have been described so far include promotion of 
neutrophil adhesion to laminin (Kuwabara and Liu, 1996), facilitation of 
extravasation (Leffler et al., 2004) and activation of NADPH-oxidase leading to 
respiratory burst (Karlsson et al., 1998). Galectin-3 may also act on naïve and primed 
neutrophils to induce events such as L-selectin shedding and production of IL-8 
(Nieminen et al., 2005). The role of galectin-3 in survival/apoptosis of neutrophils 
has not been studied to date.  
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Although several reports show pro-apoptotic action of exogenous galectin-3 on some 
cells (leukaemia T cells lines and peripheral blood mononuclear cells), there is also 
evidence of galectin-3 as a mitogen (Inohara et al., 1998), suggesting that its 
extracellular action does not necessarily trigger cell death.  
The present study showed that galectin-3 at high concentrations could rescue 
neutrophils from apoptosis in vitro. However, there are some issues which have to be 
considered before drawing conclusions about the relevance of this finding for the in 
vivo situation. First is whether the observed survival effect is directly induced by 
galectin. Two molecules, CD66a and CD66b, were previously identified as surface 
receptors for galectin-3 on neutrophils (Feuk-Lagerstedt et al., 1999). It was 
demonstrated that interaction of galectin-3 with CD66b molecule leads to a release of 
pre-formed IL-8 from neutrophil granules (Schroder et al., 2006). Intracellular stores 
of this chemokine can be mobilized during exudation from the vessels which would 
help to establish a chemotactic gradient for other neutrophils (Pellme et al., 2006) but 
in naïve cells this is unlikely to happen. It might be that release of this chemokine 
induced by cross-linking of the respective receptors by galectin-3 accounts for the 
observed rescue from apoptosis. A pro-survival effect of IL-8 on neutrophils has 
been demonstrated elsewhere (Dunican et al., 2000; Kettritz et al., 1998).  
The possibility that enhanced survival was mediated by a contaminating agent in the 
recombinant protein such as lipopolysaccharide (LPS) was also excluded. Because 
galectin-3 has high affinity for bacterial LPS it is of particular importance that all 
galectin preparations are endotoxin-free (Sarter et al., 2009). Since LPS is a potent 
activator for neutrophils even small amounts could give survival effect. We excluded 
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the possibility that the galectin-3 used was LPS-contaminated (endotoxin levels <0.1 
EU/ml as measured by Limulus amebocyte assay).  
Another issue is a possible neutralisation of galectin-3 that may occur in vivo. Study 
by Nieminen et al. showed that primed neutrophils are capable of cleaving galectin-3 
by elastase which causes inactivation of this protein (Nieminen et al., 2005). In the 
present study all experiments were performed with freshly isolated neutrophils which 
by definition are naïve. Standard isolation procedures should not activate the cells 
and any preparations showing signs of neutrophil activation (as assessed by altered 
morphology, spreading and clumping) were excluded. Galectin-3 treatment was able 
to extend the life span of naïve neutrophils, but whether similar effect would be 
observed in vivo with cells that have been primed is not clear. 
In our study the survival effect was observed with relatively high concentrations of 
galectin. It is possible that such concentrations are required for effective cross-
linking of surface receptors. Extracellular fluids at inflammatory sites may contain 
high levels of galectin-3 (Farnworth et al., 2008). The range noted in serum and 
synovial fluid of RA patients was 30-100ng/ml and 150-300ng/ml, respectively 
(Ohshima et al., 2003). However in media collected from cytokine-activated 
fibroblasts the level was much lower (2 ng/ml) and not different from that in non-
treated cells ruling out the possibility that galectin would contribute to neutrophil 
survival in this experimental setting.  
In summary, previous study by A. Filer (2006) as well as the present one eliminated 
a number of candidate neutrophil survival factors. Which other soluble molecules, 
apart from GM-CSF, are secreted by fibroblasts activated with TNFα and IL-17 that 
can delay neutrophil apoptosis remains to be established.  
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4.0 Expression of galectins and their regulation in 
fibroblasts 
4.1 Background 
Galectins are important modulators of cellular processes such as survival, apoptosis, 
adhesion or activation. As they affect many immune cell functions, galectins may be 
involved in immunoregulation elicited by stromal fibroblasts. 
One of the aims of this project was to establish a profile of galectin expression in 
fibroblasts from different anatomical sites with special regard to fibroblasts from 
patients with rheumatoid arthritis. This was necessary to determine whether there are 
differences in production of these lectins among fibroblasts which might contribute 
to site-specific differences in supporting immune cell survival.  
Numerous papers show galectin involvement in chronic inflammation (reviewed by 
(Rabinovich and Toscano, 2009). Galectin-1 administration reduced the severity of 
inflammation in several model of experimental inflammation (Rabinovich et al., 
1999; Offner et al., 1990, Santucci et al., 2000). Galectin-3 on the other hand appears 
to promote inflammation by various mechanisms described previously. Its high 
levels in serum was reported in inflammatory bowel disease,  Behcet’s disease, 
rheumatoid arthrits, as well as various cancers and correlated with disease severity 
(Frol'ova et al., 2009; Iurisci et al., 2000; Lee et al., 2007; Ohshima et al., 2003; 
Vereecken et al., 2006). Intestinal inflammation is another condition where galectins 
are important factors. Galectin-1 and -2 were shown to have a suppressive role in this 
disease by promoting T cell apoptosis, while galectin-4 exacerbated the 
inflammatory state via stimulation of CD4+ cells (Hokama et al., 2008). Galectin-9 is 
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also able to modulate autoimmune arthritis by selective reduction of Th17 responses 
and induction of regulatory T cells (Seki et al., 2008). 
Fibroblasts are known to produce many immunoregulatory mediators and may be an 
important source of galectins. It was previously shown that fibroblasts depending on 
their site of origin differentially regulated leukocyte survival (Filer et al., 2006a). For 
example, synovial fibroblasts supported the survival of T cells much better than those 
from the skin. That study also revealed galectin-3 as one of the classifiers in 
microarray gene expression analysis of fibroblasts from various sites (Filer, 2006) 
 
4.2 Expression of galectins in fibroblasts  
So far fibroblasts were reported to express galectin-3 and, upon activation, galectin-9 
(Hirashima et al., 2004; Asakura et al., 2002). Galectin-1 and -8 transcripts were 
found in extracts from multiple organs including heart, liver, prostate or thymus, but 
the specific cell types that express them were not identified (Rabinovich et al., 2002).  
Here seven primary fibroblast lines were screened for the expression of human 
galectins: 1 through 12. Galectin-13 was not considered here as it is considered only 
as a placental protein (Than et al., 1999). Two other cell lines: HT-29 (colon 
adenocarcinoma expressing galectin-2, -3, -4, -7, -8, -9) and HL-60 (acute myeloid 
leukaemia expressing galectin-1, -3, -8, -9, -10, -12) were used as positive controls. 
All fibroblast cell lines were grown in standard conditions and used between passage 
4-6. RNA extracts were treated with DNase to ensure that no contaminating cellular 
DNA was present. After conversion to cDNA PCR reactions with specially designed 
primers (Table. 2.2) were performed. PCR without RT yielded negative results. 
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Figure 4.1 shows representative images of the PCR amplification results. It was 
found that mRNA for galectin-1, -3 and -8 was present in all tested fibroblast 
samples. None of the samples had detectable levels of galectin-2 or -10, although 
both products were present in the positive controls HT-29 or HL-60, respectively 
(Fig. 4.1). Galectin-4 was not expressed by fibroblasts from spleen, lung, tonsil and 
thyroid. However, it was present in synovial, bone marrow and skin fibroblasts from 
RA patients, although the expression pattern varied between individuals. Galectin-7 
product could be seen in some samples only with a high number of rounds of PCR 
amplification (38 cycles), therefore it was uncertain if this was an artefact or not. 
With the exception of tonsilar fibroblasts, galectin-9 mRNA was detected in all other 
fibroblast types. Similar to galectin-4, there was significant variation among different 
individuals. Galectin-12 mRNA was detected in some synovial samples but not bone 
marrow or skin (Figure 4.1).  
As the traditional end-point PCR reaction is not accurate enough to measure 
quantitative differences in gene transcription products, all galectins were also 
analysed by the real-time PCR method in 4-6 matched fibroblast cell lines. Galectin-
7 expression was also checked by this method since the results obtained previously 
were rather inconclusive. Real-time PCR revealed high levels of galectin-1 and -3 
mRNAs in synovial, bone marrow and skin fibroblasts (Fig 4.2A). Expression of 
galectin-4 in all samples from five matched RA fibroblast lines (synovium, bone 
marrow, skin) was confirmed, but no significant site-specific differences in its 
expression were detected. Similar results were seen with galectin-8. Galectin-9 was 
present at all three sites. Interestingly, its level in synovial fibroblasts was 
significantly higher compared to bone marrow or skin fibroblasts (Fig.4.2B). Real-
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time PCR revealed the presence of galectin-12 mRNA in synovial fibroblasts from 
four out of six cell lines tested, but the levels of expression were quite variable. Skin 
fibroblasts did not show any expression of this galectin (Fig 4.2A). Due to lack of 
information on clinical parameters of patients from whom the biological material 
came, it was not possible to check whether the presence of galectin-12 in synovial 
fibroblasts correlated with any specific characteristics of those patients. 
It was also confirmed that galectins 2, 7 and 10 were not expressed by synovial, bone 
marrow or skin fibroblasts. It is worth noting that the real quantities of galectin 
transcripts were very different for each galectin. For example, the highest level of 
mRNA was noted for galectin-1 and galectin-3. The amount of galectin-8 was 10 
times lower than that of galectin-3 and galectins -4, -9 and -12 were about three logs  
lower than galectin-3 (Fig. 4.2A). 
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Fig. 4.1   Expression profile of galectins in fibroblasts of different origin. 
All fibroblasts were cultured in complete fibroblast media in standard conditions. 
Synovial, bone marrow and skin fibroblasts were from RA patients. Total RNA was 
extracted and reverse transcription-PCR reactions performed. Products were 
separated on agarose gel and visualised with ethidium bromide. Amplification of β-
actin was used to ensure cDNA presence in all samples. 
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Fig. 4.2  Quantitative differences in galectins mRNA expression in RA 
fibroblasts. 
A. cDNA from matched lines of synovial (SY), bone marrow (BM) and skin (DF) 
fibroblasts taken from 4-6 different RA patients was amplified using specific 
TaqMan probes. Bars represent relative quantities of target genes normalized to β-
actin and presented on log scale.  B. Dot plot showing differences in galectin-9 
expression in fibroblasts from different sites. Relative expression of galectin-9 
mRNA was quantified by real-time PCR in synovial (SY), bone marrow (BM), and 
skin (DF) fibroblasts from 5 matched lines, ** p<0.01 
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4.3 Expression of galectin-3 and -9 in synovial fibroblasts and tissue 
Galectins 3 and 9 were chosen for further study. Expression of galectin-3 in inflamed 
synovium was reported previously (Ohshima et al., 2003) and galectin-9 was 
potentially interesting because of its site-specific expression with higher levels in 
fibroblasts from RA synovium. Since fibroblasts from rheumatoid arthritis synovium 
differ in many respects from those derived from osteoarthritis patients, they were 
compared for the expression of galectin-3 and -9. 
Synovial fibroblasts from 12 RA and 9 OA patients were grown in culture and then 
analysed by real-time PCR for RNA expression and by Western blot for protein 
expression of galectin-3 and -9. There were no significant differences in the mRNA 
levels of these two galectins between RA and OA fibroblasts (Fig. 4.3 A and C). 
Both types of fibroblasts in culture had considerable amounts of intracellular 
galectin-3 and much lower levels of galectin-9 which was consistent with RNA 
levels. Although OA fibroblasts showed greater variation in protein levels of 
galectin-9 there was no disease-specific pattern in their expression (Fig.4.3 B and D). 
Next the expression of galectins in situ in RA and OA synovial tissue sections was 
examined. Synovial tissue specimens were fixed in 4% paraformaldehyde, embedded 
in paraffin and cut into 3 µm sections. Immunohistochemical staining was performed 
with specific anti-galectin antibodies (Table 2.1). Synovial tissue from rheumatoid 
arthritis patients showed strong galectin-3 expression throughout the expanded  
lining and sublining layers (Fig. 4.4 A). Osteoarthritic synovium also stained 
positively for galectin-3 but due to the lower cellularity of the tissue the staining 
appeared less intense (Fig. 4.4 E). To identify which cells express galectins double 
staining procedures were performed.  
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Fig. 4.3 Galectin-3 and -9 expression in fibroblasts from RA and OA patients. 
Upper panel (grey boxes) shows mRNA level measured by real-time PCR with 
specific Taqman probes normalized to 18S. Lower panel (white boxes) shows protein 
level measured by Western blot and expressed as ratio galectin/α-tubulin. A-B. 
Galectin-3 C-D. Galectin-9. Boxes represent 5-95 percentile, whiskers show range. 
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 Prolyl-hydroxylase-β was used as a marker for fibroblasts. This enzyme catalyses 
hydoxylation of proline residues during biosynthesis of collagen and is expressed 
mostly by fibroblasts. RA tissue displayed stronger staining for fibroblasts than OA 
confirming marked hyperplasia of these cells (Fig 4.4 B and F), but in both cases 
galectin-3 co-localized with the fibroblast marker (Fig. 4.4 C and G).  
To assess galectin-3 expression in macrophages, double staining with the 
macrophage surface marker CD68 was performed. The antibody clone used (PG-M1) 
specifically recognizes CD68 molecule present in macrophages. Double positive 
cells were seen in RA synovium, mostly in the sublining layer (Fig. 4.5). In OA 
tissue hardly any macrophages were observed which is in agreement with the general 
lack of subintimal cellular infiltration in this disease. 
 
Galectin-9 both in RA and OA was expressed in cells of the lining and scattered cells 
in the sublining, particularly around the microvessels (Fig. 4.6 and 4.8). Galectin-9-
expressing cells could be identified as fibroblasts (Fig. 4.6 B and D), macrophages 
(Fig. 4.7) and endothelial cells (Fig. 4.8 B, C and E) In addition, strong galectin-9 
expression in RA synovial tissue was observed at sites of invasion into the cartilage 
and subchondrial bone (Fig. 4.9) Interestingly, in contrast to galectin-3, galectin-9 
often displayed nuclear localization (Fig. 4.6 D, 4.8 C and E). 
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Fig. 4.4 Immunohistochemical detection of galectin-3 in synovial tissues from 
RA and OA patients – fibroblasts. 
Left panel (A-D) shows RA, right panel (E-H) OA synovia. Tissue sections were 
stained with anti-galectin-3 antibodies (red) (A, E), with anti-galectin-3 (red) and 
anti-prolyl hydroxylase (blue) (B-C, F-G) or with irrelevant IgG of the same isotype 
as controls (D, H). Original magnification x200, C and G x400.    
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Fig. 4.5 Detection of galectin-3 in RA synovial tissue – macrophages.  
Tissue sections were stained with anti-galectin-3 antibodies (red) and anti-CD68 
(blue). A. magnification 200x, B. magnification x400. 
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Fig. 4.6 Immunohistochemical detection of galectin-9 in synovial tissue from RA 
and OA patients – fibroblasts. 
Left panel (A-B) shows RA, right panel (C-D) OA synovia. Tissue sections were 
stained with anti-galectin-9 antibodies (red) (A, C), with anti-galectin-9 (red) and 
anti-prolyl hydroxylase (blue) (B, D). Original magnification x200. 
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Fig. 4.7  Detection of galectin-9 in RA synovial tissue – macrophages.  
Tissue sections were stained with anti-galectin-9 antibodies (red) and anti-CD68 
(blue). A. magnification x200, B. magnification x400. 
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Fig. 4.8 Immunohistochemical detection of galectin-9 in synovial tissue from RA 
and OA patients – endothelial cells. 
Left panel (A-C) shows RA, right panel (D-E) OA synovia. Tissue sections were 
stained with anti-galectin-9 antibodies (red) (A, D), with anti-galectin-9 (red) and 
anti-von Willebrand factor (blue) (B, E). Fig. C shows galectin-9 staining (purple). 
Original magnification A, B, D x200, C and E x400. 
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Fig. 4.9 Galectin-9 in RA fibroblasts at sites of invasion. 
RA tissue sections of synovium invading cartilage and bone were stained with anti-
galectin-9 (red) (A) or with anti-galectin-9 (red) and anti-prolyl hydroxylase (blue) 
antibodies (B). Magnification x200.  
A 
B 
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4.4 Regulation of expression of galectin-3 and galectin-9 
Having established the profile of galectin expression in resting fibroblasts it was 
investigated how they might be regulated in pathological conditions. Possible factors 
affecting galectin expression in the rheumatoid joint microenvironment could be 
inflammatory cytokines or ligands for pattern recognition receptors such as Toll-like 
receptors. It was also hypothesised that epigenetic mechanisms may be involved in 
regulation of galectin expression in RA fibroblasts, as the pattern of expression is 
maintained through many passages in culture. 
 
4.4.1 Cytokines 
Studies on the regulation of galectins in fibroblasts so far showed increased galectin-
3 protein in RA synovial fibroblasts after TNFα treatment (Ohshima et al., 2003). It 
was also reported that IFNγ may induce galectin-9 in lung and dermal fibroblasts 
(Asakura et al., 2002). In the present study a potential role for other macrophage, 
stromal and T cell-derived cytokines on galectin expression by fibroblasts was 
assessed. IL-1β, TNFα and IL-6 are among the most prominent cytokines found in 
the synovium (Arend and Gabay, 2006). TNFα is of primary importance in the 
pathogenesis of RA (Feldmann et al., 1996). Together with IL-1β it is a potent 
activator of synovial fibroblasts inducing production of inflammatory mediators 
(cytokines, chemokines, prostaglandins), enzymes and adhesion molecules (McInnes 
and Schett, 2007; Konttinen et al., 2000). IL-6 mediates some systemic 
manifestations of the disease and is considered a marker of the disease severity 
(Nishimoto, 2006). IFNγ was also detected in RA synovium (Simon et al., 1994; 
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Kotake et al., 1997) although other reports describe low levels of this cytokine in 
established disease (Firestein and Zvaifler, 1987). IFNγ antagonizes some of the 
actions of TNFα such as induced proliferation or MMP production (Alvaro-Gracia et 
al., 1990) by synovial fibroblasts. Presence of IL-17 and its role in arthritis gained 
much interest in the last few years and has already been discussed. IL-4 is a Th2-type 
cytokine with mostly anti-inflammatory properties (Arend and Gabay, 2006; Horsfall 
et al., 1997). It was detected at early stages of RA (Raza et al., 2005a) and in certain 
histological types of synovitis (i.e. granulomatous, (Klimiuk et al., 1997)). Similarly 
to interferons, IL-4 decreases collagen synthesis by fibroblasts (Konttinen et al., 
2000). It also regulates inflammatory mediators production (Dechanet et al., 1995b). 
TGFβ is another pleiotropic cytokine associated with rheumatoid arthritis (Miossec 
et al., 1990). It is produced by various stromal cells and modulates fibroblast 
recruitment and proliferation as well as production of chemokines, enzymes and 
matrix components (Konttinen et al., 2000). 
 To assess the role of these inflammatory cytokines on the expression of galectins, 
matched lines of synovial, bone marrow and skin fibroblasts derived from RA 
patients were stimulated for 24h with the following cytokines: IL-1β, IL-6, IL-17, IL-
4, IFNγ, TNF-α or TGFβ. Galectin-3 mRNA levels in synovial fibroblasts were not 
affected by cytokine treatments (Fig. 4.10 A). Only fibroblasts derived from skin up-
regulated galectin-3 after exposure to IL-4. A similar tendency was seen with IL-6 
and IL-17 treatments but the response was more variable among individual samples 
and therefore statistically not significant. Interestingly, bone marrow fibroblasts 
down-regulated galectin-3 after IFNγ or TNFα treatment (Fig. 4.10 A). 
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Fig. 4.10  Effect of cytokine stimulation on expression of galectin-3 and -9 
mRNA.  
Synovial (SY), bone marrow (BM) and skin (DF) fibroblasts were treated for 24 h 
with 10ng/ml of indicated cytokines. Galectin mRNA expression was quantified by 
real-time PCR and represented as fold change of expression by non-treated cells (C-
control).  Bars represent mean values from 5-6 synovial and skin cell lines and 3-4 
bone marrow lines. A. Changes in galectin-3 expression B. Changes in galectin-9 
expression. * p<0.05, ** p<0.01 as compared to expression in control cells from the 
same site. 
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Increased levels of galectin-9 transcript were observed in synovial fibroblasts 
stimulated with IL-1β and TNFα (Fig. 4.10 B). However, because responses to the 
latter varied considerably among individual samples they did not reach significance 
with such low numbers of samples. IL-1β, on the other hand, had a modest but much 
more consistent effect on galectin-9 transcription (2-3 fold increase). However, the 
most pronounced effect on expression of galectin-9 was observed upon IFNγ 
treatment (Fig. 4.10 B). This induction at the mRNA level was followed by increase 
of galectin-9 protein (Fig. 4.11). Simultaneous addition of IFNγ-neutralising 
antibody (5µg/ml) with IFNγ treatment resulted in inhibition of this effect (Fig. 
4.11). Since the estimated molecular weight of galectin-9 short, medium and long 
isoform is 34.5 kDa, 35.9 kDa and 39.5 kDa, respectively (Chabot et al., 2002), the 
observed isoforms most likely correspond to medium and long forms. 
To elucidate the mechanism underlying IFNγ-induced galectin-9 upregulation 
the signalling pathways involved were studied further. IFNγ can signal by a classical 
pathway involving receptor-associated tyrosine kinases of the Janus family (JAK1, 
JAK2) and transcription factor STAT (signal transducer and activator of 
transcription) but also activate alternative STAT-independent ways involving Akt 
kinase or Rap-1 (Kaur et al., 2008; Alsayed et al., 2000). STAT molecules are 
recruited to the activated receptor and phosphorylated in order to transduce the 
signal. p38 MAP kinase performs additional phosphorylation of STAT1 molecule 
which enhances its transcriptional acitivity (Schindler et al., 2007; Platanias, 2003).  
To assess the activation of STAT1 transcription factor following IFNγ stimulation 
synovial fibroblasts were treated with 10ng/ml recombinant cytokine for various 
periods of time and then cell lysates prepared and analysed by Western blotting. 
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Phosphorylation of STAT1 could be seen as soon as 5 min. after addition of IFNγ 
and steadily increased over time (Fig. 4.12). Additionally blots were probed with an 
antibody for phosphorylated form of p38 MAPK. Activation of p38 was greatest 
after 15 min. and then decreased thereafter (Fig. 4.12). 
Phosphorylated STAT1 translocates to the nucleus where it can bind to promoters of 
IFN-inducible genes (Schindler et al., 2007). To verify whether the activated 
transcription factor changed its subcellular localization in fibroblasts after treatment 
with IFNγ, cells were stimulated for 15 min. then fixed, permeabilized, stained with 
anti-STAT1 antibody and analyzed by confocal microscopy. As seen in Fig. 4.13A 
untreated cells show cytoplasmic STAT1 staining, but in IFNγ-stimulated cells 
STAT1 co-localized with the red nuclear staining indicating an effective 
translocation into the nucleus (Fig. 4.13B). Because STAT phosphorylation can 
occur in response to various growth factors present in serum, in both experiments 
cells were grown in low-serum medium (0.5% FCS) for 3 days prior to treatment. 
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Fig. 4.11 Galectin-9 protein in synovial fibroblasts after IFNγ treatment. 
RA synovial fibroblasts were treated with 10ng/ml IFNγ for 24h, 48h or with IFNγ 
and 5µg/ml neutralising anti- IFNγ antibody for 24h. Cell lysates were prepared and 
analysed by Western blot. Two bands correspond to galectin-9 isoforms of different 
length.  
 
 
Fig. 4.12 Activation of STAT and p38 MAPK in synovial fibroblasts stimulated 
with IFNγ.  
RA synovial fibroblasts were treated with 10ng/ml IFNγ for 5, 15, 30, 60 min. Cell 
lysates were prepared for Western blot. Phosphorylation of STAT1 and p38 was 
assessed by probing with phospho-specific antibodies. β-actin was used as loading 
control.  
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Fig. 4.13 Translocation of STAT in synovial fibroblasts stimulated with IFNγ. 
RA synovial fibroblasts were stained with anti-STAT1 antibody (green), nuclei were 
counterstained with propidium iodide (red). Bar indicates a 50µm scale. A. untreated 
cells B. cells treated with 100ng/ml IFNγ for 15min. C. negative control (primary 
antibody omitted) 
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4.4.2 Toll-like receptors ligands 
Toll-like receptors constitute an important part of innate immune system and allow 
for early detection of infectious agents. They recognize pathogen-associated 
molecular patterns (PAMPs) such as conserved bacterial cell wall structures 
(lipopolysaccharides, lipopeptides, proteoglycan), bacterial unmethylated DNA or 
viral RNA (Akira et al., 2001). Engagement of Toll-like receptors leads to activation 
of antigen-presenting cells expressing them and to presentation of microbial antigens 
to cells of the adaptive immune system (Schnare et al., 2001). It was demonstrated 
that stimulation of immune responses by bacterial TLR ligands can induce arthritis in 
animal models (Joosten et al., 2003).   
 While no specific infectious organism has been isolated from joints of RA patients, 
bacterial products were often noted in rheumatoid patients and those with other 
arthritides (Wilkinson et al., 1999; Siala et al., 2009). This suggests that such agents 
may contribute to inflammatory reaction in the joint by acting as adjuvants in the 
host response.  
However, it was also suggested that TLRs bind some endogenous ligands and can 
cause activation of immune response in the absence of infection. They are involved 
in response to injury, repair of damaged tissues or clearance of cell debris (Marshak-
Rothstein, 2006). Certain heat shock proteins, fibronectin and HMGB (high mobility 
group box 1 protein) released from damaged cells or breakdown products from 
extracellular matrix such as hyaluronate may serve as ligands for TLR2 and/or 4 
(Ohashi et al., 2000; Roelofs et al., 2006; Park et al., 2006; Termeer et al., 2002). 
Moreover, double or single stranded RNA from dead cells can be detected by TLR3 
and TLR7/8, respectively (Kariko et al., 2004; Zare et al., 2004).  
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RA synovial fibroblasts were shown to express TLR2 and TLR4, both  in culture and 
in synovial tissue (Seibl et al., 2003; Radstake et al., 2004). Expression of TLR 3 
which recognizes double stranded RNA was also reported in RA synovium 
(Brentano et al., 2005; Ospelt et al., 2008). Stimulation of these receptors with 
specific ligands (peptidoglycan or lipopeptide for TLR2) led to increased secretion of 
inflammatory mediators such as cytokines (IL-6), chemokines (CXCL8, CCL5, 
CCL8, CXCL6, CXCL2),  cyclooxygenase and matrix metalloproteinases (MMP-1, -
3, -13) (Pierer et al., 2004; Kyburz et al., 2003; Ospelt et al., 2008). Similar 
responses were observed upon TLR3 activation, namely production of  IFNβ, IL-6, 
CCL5, CXCL10, MMP-3 and -13 (Brentano et al., 2005). 
 
To address the question whether activation of toll-like receptors can affect expression 
of galectins, RA synovial fibroblasts were stimulated with specific ligands. Bacterial 
lipopeptide (bLP) which is a component of Gram-positive cell wall was used as 
ligand for TLR2. Polyinosinic–polycytidylic acid (poly I:C), an authentic double-
stranded RNA was used to trigger TLR3 and lipopolysaccharide (LPS), an integral 
component of the outer membranes of Gram-negative bacteria for TLR4. IL-1β and 
TNFα treatments were also used for comparison with the previous results. RNA 
expression of galectins was measured by real-time PCR. While galectin-3 mRNA 
level was not affected by any of the ligands (Fig. 4.14A), galectin-9 showed marked 
increase following TLR3 engagement. It was also up-regulated by 
lipopolysaccharide though to a lesser extent (Fig. 4.14B). IL-1β had a similar effect 
as in previous experiments, although it was used at a lower concentration (1ng/ml).  
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Fig. 4.14 Effect of TLR-ligands on expression of galectin-3 and -9 mRNA. 
Synovial fibroblasts were treated with: 10ng/ml TNF, 1ng/ml IL-1β, 300ng/ml 
bacterial lipoprotein (bLP), 10µg/ml poly(I-C), 100ng/ml lipopolysaccharide (LPS) 
for 24h. RNA was extracted and reverse-transcribed into cDNA. Galectin levels were 
measured using specific Taqman probes and normalized with 18S. A. Galectin-3 B. 
Galectin-9. Bars represent mean +SEM from 4 experiments, * p<0.05, ** p<0.01 
compared to expression in untreated cells.   
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4.4.3 Epigenetic factors – DNA methylation 
Epigenetic changes define all heritable changes to gene expression which are not 
encoded by DNA sequence itself. The major epigenetic regulatory mechanisms 
comprise posttranslational modifications to histones or other chromatin-associated 
proteins, methylation of DNA and microRNA activity (Karouzakis et al., 2009; 
Kouzarides, 2007). In mammalian cells methylation is found throughout the genome 
(Suzuki and Bird, 2008). This contrasts with bacterial genetic material which has a 
low status of methylation and allows for specific recognition of foreign DNA via 
TLR9 (Pedersen et al., 2005). 
In normal conditions addition of methyl residue to cytosine by methyl transferases 
(DNMT) prevents binding of transcription factors to DNA molecules and leads to 
stable transcriptional silencing of a gene (Sanchez-Pernaute et al., 2008; Miranda and 
Jones, 2007). This mechanism has a fundamental role in embrionic development, X 
chromosome inactivation, cell differentiation as well as silencing of retroviral 
elements (Karouzakis et al., 2009; Suzuki and Bird, 2008). Incorrect methylation 
patterns can result in dedifferetiation of cells and impose new characteristics on 
them. Indeed, altered DNA methylation of many genes has been associated with 
transformation of cells into tumour phenotype (Jones and Baylin, 2007). 
Hypomethylation can also occur in inflammatory diseases (Kim et al., 1996). It is 
becoming evident that epigenetic processes may influence the development of 
rheumatic diseases (Strietholt et al., 2008). Recent reports on global genomic 
hypomethylation in RA synovial fibroblasts suggest that activation of many genes 
normally silenced by methylation may contribute to the appearance of activated 
transformed phenotype of these cells (Karouzakis and et al., 2007; Karouzakis et al., 
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2008). For example, demethylation of IL-6 promoter could be responsible for the 
constitutive production of this cytokine (Nile et al., 2008). IL-6 in turn regulates 
DNA methyltransferase affecting methylation of other genes (Karouzakis et al., 
2009). 
Promoter regions with a high frequency of CpG dinucleotides, referred to as CpG 
islands, are indicative of a gene’s susceptibility to regulation by methylation. As for 
galectins, it was demonstrated that DNA methylation is responsible for changes in 
galectin-1 gene expression during development (Benvenuto et al., 1996) as well as 
for silenced expression of galectin-7 in nonaggressive lymphoma cells (Moisan et al., 
2003). Galectin-3 promoter sequence is also CG rich (74%) (Kadrofske et al., 1998). 
As depicted in Fig. 4.15 this region can be identified as a CpG island. In contrast, the 
galectin-9 promoter sequence does not display such properties. 
To assess if methylation status can affect expression of galectin-3 and -9 in RA 
synovial fibroblasts, cells were cultured in the presence of the methylation inhibitor 
5-aza-deoxycytidine (0.1 or 1µM). This cytidine analog does not change methylation 
status of quiescent cells, but inhibits DNA methyltransferase action during cell 
division causing demethylation in daughter cells. Fibroblasts were seeded at low 
density and allowed to expand in culture for 7 days in the hypomethylating milieu. 
At the end of culture the majority of cells would come from new cells divisions and 
have global DNA hypomethylation. Cell lysates were then prepared and analyzed by 
Western blotting for quantification of galectin-3 and -9 levels. Though galectin-9 
levels did not change, galectin-3 showed an approximately 30% increase after 
treatment with 1µM 5-aza-deoxycytidine as compared to untreated cells, indicating 
that its promoter was demethylated and further activated (Fig. 4.16). 
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Fig. 4.15 Schematic representation of galectin-3 and galectin-9 promoters. 
Figures show results of methylation sites prediction from MethPrimer website 
(http://www.urogene.org/methprimer/index1.html). Galectin-3 (A) and galectin-9 (B) 
promoter sequences were taken from Gene Bank. Red ticks show CpG dinucleotides 
in the DNA sequence, CpG island shaded in blue. 
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Fig. 4.16 Effect of DNA demethylation on expression of galectin-3 and -9 
protein. 
Synovial fibroblasts were treated with 0.1 or 1 µM 5-aza-2'-deoxycytidine (5-azaC) 
for 7 days. Cell lysates were prepared and analysed by Western blotting.  
A. Representative blots showing galectin-3, -9 and loading control (α-tubulin).  
B and C. Quantification of Western blot results. Protein levels expressed as % of 
control (untreated) cells. Bars represent mean+SD from 4 experiments.*p<0.05 
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4.5 DISCUSSION 
Galectin expression profile 
This chapter set out to examine the profile of expression of a broad range of galectins 
and to see if there were site-specific differences among fibroblasts of different 
anatomical origin. The main focus was on synovium, bone marrow and skin 
fibroblasts from RA patients, but these were also compared to 4 other primary 
fibroblast lines (from lung, spleen, tonsil and thyroid). These fibroblasts were 
assumed to be normal although there is a possibility that the tonsil fibroblasts might 
have been from inflamed tissue. Due to the lack of complete information on the 
condition of individuals they were taken from, it was not possible to rule this out. 
The advantage of using matched cell lines from synovium, bone marrow and skin of 
the same RA patients is the elimination of genetic variations or possible differences 
arising from various disease courses and types of treatment. The individual patients’ 
characteristics (disease severity, clinical parmeters, treatment history) may affect the 
phenotypes and behaviour of fibroblasts obtained from these individuals and account 
for a wide range of expression levels or responses of cells observed in many 
experiments. Lack of clinical data to correlate with particular cell lines made 
interpretation of the results more difficult. 
In all fibroblast subsets tested the expression of ubiquitous galectins -1 and -8 was 
confirmed but without any site-specific differences. These galectins are known to be 
expressed in a wide range of tissues (Chiariotti et al., 2004) and so the data gained 
here confirms that reported in the literature. With regard to cells present in the 
rheumatoid joint, the expression of galectin-1 was previously shown for 
macrophages, T and B cells (Blaser et al., 1998, Zuniga et al., 2001, Rabinovich et 
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al., 1998) and in the lining of RA synovium (Ohshima et al., 2003). Galectin-8 has 
not been reported specifically in fibroblasts although the expression was found in 
multiple organs (Table 1.1). This galectin is thought to mainly mediate cell adhesion 
so may have a role in the structural functions provided by fibroblasts. Only one 
report indicates of a role for galectin-8 in rheumatoid arthritis. It was shown to be a 
ligand for CD44 expressed on synovial fluid cells and can induce their apoptosis 
(Eshkar Sebban et al., 2007). The authors suggest that binding of galectin-8 in 
complexes with CD44 and fibrinogen can cause its sequestration and exacerbation of 
an inflammatory state. 
Galectin-4, on the other hand, seemed to be expressed differently in RA vs. normal 
fibroblasts. This lectin has been reported as connected with the gastro-intestinal tract 
(Chiarcotti et al., 2004) but its expression can also be induced in tumours from other 
tissues (Huflejt and Leffler, 2004). Therefore, its presence in the RA patient tissues 
was interesting. The expansion of the pannus tissue in the rheumatoid joint has been 
compared to a transformed tissue and galectin-4 expression may reflect the 
proliferative state of the synovial stromal tissue. However, it does not explain 
galectin-4 presence in fibroblasts from the skin, which should not be affected by the 
inflammatory process.  
Another galectin that was found to differentiate synovial fibroblasts from the others 
was galectin-12. Its transcript has previously been reported in adipose tissue, heart, 
pancreas, spleen, thymus, and peripheral leukocytes (Yang et al., 2001). Moreover, 
galectin-12 is up-regulated in cells synchronized at the G1 phase or the G1/S 
boundary of the cell cycle (Wang et al., 2004). There was no data on its presence in 
fibroblasts. The function of this galectin was documented as a cell cycle regulator 
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able to arrest its progression at the G1 phase and induce cell apoptosis (Yang et al., 
2001; Hotta et al., 2001). Finding that galectin-12 may be present in RA synovial 
fibroblasts but not those from skin may reflect greater proliferative activity of these 
cells or induction of a regulatory mechanism to suppress it. Lack of expression of 
galectins 2, -7 and -10 in resting fibroblasts agrees with their restricted cell type-
specific expression reported in the literature (Table 1.1). 
 
Galectin-3 
Abundant expression of galectin-3 was found in all fibroblasts tested regardless of 
their site of origin or condition they were taken from (rheumatoid arthritis or 
osteoarthritis). Studies of synovial tissue in situ revealed also galectin-3 expression 
by other cell types such as macrophages. 
Galectin-3 has been documented previously in macrophages, fibroblasts, 
chondrocytes and activated T cells (Rabinovich et al., 2002; Perillo et al., 1998). It 
may be overexpressed in some types of cancers (van den Brule et al., 2004). 
Increased galectin-3 together with decrease in galectin-1 expression has been 
associated with inflammation (Andre et al., 1999; Ellerhorst et al., 1999). Indeed, 
such an altered pattern can be observed in synovial tissue of patients with juvenile 
idiopathic arthritis (Harjacek et al., 2001). With regard to RA, galectin-3 presence 
was found previously in cultured synovial fibroblasts and in situ in the synovium but 
without identification of specific cell types (Ohshima et al., 2003). Here it was 
confirmed that synovial fibroblasts expressed high levels of galectin-3, however no 
disease specific differences between cells from RA and OA patients were seen. 
Because of technical difficulties in obtaining synovial fibroblasts from healthy 
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individuals only one such cell line was analysed. The results of galectin-3 expression 
levels were similar to those from RA and OA patients suggesting that the disease 
process does not result in intracellular accumulation of RNA or protein. Ohshima et 
al. reported increased levels of galectin-3 in serum and synovial fluid of RA patients 
compared to OA and healthy controls but also failed to observe differences at the 
RNA or intracellular protein levels in synovial fibroblasts (Ohshima et al., 2003). 
This indicates that the regulation of galectin-3 production may occur during 
translation or secretion of the protein.  
It could be argued that in vitro culture conditions influence the expression of 
galectin-3 and cause all fibroblasts to converge to a similar phenotype. Galectin-3 
has a serum response element in its promoter (Kadrofske et al., 1998) and therefore 
could be induced in cells expanded in standard medium containing 10% fetal calf 
serum. However, the previous study which used serum-starved cells did not show 
significant difference in galectin-3 mRNA level in low (0.05%) vs. high (10%) 
serum (Ohshima et al., 2003). 
Another possibility to explain the elevated levels of galectin-3 in RA is that other 
cells in the synovium apart from synovial fibroblasts contribute to its production.  In 
order to identify them tissue sections of RA and OA synovium were examined by 
immunohistochemistry. Both in RA and OA fibroblasts showed intense positive 
staining for galectin-3 protein. Due to higher numbers of cells in the hyperplastic 
synovial layers, RA tissue samples had more galectin-3. Macrophages were also 
abundant in RA, but not OA synovium, and therefore may significantly contribute to 
enhanced galectin-3 production in this disease.   
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Expression of galectin-3 in synovial fibroblasts can be regulated by external stimuli. 
This study revealed that epigenetic modifications in galectin-3 promoter may be 
more important for the regulation of its expression in RA synovial fibroblasts than 
the action of cytokines or TLR ligands. 
Previously it was shown that RA fibroblasts up-regulate galectin-3 upon adhesion to 
cartilage components (cartilage oligomeric matrix protein, COMP), a process 
mediated by integrins (Neidhart et al., 2005). Fibroblasts derived from osteoarthritis 
patients’ joints showed less adhesion to this substrate. This observation would 
suggest that increased galectin-3 in RA synovium may be a secondary effect caused 
by higher expression of integrins and presence of their ligands (Neidhart et al., 1997) 
rather than being an intrinsic property of RA synovial fibroblasts.  
Other factors potentially influencing galectin expression in rheumatoid joint are 
inflammatory cytokines. We did not observe significant changes in galectin-3 mRNA 
in synovial fibroblasts following various treatments, although in some fibroblast cell 
lines it seemed to be up-regulated by TNFα. It was reported that intracellular 
galectin-3 protein level may increase upon stimulation with TNFα, even though no 
change in mRNA level could be detected (Ohshima et al., 2003). Therefore RNA 
transcription rates do not necessarily reflect changes in protein production and in the 
case of galectin-3 regulation can occur at other levels. Enhanced production of 
galectin-3 in skin fibroblasts after treatment with IL-4 is consistent with the recently 
described role for this lectin in skin inflammation, a typically Th2 driven process 
(Saegusa et al., 2009). 
Since exposure to cytokines did not seem to affect galectin-3 expression in synovial 
fibroblasts, it was examined whether epigenetic regulatory mechanisms may be 
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involved. Methylation of galectin-3 promoter was previously shown in pituitary 
tumours, breast and thyroid carcinoma cell lines (Ruebel et al., 2005) and prostate 
cancer cells (Ahmed et al., 2007). In all cases methylation correlated with silencing 
of the gene and lack of galectin-3, whereas cells producing the protein had 
unmethylated promoters. RA fibroblasts produce galectin-3 constitutively, therefore 
the promoter in these cells cannot be completely silenced. However, treatment with 
demethylating agent 5-aza-cytidine resulted in further upregulation of galectin-3 
expression which might indicate partial methylation. Alternatively, the observed 
effect may be indirect, i.e. hypomethylation leads to increased expression of another 
factor which in turn regulates galectin-3. Given the long time point when the protein 
measurement was done such possibility cannot be excluded. 
  
Galectin-9   
Galectin-9 was found to be expressed at higher levels in synovial fibroblasts from 
rheumatoid joint than from other sites. Cytokines such as IFNγ or IL-1β and Toll-like 
receptor ligands may by involved in regulation of its expression.   
Galectin-9 is characteristic for some myeloid cells (eosinophils, monocytes, 
macrophages) but was also identified at certain developmental stages in the thymus 
and liver (Wada et al., 1997). Expression in fibroblasts was shown earlier by Asakura 
et al. (2002).  During the course of this study an interesting paper by Seki et al. was 
published. The authors showed expression of galectin-9 in many cells of the RA 
synovium including vimentin-positive cells, most of which are fibroblasts, 
endothelial cells and lymphocytes (Seki et al., 2007). 
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The present study compared galectin-9 expression in synovial tissue of rheumatoid 
arthritis and osteoarthritis patients. Presence of this galectin was noted in fibroblasts, 
endothelial cells and macrophages. A remarkable finding was the strong expression 
of galectin-9 in fibroblasts invading the cartilage and bone. This observation led to 
further studies on possible roles of galectin-9 in synovial fibroblasts which are 
described in chapter 5. 
Some previous reports did not detect galectin-9 in fibroblasts in physiological 
conditions but found an up-regulation of this galectin upon stimulation with 
inflammatory cytokines (Hirashima et al., 2004). However, in contrast to Jurkat cells 
that secrete galectin-9 after activation with phorbol 12-myristate 13-acetate (PMA) 
treatment (Chabot et al., 2002) the increased expression of galectin-9 on fibroblasts 
was not matched with its release measured as eosinophil chemoattractant activity 
(ECA) (Asakura et al., 2002). The authors therefore suggested that fibroblasts may 
lack specific protease (MMP) involved in shedding of galectin-9 from the surface. 
The present study showed that galectin-9 was expressed in fibroblasts in culture but 
at a very low level (both mRNA and protein) compared to other galectins, for 
example galectin-3.  Interestingly, fibroblasts of synovial origin had significantly 
higher levels of galectin-9 transcripts compared to skin-derived fibroblasts from the 
same individuals. This might reflect either site-specific imprinted phenotypes of 
fibroblasts or changes acquired in the inflammatory microenvironment.  Therefore, it 
was necessary to examine how pathogenic agents from rheumatoid joint modulate 
galectin-9 expression. Studies on inflammatory cytokine stimulation revealed that 
galectin-9 expression in synovial fibroblasts was enhanced after exposure to IL-1β 
and TNFα. However, response to the latter showed great variability (3 to 15 fold) 
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among different cell lines and with a low number of samples the effect was not 
statistically significant. The observed variations might be due to previous treatments 
(for example anti-TNF agents) received by individual patients. 
The greatest change in galectin-9 mRNA production was observed following IFNγ 
stimulation. A similar effect was seen across all fibroblast lines but the increase in 
synovial and skin fibroblast was a few times higher compared to bone marrow cells. 
This finding is in agreement with previous reports on skin (Igawa et al., 2006) and 
lung fibroblasts (Asakura et al., 2002) where galectin-9 mediated eosinophil 
attraction and adhesion which was implicated in development of fibrotic disease. 
Enhanced production was also observed at the protein level and could be inhibited by 
IFNγ-neutralising antibody. Whether the up-regulation of intracellular galectin-9 in 
RA synovial fibroblasts is followed by increased release into the extracellular space 
is not known. 
Extracellular galectin-9 was shown to induce apoptosis of activated T helper 1 (Th1) 
cells by interacting with TIM-3 ligand on their surface (Kashio et al., 2003; Zhu et 
al., 2005). Th1 cells produce large amounts of IFNγ upon activation. Therefore 
induction of galectin-9 from fibroblasts would serve as a negative feedback loop to 
prevent an uncontrolled inflammatory response. In RA joint, however, T cells seem 
to be defective in terms of cytokine production. They are capable of producing this 
cytokine in vitro when stimulated (Abreu et al., 2009) but the level of IFNγ in 
synovial fluids of established RA is much lower than in other Th1-mediated diseases 
(Firestein et al., 1990; Kotake et al., 1997). Suppressed production of interferon-γ as 
well as IL-2 may result from the presence of large amounts of IL-10 in synovial 
tissue and fluid (Arend and Gabay, 2006). Given the fact that IFNγ has 
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antiproliferative effects on fibroblasts (Elias et al., 1987), can counteract certain 
TNFα-induced effects (Alvaro-Gracia et al., 1990; Williams et al., 2007) and 
regulates T cell apoptosis via galectin-9-TIM3 interactions, this cytokine could have 
a homeostatic role in inflammation. However, its regulatory mechanisms are 
defective in RA and consequently lead to persistent inflammation (Raza et al., 
2005a). 
Another interesting finding was the up-regulation of galectin-9 by Toll-like receptor 
ligands: double stranded RNA and bacterial LPS. In contrast, galectin-3 was not 
affected by these treatments. Induction of galectin-9 by dsRNA was shown 
previously in vascular endothelium (Imaizumi et al., 2007). In HUVECs LPS also 
induced galectin-9 mRNA but not protein indicating that control by post-
transcriptional mechanisms is important for the effects in these cells. Galectin protein 
production in fibroblasts following TLRs stimulation was not tested, so it is not clear 
whether the effect at RNA level translates into functional changes.   
Up-regulation of a protein upon IFNγ and TLR3 stimulation may suggest 
involvement in antiviral responses but this area with regard to galectins remains 
unexplored. However, it was shown in an animal model that galectin-9 is induced  in 
LPS-triggered inflammation and has a protective, anti-inflammatory role (Tsuboi et 
al., 2007). 
Although evidence for infectious events in pathogenesis of rheumatoid arthritis is 
scarce, in some patients bacterial products were identified in diseased joints (Siala et 
al., 2009). Therefore early induction of inflammatory process by activation of 
synovial fibroblasts via Toll-like receptors cannot be excluded. More importantly, in 
the absence of pathogenic material TLRs can provoke an inflammatory response by 
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recognition of endogenous ligands (Kawane et al., 2006; Marshak-Rothstein and 
Rifkin, 2007). RNA or intracellular proteins released from dead cells and matrix 
breakdown products such as hyaluranate, fibronogen can engage TLRs. These 
products are readily available in inflamed joint (Roelofs et al., 2006; Brentano et al., 
2005) and can cause activation of resident fibroblasts and perpetuation of 
inflammatory process at this site (Sacre et al., 2007; Ospelt et al., 2004a).  Moreover, 
inhibition of TLR activation prevented the development of collagen-induced arthritis 
(Abdollahi-Roodsaz et al., 2007).  
Because of the possible induction of galectin-9 in the synovium by cytokines and 
TLR ligands its potential role was studied further (chapter 5).  
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5.0  Role of galectin-9 in RA synovial fibroblast function 
5.1 Background  
Galectin-9 is well recognized as an eosinophil chemoattractant (Mastumoto, 
Spitzenberger et al., 2001). It is also known to trigger apoptosis of T cells expressing 
TIM-3 on their surface (Zhu et al., 2005; van de Weyer et al., 2006). Recently Seki et 
al. identified significant galectin-9 expression in rheumatoid arthritis synovium. The 
authors also demonstrated induction of apoptosis in synovial fibroblasts by a mutant 
form of galectin-9 and reported the ability of the mutant galectin-9 to reduce 
inflammation in the mouse collagen-induced arthritis model (Seki et al., 2007). 
Whether the effects of the mutant galectin-9 in vivo extended beyond induction of 
apoptosis was not determined. Moreover, the role for a naturally occurring galectin-9 
in these fibroblasts was not established.  
 
The present study revealed that expression of galectin-9 in RA synovial fibroblasts 
was higher than in skin samples from the same individuals. In addition, RA synovial 
fibroblasts from the aggressive pannus tissue displayed strong positive staining for 
galectin-9. It was hypothesised that expression of this galectin may affect synovial 
fibroblast functions such as proliferation, apoptosis or production of inflammatory 
mediators and matrix degrading enzymes. This hypothesis was tested in this chapter 
using an siRNA approach. 
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5.2 Effect of galectin-9 silencing on fibroblast apoptosis and 
production of inflammatory mediators 
 
To elucidate what role intracellular galectin-9 may play in RA synovial fibroblasts, 
the small interfering RNA (siRNA) technique was used to silence its expression. 
Fibroblasts grown in culture were transfected with 33 nM siRNA designed to bind to 
all galectin-9 isoforms or with control RNA sequences which do not bind to any 
known mRNAs. Expression of galectin-9 mRNA was assessed by real-time PCR at 
24, 48 and 72h after transfection. Fig. 5.1A shows that the greatest effect at mRNA 
level was obtained after 72h (96% inhibition). Galectin-9 protein at this time point 
was also dramatically reduced (Fig. 5.1B).  
 
Spontaneous and induced apoptosis of RA synovial fibroblasts in culture was 
assessed by staining the cells with annexin-V-FITC and analysed by flow cytometry. 
It was found that the rates of both spontaneous apoptosis and that induced by the 
broad spectrum kinase inhibitor staurosporine were higher in galectin-9 knockdown 
cells than in controls. Galectin-9 silencing resulted in an increase in apoptosis from 5 
to 10% for untreated cells and from 35 to over 60% for staurosporine treated cells 
(Figure 5.2). 
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Fig. 5.1 Galectin-9 silencing in RA synovial fibroblasts.  
Cells were transfected with galectin-9 siRNA or control siRNA. A. Galectin-9 
mRNA measured by real-time PCR 24, 48 and 72h after transfection and normalized 
to 18S. Data are mean +SD from three independent experiments. ***p<0.001, 
compared to cells transfected with control siRNA.  B. Galectin-9 protein in synovial 
fibroblasts 72h after transfection with galectin-9 or control siRNA. α-tubulin was 
assessed as a loading control. 
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Fig. 5.2  Effect of galectin-9 silencing on synovial fibroblast apoptosis. 
Fibroblasts were transfected with galectin-9 or control siRNA. After 72h cells were 
treated with 5µM staurosporine (STP) for 5h or left untreated. Cells were stained 
with Annexin-V-FITC and analyzed by flow cytometry to identify apoptotic cells. A. 
Representative histograms showing annexin-V positive cells transfected with control 
siRNA (left) and gal-9 siRNA (right). Single line-untreated cells, filled-cells treated 
with STP. B. Cumulative data from 6 experiments. Circles-control siRNA transfected 
cells, squares-gal-9 siRNA transfected cells. * p<0.05.  
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Proliferation of control siRNA and galectin-9 siRNA transfected cells was measured 
using the XTT Cell Proliferation kit. Cells were transfected with respective siRNAs 
and either treated with 10ng/ml IL1-β and 10ng/ml TNFα to stimulate proliferation 
or cultured in medium alone. No significant changes between control and galectin-9 
siRNA transfected cells were noted at 2-4 days after transfection (Fig. 5.3).  
 
To determine whether galectin-9 influences the production of mediators of 
inflammation and cartilage destruction by synovial fibroblasts, supernatants from 
galectin-9 silenced and control cells were analysed by ELISA for their output of 
inflammatory cytokines. Although some cell lines displayed a trend towards reduced 
IL-6 secretion the overall effect was not significant (Fig. 5.4A). There were also no 
differences in production of the chemokines, IL-8 and CCL5 (Fig. 5.4 C, D), or 
matrix metalloproteinase-3 (Fig.5.4 B).  
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Fig. 5.3 Effect of galectin-9 silencing on synovial fibroblasts proliferation. 
Cells were transfected with galectin-9 (black bars) or control siRNA (grey bars). 
Proliferation was measured by XTT assay at the indicated time points and data are 
shown as OD values. Data are mean +SEM from 4 experiments run in duplicate. A. 
Unstimulated cells. B. Cells stimulated with 10ng/ml IL1-β and 10ng/ml TNFα 24h 
after transfection.  
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Fig. 5.4 Effect of galectin-9 silencing on production of IL-6, MMP-3, IL-8 and 
CCL5 by synovial fibroblasts. 
Fibroblasts were transfected with galectin-9 or control siRNA. After 72h 
supernatants were collected and protein measured by ELISA. Lines show results 
from individual samples. Circles-control siRNA transfected cells, triangles-galectin-9 
siRNA transfected cells. A. IL-6 B. MMP-3 C. IL-8 D. CCL5 
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5.3 DISCUSSION 
Galectin-9 silencing in RA synovial fibroblasts resulted in increased rates of 
apoptosis in these cells. However it did not affect cell proliferation or production of 
cytokine IL-6, chemokines (IL-8 and CCL5) or MMP-3. 
Up to now the only report on galectin-9 in RA synovium was published by Seki et al.  
(2007). The authors demonstrated that a mutant galectin-9 with deleted linker peptide 
has a pro-apoptotic effect on synovial fibroblasts. This mutation confers increased 
stability to the protein which otherwise is susceptible to enzymatic cleavage in vivo 
(Nishi et al., 2005). Such modified galectin-9 was also effective for HTLV-1-
infected T cells (Okudaira et al., 2007). Wild-type molecules (short and medium 
isoforms) were much less potent in inducing apoptosis of synovial fibroblasts, 
although other biological activities of all forms were similar (Seki et al., 2007). The 
above study showed also a beneficial effect of treatment with exogenous galectin-9 
mutant in a mouse model of collagen-induced arthritis (CIA), however a role for the 
naturally occurring protein was not established.  
Here it was demonstrated that the intracellular presence of galectin-9 in synovial 
fibroblasts may confer greater resistance to apoptosis, both spontaneous and induced. 
In that respect galectin-9 would act similarly to galectin-3. Galectin-3 is capable of 
triggering apoptosis of T cells and thymocytes when found outside the cell 
(Fukumori et al., 2003; Stillman et al., 2006) but when it is localized intracellularly it 
has a protective effect by interacting with anti-apoptotic proteins from the Bcl-2 
family (Yang et al., 1996; Matarrese et al., 2000; Akahani et al., 1997). A pro-
apoptotic effect of exogenous galectin-9 was previously described for thymocytes, 
activated T cells and some tumour cells such as melanoma or Burkitt lymphoma 
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(Makishi et al., 2008; Kageshita et al., 2002). The data reported here suggest that the 
upregulation of intracellular galectin-9 might induce some degree of resistance to 
apoptosis in synovial fibroblasts at sites of joint destruction and thus contribute to the 
expansion of the pannus tissue in RA. 
 
Because higher numbers of apoptotic cells in culture may often be due to increased 
rates of proliferation, it was examined whether intracellular galectin-9 also affects 
that process. Both spontaneous and cytokine-induced cell proliferation of RA 
synovial fibroblasts were similar in control and galectin-9 silenced cells confirming 
that these processes were independent and not affected by galectin-9.  Pro-
proliferative role independent of apoptotic processes was documented earlier for 
galectin-3 in Jurkat T cells (Yang et al., 1996). However, the same galectin 
overexpressed in prostate cancer cells slowed down their growth (Ellerhorst et al., 
1999). Biphasic modulation of proliferation also characterizes extracellular galectin-
1 which, depending on its concentration, either promotes cell growth or inhibits it 
(Adams et al., 1996; Vas et al., 2005). Intracellularly galectin-1 may contribute to 
cell transformation by association with oncogenic H-Ras (Paz et al., 2001; Elad-
Sfadia et al., 2004). 
 
A recent paper by Matsuura et al. implicated intracellular galectin-9 in cytokine 
production in the monocytic cell line THP-1. Transfection with galectin-9 resulted in 
activation of promoters for IL-1α, IL-1β and IFNγ in these cells (Matsuura et al., 
2009). In the present study we looked for an effect of galectin-9 on the production of 
cytokines, chemokines and matrix metalloproteinase relevant to RA in synovial 
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fibroblasts but found no difference in either IL-6, IL-8, CCL5 or MMP-3 output 
when galectin-9 was suppressed. It would be interesting to investigate the influence 
of galectin-9 on the expression of other inflammatory mediators, adhesion molecules 
or molecules of signalling pathways. 
 
In summary, the different roles of galectin-9 depending on its localization seem to be 
a common feature shared with other galectins. As described previously intracellular 
galectin-3 interfere with apoptotic pathways rescuing cells from death, while acting 
from outside of the cell it promotes this process (Yang et al., 1996; Fukumori et al., 
2003). Galectin-1 can also exhibit differential effects on cell death (Adams et al., 
1996; Paz et al., 2001). To establish which of these functions of galectin-9 
predominates in the RA joint it would be crucial to determine whether the protein is 
released in soluble form and how stable it is in this environment. 
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6.0 Response of fibroblasts to galectin-3 
6.1 Background 
Galectins are widely described as regulators of various immune cell subsets, but their 
influence on stromal cell functions is less well recognized. Galectin-1 was found to 
be a mitogenic factor for vascular endothelial cells (Hsu and Liu, 2004) but cytostatic 
for mouse embryonic fibroblasts (Wells and Mallucci, 1992). Galectin-3 similarly 
induced morphogenesis of endothelial cells and angiogenesis (Nangia-Makker et al., 
2000) and also stimulated DNA synthesis and proliferation in lung fibroblasts 
(Inohara et al., 1998). In the context of synovitis, galectin-3 has been shown to 
enhance the growth of RA and OA synovial fibroblasts in culture (Ohshima et al., 
2003).  
Apart from regulating cell growth, galectins can activate fibroblasts to produce 
various factors. For example galectin-3 has been shown to increase collagen 
production by liver fibroblasts resulting in organ fibrosis (Henderson et al., 2006) 
and to stimulate IL-8 secretion from fibroblasts in the colon (Lippert et al., 2007).  
Previous work from our own research group has shown that fibroblasts from 
rheumatoid arthritis patients also respond to stimulation by galectin-1 and -3 with 
increased production of cytokines, chemokines, growth factors and tissue degrading 
enzymes (Trebilcock, 2006). For instance, both galectins induced the secretion of IL-
6, IL-8 (CXCL8) and MMP-9, although galectin-3 was much more potent in that 
effect. GM-CSF, IL-1β or CCL4 (MIP-1β) were induced to a similar extent by both 
lectins. Galectin-3, however, uniquely stimulated the production of TNF-α, CCL3 
(MIP-1α), CCL5 (RANTES).  
 131
Because of the abundant expression of galectin-3 found in RA synovium, the aim of 
this chapter was to investigate its potential pathogenic role in rheumatoid arthritis, 
focussing on its modulation of fibroblasts function. This study also looked at site-
specific differences in response to galectin-3 in fibroblasts from RA synovium and 
skin. 
6.2 Differential production of cytokines and chemokines from 
fibroblasts stimulated by galectin-3 
To assess the differential production of inflammatory mediators in response to 
galectin-3 matched samples of fibroblasts derived from synovium and skin of RA 
patients were treated with galectin-3 for 24h and the supernatants analysed by ELISA 
for secretion of proteins. Since the physiological levels of galectin-3 were reported at 
around 20 µg/ml (Lippert et al., 2007), the concentration of 10 µg/ml was chosen for 
these studies. It was confirmed that synovial fibroblasts respond to galectin-3 
treatment with increased secretion of IL-6, CCL5 and CCL2 (Fig. 6.1). Interestingly 
fibroblasts from skin in general up-regulated only the production of IL-6 but did not 
increase secretion of chemokines (Fig. 6.1 B and C).  
 
IL-6 production in synovial and skin fibroblasts as well as CCL5 production in 
synovial cells was dose-dependent (Fig. 6.2). Although skin fibroblasts did not 
respond by increasing chemokine production as a rule, increased production of CCL5 
was observed in one skin fibroblast sample, but only at high concentrations of 
galectin-3 (>30µg/ml; Fig. 6.2D).  
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Fig. 6.1 Galectin-induced production of cytokines from fibroblasts. 
Matched synovial and skin fibroblasts from RA patients were stimulated with 10 
µg/ml galectin-3 for 24h. The level of cytokines (A) IL-6, (B) CCL5 and (C) CCL2, 
was measured in the supernatant by ELISA.  Bars show mean ± SEM from 5 
duplicate samples.  *p<0.05, ** p<0.01 compared to production by untreated cells. 
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Fig. 6.2  Galectin-3 - induced production of IL-6 and CCL5 is concentration 
dependent. 
Synovial and skin fibroblasts were treated with various doses as shown of galectin-3 
for 24h. The level of each cytokine was measured in the supernatant by ELISA. Left 
panel shows synovial fibroblasts, right panel skin fibroblasts. Bars indicate the mean 
value and each point is the average of duplicates in individual cell lines.  *p<0.05 
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6.3 Galectin-3-induced IL-6, CCL5 and CCL2 production is not 
mediated via autocrine TNFα 
As mentioned previously, one of the factors induced by galectin-3 in synovial 
fibroblasts was TNF-α (Trebilcock, 2006). This cytokine is considered to be at the 
top of the inflammatory cytokine cascade which results in production of IL-6 and 
other cytokines and chemokines. Hence, there was a possibility that the increase in 
the production of cytokines and chemokines might be a secondary effect caused by 
autocrine stimulation by TNF-α. To check if this was the case, 5µg/ml TNF-
neutralizing antibody was added to the culture 30 minutes prior to cell activation 
with galectin-3. 10 ng/ml TNF-α was used as a positive control. There was a 
complete blockade of the actions of exogenously added TNF-α by the blocking 
antibody, but no significant effect on either IL-6, CCL5 or CCL2 secretion from 
galectin-3 stimulated fibroblasts (Fig. 6.3). It appears that increased production of 
IL-6 and chemokines (CCL5, CCL2) induced by galectin-3 is independent of the 
presence of TNF-α in fibroblast cultures.  
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Fig. 6.3 Effect of neutralizing TNFα on galectin-3 induced IL-6, CCL2 and 
CCL2 production.  Neutralizing anti-TNFα antibody was added to synovial 
fibroblast cultures at 5 µg/ml 30 min prior to stimulation with 10 ng/ml TNF-α or 10 
µg/ml galectin-3. Supernatants were collected after 24h and IL-6, CCL5 and CCL2 
measured by ELISA. Data are expressed as % of control (either +TNF or + galectin 
3) and are the mean + SEM from four independent experiments.  
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6.4 Signaling pathways induced in fibroblasts by galectin-3 
It was next decided to determine the pathways involved in intracellular galectin-3 
signalling leading to the differential responses described above. IL-6 and CCL5 were 
chosen as examples of induced cytokine and chemokines, respectively. To 
investigate which pathways may be activated a number of inhibitors against different 
kinases involved in pro-inflammatory pathways were applied to galectin-3 stimulated 
cells (Fig. 6.4). The production of IL-6 and CCL5 was used as a readout. 
 
Fig. 6.4 Diagram of potential galectin-3 signalling pathways and inhibitors used 
to examine them.  
The figure depicts selected protein kinases that may be involved in transducing 
signals leading to cytokine/chemokine production in fibroblasts. Arrows show 
activation. Inhibitors are in red, putative receptors are shown in blue. 
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Fibroblasts were treated for 1h with one of the following inhibitors: 5 µM Bay11-
7085, 10 µM LY294002, 1 µM bisindolylmaleimide, 20 nM Gö6976, 10 µM 
SB20219, 10 µM R406 or 10 µM PD98059, before stimulation with 10 µg/ml 
galectin-3. After 24h of culture supernatants were collected and IL-6 and CCL5 
levels measured by ELISA. It was found that in synovial fibroblasts IL-6 production 
was reduced by blocking the MAPK pathway, with inhibition of p38MAPK 
(inhibited by SB202190), Syk/JNK (inhibited by R406) and ERK (inhibited via 
blockade of MEK by PD98059). Application of these inhibitors resulted in at least 
50% inhibition of IL-6 production (Fig. 6.5 A). Skin fibroblasts responded to p38 
and Syk/JNK inhibition (SB202190, R406) in a similar way, but the MEK1/ERK 
inhibitor (PD98059) had no effect on IL-6 production (Fig. 6.5B). In both cell types 
interfering with NFκB activation by Bay11-7085 also significantly reduced IL-6 
secretion. (Fig. 6.5C) by 65 % in synovial and 80% in skin fibroblasts. 
 
In contrast, CCL5 production in synovial cells was affected by inhibitors of PI3K 
and NFκB, with production reduced by 65% and 40%, respectively (Fig. 6.6), but 
MAPK inhibitors were without effect. Skin fibroblasts did not produce detectable 
amounts of CCL5 after treatment with 10 µg/ml galectin-3. The PKC pathway did 
not appear to be required for the actions of galectin-3 as both bisindolylmaleimide 
and Go6976 were without effect. The inhibitors had no significant effect on cell 
numbers or morphology so reduced protein production due to toxicity was excluded. 
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Fig. 6.5 Inhibition of IL-6 production in galectin-3 stimulated synovial and skin 
fibroblasts. 
Fibroblasts from (A) synovium or (B) skin were treated with inhibitors for 1h prior to 
addition of medium containing 10 µg/ml galectin-3 or galectin-3 and DMSO and 
cells were cultured for 24h.  IL-6 levels were measured by ELISA and expressed as 
percentage of production by positive (galectin-3-stimulated) control. Data are mean 
+SEM of 4-5 independent experiments and assayed in duplicate. *p<0.05, **p<0.01, 
***p<0.001 compared to control cells (DMSO); Bis = bisindolylmaleimide 1. Boxes 
indicate target kinases for the inhibitors. 
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Fig. 6.6 Inhibition of CCL5 production in galectin-3 stimulated synovial 
fibroblasts. 
Fibroblasts were treated with inhibitors for 1h prior to addition of medium containing 
10 µg/ml galectin-3 or galectin-3 and DMSO as a control and cells were cultured for 
24h.  CCL5 levels were measured by ELISA and expressed as percentage of 
production by positive control (galectin-3-stimulated).  Data are mean +SEM from 4 
independent experiments assayed in duplicate. **p<0.01 compared to control cells 
(DMSO); Bis = bisindolylmaleimide 1. Boxes indicate target kinases for the 
inhibitors. 
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To confirm the activation of identified signalling pathways the phosphorylation of 
selected kinases was assessed by Western blotting using phosphospecific antibodies. 
Synovial and skin fibroblasts were treated with 10 µg/ml galectin-3 for 5 to 60 min, 
then cell lysates were collected and the expression of phosphorylated (active) and 
total protein kinase was examined. As presented in Fig. 6.7 increased 
phosphorylation of ERK kinase in synovial and skin fibroblasts was seen as early as 
5 min. after addition of galectin-3 and lasted for at least 1h. Transient activation of 
p38 MAP kinase was observed in both types of fibroblasts after 15 min of galectin-3 
treatment. JNK phosphorylation was also maximal at this time point then gradually 
decreased. A similar pattern was seen for Akt phosphorylation in skin fibroblasts. 
Probing for unphosphorylated proteins confirmed that gels were equally loaded. 
 
Activation of NFκB transcription factor was measured after 1h of galectin-3 
treatment. Stimulation with 10ng/ml TNFα was used as positive control. Synovial 
fibroblasts showed significant although variable activation of the p65 subunit (Fig. 
6.8A). In skin fibroblasts the slight increase in active p65 (1.7 fold) in galectin-3-
treated cells was not significant, possibly due to the low number of samples (Fig. 
6.8B). 
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Fig. 6.7 Activation of protein kinases following galectin-3 treatment in synovial 
and skin fibroblasts. 
Synovial and skin fibroblasts were treated with 10 µg/ml galectin-3 for 5-60 min. 
Cell lysates were prepared and analysed by Western blotting with antibodies against 
the total or phosphorylated (active) form of various protein kinases. Representative 
images from four separate experiments are shown for synovial (left panel) and skin 
(right panel) fibroblasts. 
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Fig. 6.8 Activation of NFκB transcription factor in synovial and skin fibroblasts.  
 Fibroblasts were treated for 1h with 10 ng/ml TNFα or 10 µg/ml galectin-3. Nuclear 
extracts were prepared and the binding of activated NFκB p65 subunit to DNA 
oligonucleotides measured using the commercial TransAM assay kit. Data are 
expressed as fold change over untreated cells and are mean +SD from 3-4 
experiments run in duplicate. * p<0.05 compared to control (C) non-treated cells. 
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6.5 DISCUSSION 
Studies on the effects of in vitro treatment with galectin-3 showed increased 
production of IL-6 in synovial and skin fibroblasts from RA patients. Mononuclear 
cell-attracting chemokines (CCL5, CCL2) were selectively induced in fibroblasts 
from the synovium but not from the skin. These effects were not secondary events 
mediated by TNFα released from fibroblasts. It was also found the MAP kinase and 
NFκB signalling pathways were involved in IL-6 production, whereas CCL5 release 
was mediated by PI3K/Akt and NFκB pathways. 
 
Galectin-3 was demonstrated to have a destructive potential in joint tissues (Janelle-
Montcalm et al., 2007). It induced degradative enzymes from chondrocytes and 
inhibited osteoblast differentiation. Recent findings from our laboratory indicated 
another role for galectin-3 in the pathogenic role of rheumatoid synovium which is 
the induction of a variety of cytokines, chemokines, growth factors and proteases 
from synovial fibroblasts (Filer et al., 2009). Interestingly, no effect of galectins on 
fibroblast differentiation and surface molecule expression was observed (Fitton, 
2007). Unlike TNF-α stimulation which induces various chemokines also in skin 
fibroblasts (Sticherling et al., 1995; Noso et al., 1996), galectin-3 enhanced their 
production only from synovial fibroblasts. CCL2 (MCP-1), CCL3 (MIP-1α) or CCL5 
(RANTES) play a crucial role in the chemoattraction of leukocytes during the 
inflammatory response and have been implicated in rheumatoid arthritis 
(Rathanaswami et al., 1993). Their selective induction by galectin-3 present in the 
synovium may therefore contribute to the accumulation of an inflammatory infiltrate 
and initiation of the disease process at this site. Skin fibroblasts responded to 
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galectin-3 with production of cytokines (IL-6) but not chemokines. Only in one cell 
line was an increase in CCL5 noted and only at the highest doses of galectin. The 
differential response of skin fibroblasts may reflect the fact that they were derived 
from a non-inflamed tissue. On the other hand, the inflammatory process in RA 
synovium may have imprinted synovial fibroblasts causing their stable activation and 
ability to produce chemokines. 
 
Although many binding partners for galectin-3 were described, a specific receptor for 
this lectin on fibroblasts has not been identified yet. It is possible that galectin-3 
interacts with several molecules on the cell surface of fibroblasts and does not have a 
unique receptor. Therefore the approach taken in this study to determine the 
mechanism of cytokine and chemokine induction by galectin-3 was to look into 
signalling pathways potentially involved in IL-6 and CCL5 production. The 
hypothesis that differential production of these inflammatory cytokines and 
chemokines is driven by distinct signalling pathways was confirmed.  The main 
transcription factor involved in regulation of IL-6 expression in synovial fibroblasts 
is NFκB (Georganas et al., 2000). However, upstream kinases leading to NFκB 
activation and IL-6 transcription appear to be dependent on a particular stimulus and 
receptor engaged. For instance, TNF-α or IL-1β signalling is mediated by p38 
MAPK (Kunisch et al., 2007; Schett et al., 2000; Miyazawa et al., 1998), CCL2 
stimulation enhances ERK1/2 phosphorylation (Nanki et al., 2001), whereas IL-6 
induced by IL-17 activates PI3K/Akt pathway (Hwang et al., 2004).   
Galectin-3 stimulation of synovial and skin fibroblasts activated each of the main 
MAP kinase families: p38MAPK, ERK and JNK as well as Akt phoshorylation. 
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NFκB transcription factor was also activated in galectin-3 treated synovial 
fibroblasts. An inhibitor of NF-κB signalling significantly reduced IL-6 secretion 
from both types of fibroblasts confirming that this transcription factor is crucial for 
IL-6 production in RA. Using protein kinase inhibitors it was also found that 
galectin-3-induced secretion of IL-6 in synovial fibroblasts required signalling by 
MAP kinases p38, JNK and ERK. Similar synergistic actions of p38 MAP kinase and 
NF-κB in induction of IL-6 was observed in cardiac myocytes (Craig et al., 2000). 
Apart from enhancing transcriptional activity p38 MAP kinase may also regulate IL-
6 via stabilisation of its mRNA (Miyazawa et al., 1998). 
 
Remarkably, in skin fibroblasts ERK1/2 kinases were also activated, but the 
inhibition of the direct upstream ERK activator MEK1 had no effect on IL-6 output. 
Indeed, other studies suggested involvement of different pathways in regulating ERK 
phosphorylation (Cerioni et al., 2003) and the MEK1 inhibitor PD98059 was 
ineffective in inhibiting ERK phosphorylation in rat-1 fibroblasts (Bapat et al., 
2001). Induction of IL-6 may therefore show both receptor and tissue specific 
signalling pathway involvement. 
 
Although the inhibitor of NFκB signaling (Bay 11-7085) reduced IL-6 production in 
skin fibroblasts similarly as it did in the synovial cells, the present data failed to 
confirm activation of this transcription factor. RA synovial fibroblasts display 
enhanced activation of this factor which was shown to contribute to their growth, 
resistance to apoptosis and transformed phenotype (Ospelt et al., 2004b; Miagkov et 
al., 1998; Li and Makarov, 2006). In skin-derived cells the threshold for NFκB 
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induction may be higher and galectin-3 may not provide a sufficient signal in this 
respect. Alternatively, other molecules from the complex intracellular signalling 
networks that were not considered in this study may be involved. The observation of 
weaker NFκB induction could also explain the lack of chemokine production in skin 
fibroblasts upon galectin-3 stimulation. 
 
It was reported previously that CCL5 gene expression in fibroblasts requires NFκB 
(Genin et al., 2000) and JNK activation. CCL5 production induced by IL-1β or TNF-
α involves also Syk, a spleen tyrosine kinase upstream of JNK (Yamada et al., 2001; 
Cha et al., 2006). Serine/threonine kinases from the PKC family (epsilon, zeta) have 
also been implicated in IL-1β/TNFα–induced chemokine production in synovial cells 
(Jordan et al., 1996) and were therefore considered here. We did not see any effect of 
PKC inhibitors (Bisindolylmaleimide 1, Go6976) on either IL-6 or CCL5 production. 
  
In contrast to IL-6 production, CCL5 was affected only by PI3K and NFκB 
inhibitors. Therefore it can be concluded that in RA synovial fibroblasts the 
production of cytokines and chemokines is driven via distinct signaling pathways. A 
similar effect was observed previously for IL-18 driven production of angiogenic 
factors from these cells (Amin et al., 2007). In skin fibroblasts chemokines including 
CCL5 can be induced by stimuli such as TNFα, IL-1α/β or IFNγ (Sticherling et al., 
1995; Fukuoka et al., 1998; Lee et al., 2000). The fact that galectin-3 promoted 
mononuclear-attracting chemokine expression only in synovial fibroblasts may 
contribute to its inflammatory role at this specific site.   
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7.0  GENERAL DISCUSSION 
Fibroblast derived neutrophil survival factors 
The first part of this thesis was an attempt to identify neutrophil survival factors 
secreted by synovial fibroblasts in rheumatoid arthritis. It stemmed from previous 
observations of enhanced neutrophil survival elicited by TNFα and IL-17-stimulated 
fibroblasts (Filer et al., 2006a). Stromally-induced leukocyte survival appears to be 
important in sustaining inflammatory processes in the tissues. In RA synovium it was 
shown that such a mechanism applies to both plasma cells and T cells. Synovial 
fibroblasts provide functional niches for B cells where their survival and 
differentiation into plasma cells is provided mainly by direct cell contact  (Dechanet 
et al., 1995a). T cells also are believed to survive and accumulate in the joint due to 
cell contact with fibroblasts and the presence of soluble factors secreted by them 
(Pilling et al., 1999). Neutrophils in the RA joint are found mostly in synovial fluid 
and at the interface of pannus and cartilage (Edwards and Hallett, 1997) and 
therefore it was less clear whether they received survival signals from stromal cells. 
However, work from our group showed that fibroblasts could provide survival 
factors able to inappropriately retain these cells in the joint (Filer et al., 2006a).   The 
identity of the survival factors was however not known and was one of the subjects 
of this thesis. 
RA synovial fibroblasts secreted soluble molecules prolonging neutrophil life span. 
As shown previously and confirmed herein, GM-CSF accounted for much of this 
effect (Filer, 2006, Parsonage et al., 2008). In search for other mediators that provide 
survival signals for neutrophils, it was shown that the unknown factor is heat-labile, 
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therefore most likely a protein, and acts by activating PI-3K and NFκB signalling 
pathways in neutrophils (Filer, 2006). However, such other known survival factors as 
G-CSF, CCL2 were excluded. To further pursue the apoptosis delaying agent this 
study examined the role of IFNβ, IL-6, TNFα and galectin-3, but none of them 
appeared to contribute to the survival effect produced by TNF and IL-17 stimulated 
fibroblasts. Despite eliminating a number of candidates, the issue of fibroblast-
produced neutrophil survival factor has not been successfully resolved. Another way 
forward to identify this molecule could be fractionation of the supernatant and mass 
spectrometry to decide its molecular weight or microarray analysis of unstimulated 
and stimulated fibroblasts to see which genes of candidate survival factors are 
differentially expressed. 
 
Differential fibroblast phenotypes 
The role of fibroblasts as tissue-resident sentinel cells that integrate signals from the 
environment and translate into immune function by modulating leukocyte behaviour 
is gaining more interest. The research from our group focuses also on defining 
unique phenotypes characteristic for fibroblasts originating from various anatomical 
sites. It was shown that molecular profiles of these stromal cells indeed differ 
(Parsonage et al., 2003) and may constitute a basis for development of chronic 
inflammation at specific restricted sites such as the joint in rheumatoid arthritis. The 
observation of similarities in cytokine secretory patterns and responses to various 
stimuli among fibroblasts from rheumatoid, osteoarthritic and normal synovium 
suggests that site of origin may even be more important that disease specificity in 
defining fibroblast phenotype (Scaife et al., 2004). 
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This thesis sought to elucidate whether galectins as immunomodulatory molecules 
constitute a part of this site-specific expression profile in fibroblasts and if their 
expression can be changed by external stimuli. Galectins 1, 3 and 8 were found to be 
highly expressed in fibroblasts regardless of their origin. Site-specific differences in 
expression patterns were observed for galectin-9 and -12. Up to now expression of 
this latter galectin had not been reported in RA fibroblasts and its significance 
requires further investigation.  
 
Role of galectin-9 in rheumatoid joint 
Galectin-9 was recognized initially as an eosinophil chemoattractant and T cell 
survival regulator. Being a ligand for TIM-3 receptor on Th1 cells it can induce T 
cell apoptosis which has substantial implications in development of autoimmune 
disease, graft survival or anti-tumour activity (Wang et al., 2007; Seki et al., 2007). 
During the course of this thesis a publication by Seki et al. showed the presence of 
galectin-9 in RA synovium and its proapoptotic role for synovial fibroblasts and 
potential beneficial effect of such treatment in arthritis (Seki et al., 2007). The 
present findings of higher expression of galectin-9 in synovial fibroblasts compared 
to those from skin, does not support their putative pro-apoptotic function in these 
fibroblasts. However, the authors of the above mentioned study used a mutated 
molecule derived from galectin-9 which may provide an explanation for this 
discrepancy. 
This thesis focused on intracellular galectin-9 and provides a different view of the 
role of this protein in synovial fibroblast biology. It was shown that galectin-9 
silencing resulted in increased rates of apoptosis in fibroblasts implicating a 
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protective role of the intracellular protein. The mechanism of this protection would 
be an interesting subject to investigate further. Involvement of galectin-9 in specific 
apoptosis signalling pathways should be examined, for example its association with 
regulatory proteins such as Bcl-2, Bcl-xl or caspases. Overexpression of galectin-9 in 
fibroblasts and the effect on resistance to apoptotic stimuli would confirm the role of 
this molecule. 
The data from in situ examination of galectin-9 expression in synovial tissue 
demonstrated its nuclear localisation.  So far this galectin has not been reported in 
fibroblasts in the nuclear compartment and its particular role there is not known. 
However, another recent publication noted nuclear translocation of galectin-9 in 
monocytic cells challenged with LPS and its physical association with NF-IL6 
(C/EBPβ) transcription factor (Matsuura et al., 2009) suggesting involvement in the 
transcription machinery. Indeed, the presence of galectin-9 in those cells induced 
pro-inflammatory cytokine production (IL-1α, IL-1β) (Matsuura et al, 2009). Here 
we also report an upregulation of galectin-9 in response to LPS, although without an 
effect on the few inflammatory molecules tested (IL-6, CCL5, IL-8, MMP3).  
The abundant expression of galectin-9 at sites of pannus invasion into the cartilage 
and bone together with its anti-apoptotic activity indicates a potential role in the 
aggressive behaviour of RA synovial fibroblasts. Since the exogenous galectin-9 
could induce fibroblast apoptosis (Seki et al., 2007), this finding underlines that the 
localization of galectin-9 and whether it is secreted in a soluble form or not, may be 
of crucial importance for its in vivo activities in the inflamed joint. Further 
investigation on this subject such as measuring the levels of galectin-9 and testing the 
effects of a native protein would be necessary to clarify this issue.  
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Role of galectin-3 in rheumatoid joint 
Another galectin with a role in rheumatoid arthritis and present in the synovium at 
much higher levels is galectin-3. It was revealed that apart from fibroblasts other 
cells such as macrophages contribute to its production and increased levels in RA. 
Galectin-3 was shown to be a critical regulator of chronic inflammation in liver or 
renal fibrosis (Henderson et al., 2006; Henderson et al., 2008). Here it is proposed 
that galectin-3 may contribute to the pathogenesis of rheumatoid arthritis by directly 
stimulating fibroblasts to secrete leukocyte recruiting and survival factors (Filer et 
al., 2009). We also provide the evidence for site-specific responses of fibroblasts 
depending on their origin (synovium or skin). The production of mononuclear 
attracting chemokines by fibroblasts from the synovium but not from skin is a unique 
property of galectin-3 stimulation. Although the receptor(s) on both cell types are not 
yet known it was found that the secretion of inflammatory mediators is based on the 
activation of distinct pathways, PI3K/Akt in case of chemokines and MAPKs in case 
of cytokines. These differences in intracellular signaling pathways and various 
outcomes of their activation in synovial and skin fibroblasts adds to the concept of 
spatially defined imprinted phenotypes of fibroblasts.  
 
Implications for treatment of RA 
Although the role of galectins in rheumatoid arthritis is only beginning to emerge 
they might constitute another target for therapy. Current therapies for RA aim to 
slow down progression of the disease and treat the symptoms but do not represent a 
complete cure. They include traditional broad range anti-inflammatory agents such as 
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corticosteroids and cytostatic drugs and recently developed biological agents (Table 
7.1). The most successful biologics utilized for the treatment of rheumatoid arthritis 
antagonize pro-inflammatory cytokines primarily TNFα. IL-1 and IL-6 receptor 
antagonists as well as molecules targeting immune cells (T cells, B cells) were also 
developed and proven beneficial in controlling the disease.  
 
Table 7.1. Current primary medications used to treat RA. 
Analgesics/NSAIDs DMARDs Biologics 
Acetaminophen Azathioprine Etanercept fusion protein TNFR:IgG 
Tramadol D-penicillamine               Infliximab chimeric anti-TNFα antibody 
Cox-2 inhibitors Hydroxychloroquine Adalimumab human anti-TNFα antibody 
Capsaicin Sulfasalazine Anakinra recombinant IL-1Ra 
Narcotics Methotrexate Rituximab anti-CD20 antibody 
Ibuprofen Leflunomide Abatacept fusion protein CTLA-4:IgG Fc 
 Gold salts  Tocilizumab anti- IL-6R antibody 
NSAIDs - nonsteroidal anti-inflammatory drugs 
DMARDs –disease-modyfying antirheumatic drugs 
 
However, even with these treatments still only about 60-70% of RA patients show 
clinical improvement. The reason for this might be that most of the current therapies 
focus on targeting the adaptive immune system without tackling the innate immunity 
such as neutrophils and stromal cells. Fibroblasts are now recognized as important 
players in inflammatory processes not only in the joint. Their huge capacity to attract 
and activate cells of the adaptive system as well as responsiveness to stimuli 
provided by incoming immune cells make them indispensable to sustain 
inflammation in the tissues. As shown in this thesis fibroblasts may be crucially 
responsible for maintaining neutrophil infiltrate in the joint. Targeting them to 
remove the source of factors causing inappropriate neutrophil survival would present 
additional option for treatment of RA. 
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In addition, synovial fibroblasts are an important source of inflammatory galectin-3 
which also acts in an autocrine manner causing their further activation and triggering 
cytokine and chemokine production. It can be concluded that interfering with this 
pathway could restrict synovial inflammation and aid to improve available treatment 
strategies.  
Finally, another galectin produced by fibroblasts, galectin-9 may contribute to their 
resistance to apoptosis. This should also be considered before attempting to utilize 
galectin-9 as a therapeutical agent.  
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